

COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION

CROSS-REFERENCE TO RELATED APPLICATIONS

SUB
A'

This application claims priority from U.S. Provisional Application
5 No. 60/110,283 filed November 27, 1998, which application is incorporated by
reference in its entirety.

TECHNICAL FIELD

The present invention relates generally to pharmaceutical products and
methods and, more specifically, to methods and compositions suitable for increasing the
10 mineral content of bone. Such compositions and methods may be utilized to treat a
wide variety of conditions, including for example, osteopenia, osteoporosis, fractures
and other disorders in which low bone mineral density are a hallmark of the disease.

BACKGROUND OF THE INVENTION

Two or three distinct phases of changes to bone mass occur over the life
15 of an individual (see Riggs, *West J. Med.* 154:63-77, 1991). The first phase occurs in
both men and women, and proceeds to attainment of a peak bone mass. This first phase
is achieved through linear growth of the endochondral growth plates, and radial growth
due to a rate of periosteal apposition. The second phase begins around age 30 for
trabecular bone (flat bones such as the vertebrae and pelvis) and about age 40 for
20 cortical bone (e.g., long bones found in the limbs) and continues to old age. This phase
is characterized by slow bone loss, and occurs in both men and women. In women, a
third phase of bone loss also occurs, most likely due to postmenopausal estrogen
deficiencies. During this phase alone, women may lose an additional 10% of bone mass
from the cortical bone and 25% from the trabecular compartment (see Riggs, *supra*).

25 Loss of bone mineral content can be caused by a wide variety of
conditions, and may result in significant medical problems. For example, osteoporosis
is a debilitating disease in humans characterized by marked decreases in skeletal bone

mass and mineral density, structural deterioration of bone including degradation of bone microarchitecture and corresponding increases in bone fragility and susceptibility to fracture in afflicted individuals. Osteoporosis in humans is preceded by clinical osteopenia (bone mineral density that is greater than one standard deviation but less than 2.5 standard deviations below the mean value for young adult bone), a condition found in approximately 25 million people in the United States. Another 7-8 million patients in the United States have been diagnosed with clinical osteoporosis (defined as bone mineral content greater than 2.5 standard deviations below that of mature young adult bone). Osteoporosis is one of the most expensive diseases for the health care system, costing tens of billions of dollars annually in the United States. In addition to health care-related costs, long-term residential care and lost working days add to the financial and social costs of this disease. Worldwide approximately 75 million people are at risk for osteoporosis.

The frequency of osteoporosis in the human population increases with age, and among Caucasians is predominant in women (who comprise 80% of the osteoporosis patient pool in the United States). The increased fragility and susceptibility to fracture of skeletal bone in the aged is aggravated by the greater risk of accidental falls in this population. More than 1.5 million osteoporosis-related bone fractures are reported in the United States each year. Fractured hips, wrists, and vertebrae are among the most common injuries associated with osteoporosis. Hip fractures in particular are extremely uncomfortable and expensive for the patient, and for women correlate with high rates of mortality and morbidity.

Although osteoporosis has been defined as an increase in the risk of fracture due to decreased bone mass, none of the presently available treatments for skeletal disorders can substantially increase the bone density of adults. There is a strong perception among all physicians that drugs are needed which could increase bone density in adults, particularly in the bones of the wrist, spinal column and hip that are at risk in osteopenia and osteoporosis.

Current strategies for the prevention of osteoporosis may offer some benefit to individuals but cannot ensure resolution of the disease. These strategies

include moderating physical activity (particularly in weight-bearing activities) with the onset of advanced age, including adequate calcium in the diet, and avoiding consumption of products containing alcohol or tobacco. For patients presenting with clinical osteopenia or osteoporosis, all current therapeutic drugs and strategies are
5 directed to reducing further loss of bone mass by inhibiting the process of bone absorption, a natural component of the bone remodeling process that occurs constitutively.

For example, estrogen is now being prescribed to retard bone loss. There is, however, some controversy over whether there is any long term benefit to patients
10 and whether there is any effect at all on patients over 75 years old. Moreover, use of estrogen is believed to increase the risk of breast and endometrial cancer.

High doses of dietary calcium, with or without vitamin D has also been suggested for postmenopausal women. However, high doses of calcium can often have unpleasant gastrointestinal side effects, and serum and urinary calcium levels must be
15 continuously monitored (see Khosla and Riggs, *Mayo Clin. Proc.* 70:978-982, 1995).

Other therapeutics which have been suggested include calcitonin, bisphosphonates, anabolic steroids and sodium fluoride. Such therapeutics however, have undesirable side effects (e.g., calcitonin and steroids may cause nausea and provoke an immune reaction, bisphosphonates and sodium fluoride may inhibit repair
20 of fractures, even though bone density increases modestly) that may prevent their usage (see Khosla and Riggs, *supra*).

No currently practiced therapeutic strategy involves a drug that stimulates or enhances the growth of new bone mass. The present invention provides compositions and methods which can be utilized to increase bone mineralization, and
25 thus may be utilized to treat a wide variety of conditions where it is desired to increase bone mass. Further, the present invention provides other, related advantages.

SUMMARY OF THE INVENTION

As noted above, the present invention provides a novel class or family of TGF-beta binding-proteins, as well as assays for selecting compounds which increase

bone mineral content and bone mineral density, compounds which increase bone mineral content and bone mineral density and methods for utilizing such compounds in the treatment or prevention of a wide variety of conditions.

Within one aspect of the present invention, isolated nucleic acid molecules are provided, wherein said nucleic acid molecules are selected from the group consisting of: (a) an isolated nucleic acid molecule comprising sequence ID Nos. 1, 5, 7, 9, 11, 13, or, 15, or complementary sequence thereof; (b) an isolated nucleic acid molecule that specifically hybridizes to the nucleic acid molecule of (a) under conditions of high stringency; and (c) an isolated nucleic acid that encodes a TGF-beta binding-protein according to (a) or (b). Within related aspects of the present invention, isolated nucleic acid molecules are provided based upon hybridization to only a portion of one of the above-identified sequences (e.g., for (a) hybridization may be to a probe of at least 20, 25, 50, or 100 nucleotides selected from nucleotides 156 to 539 or 555 to 687 of Sequence ID No. 1). As should be readily evident, the necessary stringency to be utilized for hybridization may vary based upon the size of the probe. For example, for a 25-mer probe high stringency conditions could include: 60 mM Tris pH 8.0, 2 mM EDTA, 5x Denhardt's, 6x SSC, 0.1% (w/v) N-laurylsarcosine, 0.5% (w/v) NP-40 (nonidet P-40) overnight at 45 degrees C, followed by two washes with with 0.2x SSC / 0.1% SDS at 45-50 degrees. For a 100-mer probe under low stringency conditions, suitable conditions might include the following: 5x SSPE, 5x Denhardt's, and 0.5% SDS overnight at 42-50 degrees, followed by two washes with 2x SSPE (or 2x SSC) / 0.1% SDS at 42-50 degrees.

Within related aspects of the present invention, isolated nucleic acid molecules are provided which have homology to Sequence ID Nos. 1, 5, 7, 9, 11, 13, or 15, at a 50%, 60%, 75%, 80%, 90%, 95%, or 98% level of homology utilizing a Wilbur-Lipman algorithm. Representative examples of such isolated molecules include, for example, nucleic acid molecules which encode a protein comprising Sequence ID NOs. 2, 6, 10, 12, 14, or 16, or have homology to these sequences at a level of 50%, 60%, 75%, 80%, 90%, 95%, or 98% level of homology utilizing a Lipman-Pearson algorithm.

Isolated nucleic acid molecules are typically less than 100kb in size, and,

within certain embodiments, less than 50kb, 25kb, 10kb, or even 5kb in size. Further, isolated nucleic acid molecules, within other embodiments, do not exist in a "library" of other unrelated nucleic acid molecules (*e.g.*, a subclone BAC such as described in GenBank Accession No. AC003098 and EMB No. AQ171546). However, isolated
5 nucleic acid molecules can be found in libraries of related molecules (*e.g.*, for shuffling, such as is described in U.S. Patent Nos. 5,837,458; 5,830,721; and 5,811,238). Finally, isolated nucleic acid molecules as described herein do not include nucleic acid molecules which encode Dan, Cerberus, Gremlin, or SCGF (U.S. Patent No. 5,780,263).

10 Also provided by the present invention are cloning vectors which contain the above-noted nucleic acid molecules, and expression vectors which comprise a promoter (*e.g.*, a regulatory sequence) operably linked to one of the above-noted nucleic acid molecules. Representative examples of suitable promoters include tissue-specific promoters, and viral - based promoters (*e.g.*, CMV-based promoters such as CMV I-E,
15 SV40 early promoter, and MuLV LTR). Expression vectors may also be based upon, or derived from viruses (*e.g.*, a "viral vector"). Representative examples of viral vectors include herpes simplex viral vectors, adenoviral vectors, adenovirus-associated viral vectors and retroviral vectors. Also provided are host cells containing or comprising any of above-noted vectors (including for example, host cells of human, monkey, dog, rat,
20 or mouse origin).

Within other aspects of the present invention, methods of producing TGF-beta binding-proteins are provided, comprising the step of culturing the aforementioned host cell containing vector under conditions and for a time sufficient to produce the TGF-beta binding protein. Within further embodiments, the protein
25 produced by this method may be further purified (*e.g.*, by column chromatography, affinity purification, and the like). Hence, isolated proteins which are encoded by the above-noted nucleic acid molecules (*e.g.*, Sequence ID NOs. 2, 4, 6, 8, 10, 12, 14, or 16) may be readily produced given the disclosure of the subject application.

It should also be noted that the aforementioned proteins, or fragments
30 thereof, may be produced as fusion proteins. For example, within one aspect fusion

proteins are provided comprising a first polypeptide segment comprising a TGF-beta binding-protein encoded by a nucleic acid molecule as described above, or a portion thereof of at least 10, 20, 30, 50, or 100 amino acids in length, and a second polypeptide segment comprising a non-TGF-beta binding-protein. Within certain embodiments, the
 5 second polypeptide may be a tag suitable for purification or recognition (*e.g.*, a polypeptide comprising multiple anionic amino acid residues – see U.S. Patent No. 4,851,341), a marker (*e.g.*, green fluorescent protein, or alkaline phosphatase), or a toxic molecule (*e.g.*, ricin).

Within another aspect of the present invention, antibodies are provided
 10 which are capable of specifically binding the above-described class of TGF-beta binding proteins (*e.g.*, human BEER). Within various embodiments, the antibody may be a polyclonal antibody, or a monoclonal antibody (*e.g.*, of human or murine origin). Within further embodiments, the antibody is a fragment of an antibody which retains the binding characteristics of a whole antibody (*e.g.*, an F(ab')₂, F(ab)₂, Fab', Fab, or Fv
 15 fragment, or even a CDR). Also provided are hybridomas and other cells which are capable of producing or expressing the aforementioned antibodies.

Within related aspects of the invention, methods are provided detecting a TGF-beta binding protein, comprising the steps of incubating an antibody as described above under conditions and for a time sufficient to permit said antibody to bind to a
 20 TGF-beta binding protein, and detecting the binding. Within various embodiments the antibody may be bound to a solid support to facilitate washing or separation, and/or labeled. (*e.g.*, with a marker selected from the group consisting of enzymes, fluorescent proteins, and radioisotopes).

Within other aspects of the present invention, isolated oligonucleotides
 25 are provided which hybridize to a nucleic acid molecule according to Sequence ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, or 18 or the complement thereto, under conditions of high stringency. Within further embodiments, the oligonucleotide may be found in the sequence which encodes Sequence ID Nos. 2, 4, 6, 8, 10, 12, 14, or 16. Within certain embodiments, the oligonucleotide is at least 15, 20, 30, 50, or 100 nucleotides in length.
 30 Within further embodiments, the oligonucleotide is labeled with another molecule (*e.g.*,

an enzyme, fluorescent molecule, or radioisotope). Also provided are primers which are capable of specifically amplifying all or a portion of the above-mentioned nucleic acid molecules which encode TGF-beta binding-proteins. As utilized herein, the term "specifically amplifying" should be understood to refer to primers which amplify the
5 aforementioned TGF-beta binding-proteins, and not other TGF-beta binding proteins such as Dan, Cerberus, Gremlin, or SCGF (U.S. Patent No. 5,780,263).

Within related aspects of the present invention, methods are provided for detecting a nucleic acid molecule which encodes a TGF-beta binding protein, comprising the steps of incubating an oligonucleotide as described above under
10 conditions of high stringency, and detecting hybridization of said oligonucleotide. Within certain embodiments, the oligonucleotide may be labeled and/or bound to a solid support.

Within other aspects of the present invention, ribozymes are provided which are capable of cleaving RNA which encodes one of the above-mentioned TGF-beta binding-proteins (*e.g.*, Sequence ID NOs. 2, 6, 8, 10, 12, 14, or 16). Such
15 ribozymes may be composed of DNA, RNA (including 2'-O-methyl ribonucleic acids), nucleic acid analogs (*e.g.*, nucleic acids having phosphorothioate linkages) or mixtures thereof. Also provided are nucleic acid molecules (*e.g.*, DNA or cDNA) which encode these ribozymes, and vectors which are capable of expressing or producing the
20 ribozymes. Representative examples of vectors include plasmids, retrotransposons, cosmids, and viral-based vectors (*e.g.*, viral vectors generated at least in part from a retrovirus, adenovirus, or, adeno-associated virus). Also provided are host cells (*e.g.*, human, dog, rat, or mouse cells) which contain these vectors. In certain embodiments, the host cell may be stably transformed with the vector.

25 Within further aspects of the invention, methods are provided for producing ribozymes either synthetically, or by *in vitro* or *in vivo* transcription. Within further embodiments, the ribozymes so produced may be further purified and/or formulated into pharmaceutical compositions (*e.g.*, the ribozyme or nucleic acid molecule encoding the ribozyme along with a pharmaceutically acceptable carrier or
30 diluent). Similarly, the antisense oligonucleotides and antibodies or other selected

molecules described herein may be formulated into pharmaceutical compositions.

Within other aspects of the present invention, antisense oligonucleotides are provided comprising a nucleic acid molecule which hybridizes to a nucleic acid molecule according to Sequence ID NOs. 1, 3, 5, 7, 9, 11, 13, or 15, or the complement thereto, and wherein said oligonucleotide inhibits the expression of TGF-beta binding protein as described herein (e.g., human BEER). Within various embodiments, the oligonucleotide is 15, 20, 25, 30, 35, 40, or 50 nucleotides in length. Preferably, the oligonucleotide is less than 100, 75, or 60 nucleotides in length. As should be readily evident, the oligonucleotide may be comprised of one or more nucleic acid analogs, ribonucleic acids, or deoxyribonucleic acids. Further, the oligonucleotide may be modified by one or more linkages, including for example, covalent linkage such as a phosphorothioate linkage, a phosphotriester linkage, a methyl phosphonate linkage, a methylene(methylimino) linkage, a morpholino linkage, an amide linkage, a polyamide linkage, a short chain alkyl intersugar linkage, a cycloalkyl intersugar linkage, a short chain heteroatomic intersugar linkage and a heterocyclic intersugar linkage. One representative example of a chimeric oligonucleotide is provided in U.S. Patent No. 5,989,912.

Within yet another aspect of the present invention, methods are provided for increasing bone mineralization, comprising introducing into a warm-blooded animal an effective amount of the ribozyme as described above. Within related aspects, such methods comprise the step of introducing into a patient an effective amount of the nucleic acid molecule or vector as described herein which is capable of producing the desired ribozyme, under conditions favoring transcription of the nucleic acid molecule to produce the ribozyme.

Within other aspects of the invention transgenic, non-human animals are provided. Within one embodiment a transgenic animal is provided whose germ cells and somatic cells contain a nucleic acid molecule encoding a TGF-beta binding-protein as described above which is operably linked to a promoter effective for the expression of the gene, the gene being introduced into the animal, or an ancestor of the animal, at an embryonic stage, with the proviso that said animal is not a human. Within other

embodiments, transgenic knockout animals are provided, comprising an animal whose germ cells and somatic cells comprise a disruption of at least one allele of an endogenous nucleic acid molecule which hybridizes to a nucleic acid molecule which encodes a TGF-binding protein as described herein, wherein the disruption prevents transcription of messenger RNA from said allele as compared to an animal without the disruption, with the proviso that the animal is not a human. Within various embodiments, the disruption is a nucleic acid deletion, substitution, or, insertion. Within other embodiments the transgenic animal is a mouse, rat, sheep, pig, or dog.

Within further aspects of the invention, kits are provided for the detection of TGF-beta binding-protein gene expression, comprising a container that comprises a nucleic acid molecule, wherein the nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15; (b) a nucleic acid molecule comprising the complement of the nucleotide sequence of (a); (c) a nucleic acid molecule that is a fragment of (a) or (b) of at least 15, 20, 30, 50, 75, or, 100 nucleotides in length. Also provided are kits for the detection of a TGF-beta binding-protein which comprise a container that comprise one of the TGF-beta binding protein antibodies described herein.

For example, within one aspect of the present invention methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) mixing one or more candidate molecules with TGF-beta-binding-protein encoded by the nucleic acid molecule according to claim 1 and a selected member of the TGF-beta family of proteins (*e.g.*, BMP 5 or 6), (b) determining whether the candidate molecule alters the signaling of the TGF-beta family member, or alters the binding of the TGF-beta binding-protein to the TGF-beta family member. Within certain embodiments, the molecule alters the ability of TGF-beta to function as a positive regulator of mesenchymal cell differentiation. Within this aspect of the present invention, the candidate molecule(s) may alter signaling or binding by, for example, either decreasing (*e.g.*, inhibiting), or increasing (*e.g.*, enhancing) signaling or binding.

Within yet another aspect, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the step of determining whether a selected molecule inhibits the binding of TGF-beta binding-protein to bone, or an analogue thereof. Representative examples of bone or analogues thereof include hydroxyapatite and primary human bone samples obtained via biopsy.

Within certain embodiments of the above-recited methods, the selected molecule is contained within a mixture of molecules and the methods may further comprise the step of isolating one or more molecules which are functional within the assay. Within yet other embodiments, TGF-beta family of proteins is bound to a solid support and the binding of TGF-beta binding-protein is measured or TGF-beta binding-protein are bound to a solid support and the binding of TGF-beta proteins are measured.

Utilizing methods such as those described above, a wide variety of molecules may be assayed for their ability to increase bone mineral content by inhibiting the binding of the TGF-beta binding-protein to the TGF-beta family of proteins. Representative examples of such molecules include proteins or peptides, organic molecules, and nucleic acid molecules.

Within other related aspects of the invention, methods are provided for increasing bone mineral content in a warm-blooded animal, comprising the step of administering to a warm-blooded animal a therapeutically effective amount of a molecule identified from the assays recited herein. Within another aspect, methods are provided for increasing bone mineral content in a warm-blooded animal, comprising the step of administering to a warm-blooded animal a therapeutically effective amount of a molecule which inhibits the binding of the TGF-beta binding-protein to the TGF-beta super-family of proteins, including bone morphogenic proteins (BMPs). Representative examples of suitable molecules include antisense molecules, ribozymes, ribozyme genes, and antibodies (e.g., a humanized antibody) which specifically recognize and alter the activity of the TGF-beta binding-protein.

Within another aspect of the present invention, methods are provided for increasing bone mineral content in a warm-blooded animal, comprising the steps of (a) introducing into cells which home to the bone a vector which directs the expression

of a molecule which inhibits the binding of the TGF-beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins (BMPs), and (b) administering the vector-containing cells to a warm-blooded animal. As utilized herein, it should be understood that cells "home to bone" if they localize within the bone matrix after peripheral administration. Within one embodiment, such methods further comprise, prior to the step of introducing, isolating cells from the marrow of bone which home to the bone. Within a further embodiment, the cells which home to bone are selected from the group consisting of CD34+ cells and osteoblasts.

Within other aspects of the present invention, molecules are provided (preferably isolated) which inhibit the binding of the TGF-beta binding-protein to the TGF-beta super-family of proteins.

Within further embodiments, the molecules may be provided as a composition, and can further comprise an inhibitor of bone resorption. Representative examples of such inhibitors include calcitonin, estrogen, a bisphosphonate, a growth factor having anti-resorptive activity and tamoxifen.

Representative examples of molecules which may be utilized in the afore-mentioned therapeutic contexts include, e.g., ribozymes, ribozyme genes, antisense molecules, and/or antibodies (e.g., humanized antibodies). Such molecules may depending upon their selection, used to alter, antagonize, or agonize the signalling or binding of a TGF-beta binding-protein family member as described herein

Within various embodiments of the invention, the above-described molecules and methods of treatment or prevention may be utilized on conditions such as osteoporosis, osteomalasia, periodontal disease, scurvy, Cushing's Disease, bone fracture and conditions due to limb immobilization and steroid usage.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures or compositions (e.g., plasmids, etc.), and are therefore incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustration comparing the amino acid sequence of Human Dan; Human Gremlin; Human Cerberus and Human Beer. Arrows indicate the Cysteine backbone.

5 Figure 2 summarizes the results obtained from surveying a variety of human tissues for the expression of a TGF-beta binding-protein gene, specifically, the Human Beer gene. A semi-quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) procedure was used to amplify a portion of the gene from first-strand cDNA synthesized from total RNA (described in more detail in EXAMPLE 2A).

10 Figure 3 summarizes the results obtained from RNA *in situ* hybridization of mouse embryo sections, using a cRNA probe that is complementary to the mouse Beer transcript (described in more detail in EXAMPLE 2B). Panel A is a transverse section of 10.5 dpc embryo. Panel B is a sagittal section of 12.5 dpc embryo and panels C and D are sagittal sections of 15.5 dpc embryos.

15 Figure 4 illustrates, by western blot analysis, the specificity of three different polyclonal antibodies for their respective antigens (described in more detail in EXAMPLE 4). Figure 4A shows specific reactivity of an anti-H. Beer antibody for H. Beer antigen, but not H. Dan or H. Gremlin. Figure 4B shows reactivity of an anti-H. Gremlin antibody for H. Gremlin antigen, but not H. Beer or H. Dan. Figure 4C shows
20 reactivity of an anti-H. Dan antibody for H. Dan, but not H. Beer or H. Gremlin.

Figure 5 illustrates, by western blot analysis, the selectivity of the TGF-beta binding-protein, Beer, for BMP-5 and BMP-6, but not BMP-4 (described in more detail in EXAMPLE 5).

25 Figure 6 demonstrates that the ionic interaction between the TGF-beta binding-protein, Beer, and BMP-5 has a dissociation constant in the 15-30 nM range.

DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

Prior to setting forth the invention in detail, it may be helpful to an understanding thereof to set forth definitions of certain terms and to list and to define the abbreviations that will be used hereinafter.

“Molecule” should be understood to include proteins or peptides (e.g., antibodies, recombinant binding partners, peptides with a desired binding affinity), nucleic acids (e.g., DNA, RNA, chimeric nucleic acid molecules, and nucleic acid analogues such as PNA); and organic or inorganic compounds.

“TGF-beta” should be understood to include any known or novel member of the TGF-beta super-family, which also includes bone morphogenic proteins (BMPs).

“TGF-beta receptor” should be understood to refer to the receptor specific for a particular member of the TGF-beta super-family (including bone morphogenic proteins (BMPs)).

“TGF-beta binding-protein” should be understood to refer to a protein with specific binding affinity for a particular member or subset of members of the TGF-beta super-family (including bone morphogenic proteins (BMPs)). Specific examples of TGF-beta binding-proteins include proteins encoded by Sequence ID Nos. 1, 5, 7, 9, 11, 13, and 15.

Inhibiting the “binding of the TGF-beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins (BMPs)” should be understood to refer to molecules which allow the activation of TGF-beta or bone morphogenic proteins (BMPs), or allow the binding of TGF-beta family members including bone morphogenic proteins (BMPs) to their respective receptors, by removing or preventing TGF-beta from binding to TGF-binding-protein. Such inhibition may be accomplished, for example, by molecules which inhibit the binding of the TGF-beta binding-protein to specific members of the TGF-beta super-family.

“Vector” refers to an assembly which is capable of directing the expression of desired protein. The vector must include transcriptional promoter

elements which are operably linked to the gene(s) of interest. The vector may be composed of either deoxyribonucleic acids ("DNA"), ribonucleic acids ("RNA"), or a combination of the two (e.g., a DNA-RNA chimeric). Optionally, the vector may include a polyadenylation sequence, one or more restriction sites, as well as one or more

5 selectable markers such as neomycin phosphotransferase or hygromycin phosphotransferase. Additionally, depending on the host cell chosen and the vector employed, other genetic elements such as an origin of replication, additional nucleic acid restriction sites, enhancers, sequences conferring inducibility of transcription, and selectable markers, may also be incorporated into the vectors described herein.

10 An "isolated nucleic acid molecule" is a nucleic acid molecule that is not integrated in the genomic DNA of an organism. For example, a DNA molecule that encodes a TGF-binding protein that has been separated from the genomic DNA of a eukaryotic cell is an isolated DNA molecule. Another example of an isolated nucleic acid molecule is a chemically-synthesized nucleic acid molecule that is not integrated in the

15 genome of an organism. The isolated nucleic acid molecule may be genomic DNA, cDNA, RNA, or composed at least in part of nucleic acid analogs.

An "isolated polypeptide" is a polypeptide that is essentially free from contaminating cellular components, such as carbohydrate, lipid, or other proteinaceous impurities associated with the polypeptide in nature. Within certain embodiments, a

20 particular protein preparation contains an isolated polypeptide if it appears nominally as a single band on SDS-PAGE gel with Coomassie Blue staining. "Isolated" when referring to organic molecules means that the compounds are greater than 90 percent pure utilizing methods which are well known in the art (e.g., NMR, melting point).

"Sclerosteosis" Sclerosteosis is a term that was applied by Hansen

25 (1967) (Hansen, H. G., Sklerosteose. In: Opitz, H.; Schmid, F., Handbuch der Kinderheilkunde. Berlin: Springer (pub.) 6 1967. Pp. 351-355) to a disorder similar to van Buchem hyperostosis corticalis generalisata but possibly differing in radiologic appearance of the bone changes and in the presence of asymmetric cutaneous syndactyly of the index and middle fingers in many cases. The jaw has an unusually

30 square appearance in this condition.

"Humanized antibodies" are recombinant proteins in which murine complementary determining regions of monoclonal antibodies have been transferred from heavy and light variable chains of the murine immunoglobulin into a human variable domain.

5 As used herein, an "antibody fragment" is a portion of an antibody such as F(ab')₂, F(ab)₂, Fab', Fab, and the like. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. For example, an anti-TGF-beta binding-protein monoclonal antibody fragment binds with an epitope of TGF-beta binding-protein.

10 The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex. For example, antibody fragments include isolated fragments consisting of the light chain variable region, "Fv" fragments consisting of the variable regions of the heavy and light chains, recombinant single chain polypeptide molecules in which light
15 and heavy variable regions are connected by a peptide linker ("sFv proteins"), and minimal recognition units consisting of the amino acid residues that mimic the hypervariable region.

A "detectable label" is a molecule or atom which can be conjugated to an antibody moiety to produce a molecule useful for diagnosis. Examples of detectable
20 labels include chelators, photoactive agents, radioisotopes, fluorescent agents, paramagnetic ions, enzymes, and other marker moieties.

As used herein, an "immunoconjugate" is a molecule comprising an anti-TGF-beta binding-protein antibody, or an antibody fragment, and a detectable label. An immunoconjugate has roughly the same, or only slightly reduced, ability to bind TGF-
25 beta binding-protein after conjugation as before conjugation.

Abbreviations: TGF-beta - "Transforming Growth Factor-beta"; TGF-bBP - "Transforming Growth Factor-beta binding-protein" (one representative TGF-bBP is designated "H. Beer"); BMP - "bone morphogenic protein"; PCR - "polymerase chain reaction"; RT-PCR - PCR process in which RNA is first transcribed

into DNA at the first step using reverse transcriptase (RT); cDNA - any DNA made by copying an RNA sequence into DNA form.

As noted above, the present invention provides a novel class of TGF-beta
 5 binding-proteins, as well as methods and compositions for increasing bone mineral
 content in warm-blooded animals. Briefly, the present inventions are based upon the
 unexpected discovery that a mutation in the gene which encodes a novel member of the
 TGF-beta binding-protein family results in a rare condition (sclerosteosis) characterized
 by bone mineral contents which are one- to four-fold higher than in normal individuals.
 10 Thus, as discussed in more detail below this discovery has led to the development of
 assays which may be utilized to select molecules which inhibit the binding of the TGF-
 beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins
 (BMPs), and methods of utilizing such molecules for increasing the bone mineral
 content of warm-blooded animals (including for example, humans).

15 DISCUSSION OF THE DISEASE KNOWN AS SCLEROSTEOSIS

Sclerosteosis is a term that was applied by Hansen (1967) (Hansen, H.
 G., Sklerosteose. In: Opitz, H.; Schmid, F., Handbuch der Kinderheilkunde. Berlin:
 Springer (pub.) 6 1967. Pp. 351-355) to a disorder similar to van Buchem hyperostosis
 corticalis generalisata but possibly differing in radiologic appearance of the bone
 20 changes and in the presence of asymmetric cutaneous syndactyly of the index and
 middle fingers in many cases.

Sclerosteosis is now known to be an autosomal semi-dominant disorder
 which is characterized by widely disseminated sclerotic lesions of the bone in the adult.
 The condition is progressive. Sclerosteosis also has a developmental aspect which is
 25 associated with syndactyly (two or more fingers are fused together). The Sclerosteosis
 Syndrome is associated with large stature and many affected individuals attain a height
 of six feet or more. The bone mineral content of homozygotes can be 1 to 6 fold over
 normal individuals and bone mineral density can be 1 to 4 fold above normal values
 (e.g., from unaffected siblings).

The Sclerosteosis Syndrome occurs primarily in Afrikaaners of Dutch descent in South Africa. Approximately 1/140 individuals in the Afrikaaner population are carriers of the mutated gene (heterozygotes). The mutation shows 100% penetrance. There are anecdotal reports of increased of bone mineral density in heterozygotes with
 5 no associated pathologies (syndactyly or skull overgrowth).

It appears at the present time that there is no abnormality of the pituitary-hypothalamus axis in Sclerosteosis. In particular, there appears to be no overproduction of growth hormone and cortisone. In addition, sex hormone levels are normal in affected individuals. However, bone turnover markers (osteoblast specific
 10 alkaline phosphatase, osteocalcin, type 1 procollagen C' propeptide (PICP), and total alkaline phosphatase; (see Comier, C., *Curr. Opin. in Rheu.* 7:243, 1995) indicate that there is hyperosteoblastic activity associated with the disease but that there is normal to slightly decreased osteoclast activity as measured by markers of bone resorption (pyridinoline, deoxypyridinoline, N-telopeptide, urinary hydroxyproline, plasma
 15 tartrate-resistant acid phosphatases and galactosyl hydroxylysine (see Comier, *supra*)).

Sclerosteosis is characterized by the continual deposition of bone throughout the skeleton during the lifetime of the affected individuals. In homozygotes the continual deposition of bone mineral leads to an overgrowth of bone in areas of the skeleton where there is an absence of mechanoreceptors (skull, jaw, cranium). In
 20 homozygotes with Sclerosteosis, the overgrowth of the bones of the skull leads to cranial compression and eventually to death due to excessive hydrostatic pressure on the brain stem. In all other parts of the skeleton there is a generalized and diffuse sclerosis. Cortical areas of the long bones are greatly thickened resulting in a substantial increase in bone strength. Trabecular connections are increased in thickness which in turn
 25 increases the strength of the trabecular bone. Sclerotic bones appear unusually opaque to x-rays.

As described in more detail in Example 1, the rare genetic mutation that is responsible for the Sclerosteosis syndrome has been localized to the region of human chromosome 17 that encodes a novel member of the TGF-beta binding-protein family
 30 (one representative example of which is designated "H. Beer"). As described in more

detail below, based upon this discovery, the mechanism of bone mineralization is more fully understood, allowing the development of assays for molecules which increase bone mineralization, and use of such molecules to increase bone mineral content, and in the treatment or prevention of a wide number of diseases.

5

TGF-BETA SUPER-FAMILY

The Transforming Growth Factor-beta (TGF-beta) super-family contains a variety of growth factors that share common sequence elements and structural motifs (at both the secondary and tertiary levels). This protein family is known to exert a wide spectrum of biological responses on a large variety of cell types. Many of them have important functions during the embryonal development in pattern formation and tissue specification; in adults they are involved, *e.g.*, in wound healing and bone repair and bone remodeling, and in the modulation of the immune system. In addition to the three TGF-beta's, the super-family includes the Bone Morphogenic Proteins (BMPs), Activins, Inhibins, Growth and Differentiation Factors (GDFs), and Glial-Derived Neurotrophic Factors (GDNFs). Primary classification is established through general sequence features that bin a specific protein into a general sub-family. Additional stratification within the sub-family is possible due to stricter sequence conservation between members of the smaller group. In certain instances, such as with BMP-5, BMP-6 and BMP-7, this can be as high as 75 percent amino acid homology between members of the smaller group. This level of identity enables a single representative sequence to illustrate the key biochemical elements of the sub-group that separates it from other members of the larger family.

TGF-beta signals by inducing the formation of hetero-oligomeric complexes of type I and type II receptors. The crystal structure of TGF-beta2 has been determined. The general fold of the TGF-beta2 monomer contains a stable, compact, cysteine knotlike structure formed by three disulphide bridges. Dimerization, stabilized by one disulphide bridge, is antiparallel.

TGF-beta family members initiate their cellular action by binding to receptors with intrinsic serine/threonine kinase activity. This receptor family consists of two subfamilies, denoted type I and type II receptors. Each member of the TGF-beta

family binds to a characteristic combination of type I and type II receptors, both of which are needed for signaling. In the current model for TGF-beta receptor activation, TGF-beta first binds to the type II receptor (TbR-II), which occurs in the cell membrane in an oligomeric form with activated kinase. Thereafter, the type I receptor (TbR-I), which can not bind ligand in the absence of TbR-II, is recruited into the complex. TbR-II then phosphorylates TbR-I predominantly in a domain rich in glycine and serine residues (GS domain) in the juxtamembrane region, and thereby activates TbR-I.

Thus far seven type I receptors and five type II receptors have been identified.

BONE MORPHOGENIC PROTEINS (BMPs) ARE KEY REGULATORY PROTEINS IN

DETERMINING BONE MINERAL DENSITY IN HUMANS

A major advance in the understanding of bone formation was the identification of the bone morphogenic proteins (BMPs), also known as osteogenic proteins (OPs), which regulate cartilage and bone differentiation in vivo. BMPs/OPs induce endochondral bone differentiation through a cascade of events which include formation of cartilage, hypertrophy and calcification of the cartilage, vascular invasion, differentiation of osteoblasts, and formation of bone. As described above, the BMPs/OPs (BMP 2-14, and osteogenic protein 1 and -2, OP-1 and OP-2) are members of the TGF-beta super-family. The striking evolutionary conservation between members the BMP/OP sub-family suggests that they are critical in the normal development and function of animals. Moreover, the presence of multiple forms of BMPs/OPs raises an important question about the biological relevance of this apparent redundancy. In addition to postfetal chondrogenesis and osteogenesis, the BMPs/OPs play multiple roles in skeletogenesis (including the development of craniofacial and dental tissues) and in embryonic development and organogenesis of parenchymatous organs, including the kidney. It is now understood that nature relies on common (and few) molecular mechanisms tailored to provide the emergence of specialized tissues and organs. The BMP/OP super-family is an elegant example of nature parsimony in programming multiple specialized functions deploying molecular isoforms with minor variation in amino acid motifs within highly conserved carboxy-terminal regions.

BMP ANTAGONISM

The BMP and Activin sub-families are subject to significant post-translational regulation. An intricate extracellular control system exists, whereby a high affinity antagonist is synthesized and exported, and subsequently complexes selectively
 5 with BMPs or activins to disrupt their biological activity (W.C. Smith (1999) *TIG* 15(1) 3-6). A number of these natural antagonists have been identified, and based on sequence divergence appear to have evolved independently due to the lack of primary sequence conservation. There has been no structural work to date on this class of proteins. Studies of these antagonists has highlighted a distinct preference for
 10 interacting and neutralizing BMP-2 and BMP-4. Furthermore, the mechanism of inhibition seems to differ for the different antagonists (S. Iemura et al. (1998) *Proc Natl Acad Sci USA* 95 9337-9342).

NOVEL TGF-BETA BINDING-PROTEINS

1. Background re: TGF-beta binding-proteins

15 As noted above, the present invention provides a novel class of TGF-beta binding-proteins that possess a nearly identical cysteine (disulfide) scaffold when compared to Human DAN, Human Gremlin, and Human Cerberus, and SCGF (U.S. Patent No. 5,780,263) but almost no homology at the nucleotide level (for background information, see generally Hsu, D.R., Economides, A.N., Wang, X., Eimon, P.M.,
 20 Harland, R.M., "The *Xenopus* Dorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities," *Molecular Cell* 1:673-683, 1998).

One representative example of the novel class of TGF-beta binding-proteins is disclosed in Sequence ID Nos. 1, 5, 9, 11, 13, and 15. Representative members of this class of binding proteins should also be understood to include variants
 25 of the TGF-beta binding-protein (e.g., Sequence ID Nos. 5 and 7). As utilized herein, a "TGF-beta binding-protein variant gene" refers to nucleic acid molecules that encode a polypeptide having an amino acid sequence that is a modification of SEQ ID Nos: 2, 10, 12, 14 or 16. Such variants include naturally-occurring polymorphisms or allelic variants of TGF-beta binding-protein genes, as well as synthetic genes that contain

conservative amino acid substitutions of these amino acid sequences. Additional variant forms of a TGF-beta binding-protein gene are nucleic acid molecules that contain insertions or deletions of the nucleotide sequences described herein. TGF-beta binding-protein variant genes can be identified by determining whether the genes
 5 hybridize with a nucleic acid molecule having the nucleotide sequence of SEQ ID Nos: 1, 5, 7, 9, 11, 13, or 15 under stringent conditions. In addition, TGF-beta binding-protein variant genes should encode a protein having a cysteine backbone.

As an alternative, TGF-beta binding-protein variant genes can be identified by sequence comparison. As used herein, two amino acid sequences have
 10 "100% amino acid sequence identity" if the amino acid residues of the two amino acid sequences are the same when aligned for maximal correspondence. Similarly, two nucleotide sequences have "100% nucleotide sequence identity" if the nucleotide residues of the two nucleotide sequences are the same when aligned for maximal correspondence. Sequence comparisons can be performed using standard software
 15 programs such as those included in the LASERGENE bioinformatics computing suite, which is produced by DNASTAR (Madison, Wisconsin). Other methods for comparing two nucleotide or amino acid sequences by determining optimal alignment are well-known to those of skill in the art (see, for example, Peruski and Peruski, *The Internet and the New Biology: Tools for Genomic and Molecular Research* (ASM Press, Inc. 1997), Wu et al. (eds.), "Information Superhighway and Computer Databases of Nucleic
 20 Acids and Proteins," in *Methods in Gene Biotechnology*, pages 123-151 (CRC Press, Inc. 1997), and Bishop (ed.), *Guide to Human Genome Computing*, 2nd Edition (Academic Press, Inc. 1998)).

A variant TGF-beta binding-protein should have at least a 50% amino
 25 acid sequence identity to SEQ ID NOs: 2, 6, 10, 12, 14 or 16 and preferably, greater than 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity. Alternatively, TGF-beta binding-protein variants can be identified by having at least a 70% nucleotide sequence identity to SEQ ID NOs: 1, 5, 9, 11, 13 or 15. Moreover, the present invention contemplates TGF-beta binding-protein gene variants having greater than 75%, 80%,
 30 85%, 90%, or 95% identity to SEQ ID NO:1. Regardless of the particular method used

to identify a TGF-beta binding-protein variant gene or variant TGF-beta binding-protein, a variant TGF-beta binding-protein or a polypeptide encoded by a variant TGF-beta binding-protein gene can be functionally characterized by, for example, its ability to bind to and/or inhibit the signaling of a selected member of the TGF-beta family of proteins, or by its ability to bind specifically to an anti-TGF-beta binding-protein antibody.

The present invention includes functional fragments of TGF-beta binding-protein genes. Within the context of this invention, a "functional fragment" of a TGF-beta binding-protein gene refers to a nucleic acid molecule that encodes a portion of a TGF-beta binding-protein polypeptide which either (1) possesses the above-noted function activity, or (2) specifically binds with an anti-TGF-beta binding-protein antibody. For example, a functional fragment of a TGF-beta binding-protein gene described herein comprises a portion of the nucleotide sequence of SEQ ID Nos: 1, 5, 9, 11, 13, or 15.

2. Isolation of the TGF-beta binding-protein gene

DNA molecules encoding a binding-protein gene can be obtained by screening a human cDNA or genomic library using polynucleotide probes based upon, for example, SEQ ID NO:1.

For example, the first step in the preparation of a cDNA library is to isolate RNA using methods well-known to those of skill in the art. In general, RNA isolation techniques must provide a method for breaking cells, a means of inhibiting RNase-directed degradation of RNA, and a method of separating RNA from DNA, protein, and polysaccharide contaminants. For example, total RNA can be isolated by freezing tissue in liquid nitrogen, grinding the frozen tissue with a mortar and pestle to lyse the cells, extracting the ground tissue with a solution of phenol/chloroform to remove proteins, and separating RNA from the remaining impurities by selective precipitation with lithium chloride (see, for example, Ausubel et al. (eds.), *Short Protocols in Molecular Biology*, 3rd Edition, pages 4-1 to 4-6 (John Wiley & Sons 1995) ["Ausubel (1995)"]; Wu et al., *Methods in Gene Biotechnology*, pages 33-41 (CRC Press, Inc. 1997)

["Wu (1997)"].

Alternatively, total RNA can be isolated by extracting ground tissue with guanidinium isothiocyanate, extracting with organic solvents, and separating RNA from contaminants using differential centrifugation (see, for example, Ausubel (1995) at pages 4-1 to 4-6; Wu (1997) at pages 33-41).

In order to construct a cDNA library, poly(A)⁺ RNA must be isolated from a total RNA preparation. Poly(A)⁺ RNA can be isolated from total RNA by using the standard technique of oligo(dT)-cellulose chromatography (see, for example, Ausubel (1995) at pages 4-11 to 4-12).

Double-stranded cDNA molecules are synthesized from poly(A)⁺ RNA using techniques well-known to those in the art. (see, for example, Wu (1997) at pages 41-46). Moreover, commercially available kits can be used to synthesize double-stranded cDNA molecules. For example, such kits are available from Life Technologies, Inc. (Gaithersburg, Maryland), CLONTECH Laboratories, Inc. (Palo Alto, California), Promega Corporation (Madison, Wisconsin) and Stratagene Cloning Systems (La Jolla, California).

The basic approach for obtaining TGF-beta binding-protein cDNA clones can be modified by constructing a subtracted cDNA library which is enriched in TGF-binding-protein-specific cDNA molecules. Techniques for constructing subtracted libraries are well-known to those of skill in the art (see, for example, Sargent, "Isolation of Differentially Expressed Genes," in *Meth. Enzymol.* 152:423, 1987, and Wu et al. (eds.), "Construction and Screening of Subtracted and Complete Expression cDNA Libraries," in *Methods in Gene Biotechnology*, pages 29-65 (CRC Press, Inc. 1997)).

Various cloning vectors are appropriate for the construction of a cDNA library. For example, a cDNA library can be prepared in a vector derived from bacteriophage, such as a λ gt10 vector (see, for example, Huynh et al., "Constructing and Screening cDNA Libraries in λ gt10 and λ gt11," in *DNA Cloning: A Practical Approach Vol. I*, Glover (ed.), page 49 (IRL Press, 1985); Wu (1997) at pages 47-52).

Alternatively, double-stranded cDNA molecules can be inserted into a plasmid vector, such as a pBluescript vector (Stratagene Cloning Systems; La Jolla,

California), a LambdaGEM-4 (Promega Corp.; Madison, Wisconsin) or other commercially available vectors. Suitable cloning vectors also can be obtained from the American Type Culture Collection (Rockville, Maryland).

In order to amplify the cloned cDNA molecules, the cDNA library is
5 inserted into a prokaryotic host, using standard techniques. For example, a cDNA library can be introduced into competent *E. coli* DH5 cells, which can be obtained from Life Technologies, Inc. (Gaithersburg, Maryland).

A human genomic DNA library can be prepared by means well-known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-
10 327). Genomic DNA can be isolated by lysing tissue with the detergent Sarkosyl, digesting the lysate with proteinase K, clearing insoluble debris from the lysate by centrifugation, precipitating nucleic acid from the lysate using isopropanol, and purifying resuspended DNA on a cesium chloride density gradient.

DNA fragments that are suitable for the production of a genomic library
15 can be obtained by the random shearing of genomic DNA or by the partial digestion of genomic DNA with restriction endonucleases. Genomic DNA fragments can be inserted into a vector, such as a bacteriophage or cosmid vector, in accordance with conventional techniques, such as the use of restriction enzyme digestion to provide appropriate termini, the use of alkaline phosphatase treatment to avoid undesirable joining of DNA molecules,
20 and ligation with appropriate ligases. Techniques for such manipulation are well-known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-327).

Nucleic acid molecules that encode a TGF-beta binding-protein gene can also be obtained using the polymerase chain reaction (PCR) with oligonucleotide
25 primers having nucleotide sequences that are based upon the nucleotide sequences of the human TGF-beta binding-protein gene, as described herein. General methods for screening libraries with PCR are provided by, for example, Yu et al., "Use of the Polymerase Chain Reaction to Screen Phage Libraries," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.),
30 pages 211-215 (Humana Press, Inc. 1993). Moreover, techniques for using PCR to

isolate related genes are described by, for example, Preston, "Use of Degenerate Oligonucleotide Primers and the Polymerase Chain Reaction to Clone Gene Family Members," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.), pages 317-337 (Humana Press, Inc. 1993).

5 Alternatively, human genomic libraries can be obtained from commercial sources such as Research Genetics (Huntsville, AL) and the American Type Culture Collection (Rockville, Maryland).

A library containing cDNA or genomic clones can be screened with one or more polynucleotide probes based upon SEQ ID NO:1, using standard methods (*see, for*
10 *example*, Ausubel (1995) at pages 6-1 to 6-11).

Anti-TGF-beta binding-protein antibodies, produced as described below, can also be used to isolate DNA sequences that encode TGF-beta binding-protein genes from cDNA libraries. For example, the antibodies can be used to screen λ gt11 expression libraries; or the antibodies can be used for immunoscreening following
15 hybrid selection and translation (*see, for example*, Ausubel (1995) at pages 6-12 to 6-16; Margolis et al., "Screening λ expression libraries with antibody and protein probes," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), pages 1-14 (Oxford University Press 1995)).

The sequence of a TGF-beta binding-protein cDNA or TGF-beta
20 binding-protein genomic fragment can be determined using standard methods. Moreover, the identification of genomic fragments containing a TGF-beta binding-protein promoter or regulatory element can be achieved using well-established techniques, such as deletion analysis (*see, generally*, Ausubel (1995)).

As an alternative, a TGF-beta binding-protein gene can be obtained by
25 synthesizing DNA molecules using mutually priming long oligonucleotides and the nucleotide sequences described herein (*see, for example*, Ausubel (1995) at pages 8-8 to 8-9). Established techniques using the polymerase chain reaction provide the ability to synthesize DNA molecules at least two kilobases in length (Adang et al., *Plant Molec. Biol.* 21:1131, 1993; Bambot et al., *PCR Methods and Applications* 2:266, 1993; Dillon
30 et al., "Use of the Polymerase Chain Reaction for the Rapid Construction of Synthetic

Genes," in *Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications*, White (ed.), pages 263-268, (Humana Press, Inc. 1993); Holowachuk et al., *PCR Methods Appl.* 4:299, 1995).

3. Production of TGF-beta binding-protein genes

5 Nucleic acid molecules encoding variant TGF-beta binding-protein genes can be obtained by screening various cDNA or genomic libraries with polynucleotide probes having nucleotide sequences based upon SEQ ID NO:1, 5, 9, 11, 13, or 15, using procedures described above. TGF-beta binding-protein gene variants can also be constructed synthetically. For example, a nucleic acid molecule can be
10 devised that encodes a polypeptide having a conservative amino acid change, compared with the amino acid sequence of SEQ ID NOs: 2, 6, 8, 10, 12, 14, or 16. That is, variants can be obtained that contain one or more amino acid substitutions of SEQ ID NOs: 2, 6, 8, 10, 12, 14 or 16, in which an alkyl amino acid is substituted for an alkyl amino acid in a TGF-beta binding-protein amino acid sequence, an aromatic amino acid
15 is substituted for an aromatic amino acid in a TGF-beta binding-protein amino acid sequence, a sulfur-containing amino acid is substituted for a sulfur-containing amino acid in a TGF-beta binding-protein amino acid sequence, a hydroxy-containing amino acid is substituted for a hydroxy-containing amino acid in a TGF-beta binding-protein amino acid sequence, an acidic amino acid is substituted for an acidic amino acid in a
20 TGF-beta binding-protein amino acid sequence, a basic amino acid is substituted for a basic amino acid in a TGF-beta binding-protein amino acid sequence, or a dibasic monocarboxylic amino acid is substituted for a dibasic monocarboxylic amino acid in a TGF-beta binding-protein amino acid sequence.

Among the common amino acids, for example, a "conservative amino
25 acid substitution" is illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine. In making such substitutions, it is important to, where possible, maintain the cysteine

backbone outlined in Figure 1.

Conservative amino acid changes in a TGF-beta binding-protein gene can be introduced by substituting nucleotides for the nucleotides recited in SEQ ID NO:1. Such "conservative amino acid" variants can be obtained, for example, by
 5 oligonucleotide-directed mutagenesis, linker-scanning mutagenesis, mutagenesis using the polymerase chain reaction, and the like (see Ausubel (1995) at pages 8-10 to 8-22; and McPherson (ed.), *Directed Mutagenesis: A Practical Approach* (IRL Press 1991)). The functional ability of such variants can be determined using a standard method, such as the assay described herein. Alternatively, a variant TGF-beta binding-protein
 10 polypeptide can be identified by the ability to specifically bind anti-TGF-beta binding-protein antibodies.

Routine deletion analyses of nucleic acid molecules can be performed to obtain "functional fragments" of a nucleic acid molecule that encodes a TGF-beta binding-protein polypeptide. As an illustration, DNA molecules having the nucleotide
 15 sequence of SEQ ID NO:1 can be digested with *Bal31* nuclease to obtain a series of nested deletions. The fragments are then inserted into expression vectors in proper reading frame, and the expressed polypeptides are isolated and tested for activity, or for the ability to bind anti-TGF-beta binding-protein antibodies. One alternative to exonuclease digestion is to use oligonucleotide-directed mutagenesis to introduce
 20 deletions or stop codons to specify production of a desired fragment. Alternatively, particular fragments of a TGF-beta binding-protein gene can be synthesized using the polymerase chain reaction.

Standard techniques for functional analysis of proteins are described by, for example, Treuter et al., *Molec. Gen. Genet.* 240:113, 1993; Content et al.,
 25 "Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon," in *Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems*, Cantell (ed.), pages 65-72 (Nijhoff 1987); Herschman, "The EGF Receptor," in *Control of Animal Cell Proliferation, Vol. 1*, Boynton et al., (eds.) pages 169-199 (Academic Press 1985); Coumailleau et al., *J. Biol. Chem.*
 30 270:29270, 1995; Fukunaga et al., *J. Biol. Chem.* 270:25291, 1995; Yamaguchi et al.,

Biochem. Pharmacol. 50:1295, 1995; and Meisel et al., *Plant Molec. Biol.* 30:1, 1996.

The present invention also contemplates functional fragments of a TGF-beta binding-protein gene that have conservative amino acid changes.

A TGF-beta binding-protein variant gene can be identified on the basis of structure by determining the level of identity with nucleotide and amino acid sequences of SEQ ID NOS: 1, 5, 9, 11, 13, or, 15 and 2, 6, 10, 12, 14, or 16, as discussed above. An alternative approach to identifying a variant gene on the basis of structure is to determine whether a nucleic acid molecule encoding a potential variant TGF-beta binding-protein gene can hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID Nos: 1, 5, 9, 11, 13, or, 15, or a portion thereof of at least 15 or 20 nucleotides in length. As an illustration of stringent hybridization conditions, a nucleic acid molecule having a variant TGF-beta binding-protein sequence can bind with a fragment of a nucleic acid molecule having a sequence from SEQ ID NO:1 in a buffer containing, for example, 5xSSPE (1xSSPE = 180 mM sodium chloride, 10 mM sodium phosphate, 1 mM EDTA (pH 7.7), 5xDenhardt's solution (100xDenhardt's = 2% (w/v) bovine serum albumin, 2% (w/v) Ficoll, 2% (w/v) polyvinylpyrrolidone) and 0.5% SDS incubated overnight at 55-60°C. Post-hybridization washes at high stringency are typically performed in 0.5xSSC (1xSSC = 150 mM sodium chloride, 15 mM trisodium citrate) or in 0.5xSSPE at 55-60°C.

Regardless of the particular nucleotide sequence of a variant TGF-beta binding-protein gene, the gene encodes a polypeptide that can be characterized by its functional activity, or by the ability to bind specifically to an anti-TGF-beta binding-protein antibody. More specifically, variant TGF-beta binding-protein genes encode polypeptides which exhibit at least 50%, and preferably, greater than 60, 70, 80 or 90%, of the activity of polypeptides encoded by the human TGF-beta binding-protein gene described herein.

4. Production of TGF-beta binding-protein in Cultured Cells

To express a TGF-beta binding-protein gene, a nucleic acid molecule

encoding the polypeptide must be operably linked to regulatory sequences that control transcriptional expression in an expression vector and then introduced into a host cell. In addition to transcriptional regulatory sequences, such as promoters and enhancers, expression vectors can include translational regulatory sequences and a marker gene
 5 which is suitable for selection of cells that carry the expression vector.

Expression vectors that are suitable for production of a foreign protein in eukaryotic cells typically contain (1) prokaryotic DNA elements coding for a bacterial replication origin and an antibiotic resistance marker to provide for the growth and selection of the expression vector in a bacterial host; (2) eukaryotic DNA elements that
 10 control initiation of transcription, such as a promoter; and (3) DNA elements that control the processing of transcripts, such as a transcription termination/polyadenylation sequence.

TGF-beta binding-proteins of the present invention are preferably expressed in mammalian cells. Examples of mammalian host cells include African green
 15 monkey kidney cells (Vero; ATCC CRL 1587), human embryonic kidney cells (293-HEK; ATCC CRL 1573), baby hamster kidney cells (BHK-21; ATCC CRL 8544), canine kidney cells (MDCK; ATCC CCL 34), Chinese hamster ovary cells (CHO-K1; ATCC CCL61), rat pituitary cells (GH1; ATCC CCL82), HeLa S3 cells (ATCC CCL2.2), rat hepatoma cells (H-4-II-E; ATCC CRL 1548) SV40-transformed monkey kidney cells
 20 (COS-1; ATCC CRL 1650) and murine embryonic cells (NIH-3T3; ATCC CRL 1658).

For a mammalian host, the transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, simian virus, or the like, in which the regulatory signals are associated with a particular gene which has a high level of expression. Suitable transcriptional and translational
 25 regulatory sequences also can be obtained from mammalian genes, such as actin, collagen, myosin, and metallothionein genes.

Transcriptional regulatory sequences include a promoter region sufficient to direct the initiation of RNA synthesis. Suitable eukaryotic promoters include the promoter of the mouse metallothionein I gene [Hamer et al., *J. Molec. Appl. Genet.* 1:273,
 30 1982], the *TK* promoter of *Herpes* virus [McKnight, *Cell* 31:355, 1982], the *SV40* early

promoter [Benoist et al., *Nature* 290:304, 1981], the Rous sarcoma virus promoter [Gorman et al., *Proc. Nat'l Acad. Sci. USA* 79:6777, 1982], the cytomegalovirus promoter [Foecking et al., *Gene* 45:101, 1980], and the mouse mammary tumor virus promoter (see, generally, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 163-181 (John Wiley & Sons, Inc. 1996)).

Alternatively, a prokaryotic promoter, such as the bacteriophage T3 RNA polymerase promoter, can be used to control TGF-beta binding-protein gene expression in mammalian cells if the prokaryotic promoter is regulated by a eukaryotic promoter (Zhou et al., *Mol. Cell. Biol.* 10:4529, 1990; Kaufman et al., *Nucl. Acids Res.* 19:4485, 1991).

TGF-beta binding-protein genes may also be expressed in bacterial, yeast, insect, or plant cells. Suitable promoters that can be used to express TGF-beta binding-protein polypeptides in a prokaryotic host are well-known to those of skill in the art and include promoters capable of recognizing the T4, T3, Sp6 and T7 polymerases, the P_R and P_L promoters of bacteriophage lambda, the *trp*, *recA*, heat shock, *lacUV5*, *tac*, *lpp-lacSpr*, *phoA*, and *lacZ* promoters of *E. coli*; promoters of *B. subtilis*, the promoters of the bacteriophages of *Bacillus*, *Streptomyces* promoters, the *int* promoter of bacteriophage lambda, the *bla* promoter of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene. Prokaryotic promoters have been reviewed by Glick, *J. Ind. Microbiol.* 1:277, 1987, Watson et al., *Molecular Biology of the Gene*, 4th Ed. (Benjamin Cummins 1987), and by Ausubel et al. (1995).

Preferred prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Suitable strains of *E. coli* include BL21(DE3), BL21(DE3)pLysS, BL21(DE3)pLysE, DH1, DH4I, DH5, DH5I, DH5IF', DH5IMCR, DH10B, DH10B/p3, DH11S, C600, HB101, JM101, JM105, JM109, JM110, K38, RR1, Y1088, Y1089, CSH18, ER1451, and ER1647 (see, for example, Brown (Ed.), *Molecular Biology Labfax* (Academic Press 1991)). Suitable strains of *Bacillus subtilis* include BR151, YB886, MI119, MI120, and B170 (see, for example, Hardy, "Bacillus Cloning Methods," in *DNA Cloning: A Practical Approach*, Glover (Ed.) (IRL Press 1985)).

Methods for expressing proteins in prokaryotic hosts are well-known to

those of skill in the art (see, for example, Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), page 15 (Oxford University Press 1995); Ward et al., "Genetic Manipulation and
 5 Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, page 137 (Wiley-Liss, Inc. 1995); and Georgiou, "Expression of Proteins in Bacteria," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), page 101 (John Wiley & Sons, Inc. 1996)).

The baculovirus system provides an efficient means to introduce cloned
 10 *TGF-beta binding-protein* genes into insect cells. Suitable expression vectors are based upon the *Autographa californica* multiple nuclear polyhedrosis virus (AcMNPV), and contain well-known promoters such as *Drosophila* heat shock protein (hsp) 70 promoter, *Autographa californica* nuclear polyhedrosis virus immediate-early gene promoter (*ie-1*) and the delayed early 39K promoter, baculovirus p10 promoter, and the
 15 *Drosophila* metallothionein promoter. Suitable insect host cells include cell lines derived from IPLB-Sf-21, a *Spodoptera frugiperda* pupal ovarian cell line, such as Sf9 (ATCC CRL 1711), Sf21AE, and Sf21 (Invitrogen Corporation; San Diego, CA), as well as *Drosophila* Schneider-2 cells. Established techniques for producing recombinant proteins in baculovirus systems are provided by Bailey et al.,
 20 "Manipulation of Baculovirus Vectors," in *Methods in Molecular Biology, Volume 7: Gene Transfer and Expression Protocols*, Murray (ed.), pages 147-168 (The Humana Press, Inc. 1991), by Patel et al., "The baculovirus expression system," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), pages 205-244 (Oxford University Press 1995), by Ausubel (1995) at pages 16-37 to 16-57, by Richardson
 25 (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc. 1995), and by Lucknow, "Insect Cell Expression Technology," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 183-218 (John Wiley & Sons, Inc. 1996).

Promoters for expression in yeast include promoters from *GALI* (galactose), *PGK* (phosphoglycerate kinase), *ADH* (alcohol dehydrogenase), *AOXI*
 30 (alcohol oxidase), *HIS4* (histidinol dehydrogenase), and the like. Many yeast cloning

vectors have been designed and are readily available. These vectors include YIp-based vectors, such as YIp5, YRp vectors, such as YRp17, YEpl vectors such as YEpl3 and YCp vectors, such as YCp19. One skilled in the art will appreciate that there are a wide variety of suitable vectors for expression in yeast cells.

5 Expression vectors can also be introduced into plant protoplasts, intact plant tissues, or isolated plant cells. General methods of culturing plant tissues are provided, for example, by Miki et al., "Procedures for Introducing Foreign DNA into Plants," in *Methods in Plant Molecular Biology and Biotechnology*, Glick et al. (eds.), pages 67-88 (CRC Press, 1993).

10 An expression vector can be introduced into host cells using a variety of standard techniques including calcium phosphate transfection, liposome-mediated transfection, microprojectile-mediated delivery, electroporation, and the like. Preferably, the transfected cells are selected and propagated to provide recombinant host cells that comprise the expression vector stably integrated in the host cell genome. Techniques for
15 introducing vectors into eukaryotic cells and techniques for selecting such stable transformants using a dominant selectable marker are described, for example, by Ausubel (1995) and by Murray (ed.), *Gene Transfer and Expression Protocols* (Humana Press 1991). Methods for introducing expression vectors into bacterial, yeast, insect, and plant cells are also provided by Ausubel (1995).

20 General methods for expressing and recovering foreign protein produced by a mammalian cell system is provided by, for example, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 163 (Wiley-Liss, Inc. 1996). Standard techniques for recovering protein produced by a bacterial system is provided by, for example,
25 Grishammer et al., "Purification of over-produced proteins from *E. coli* cells," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), pages 59-92 (Oxford University Press 1995). Established methods for isolating recombinant proteins from a baculovirus system are described by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc., 1995).

30 More generally, TGF-beta binding-protein can be isolated by standard

techniques, such as affinity chromatography, size exclusion chromatography, ion exchange chromatography, HPLC and the like. Additional variations in TGF-beta binding-protein isolation and purification can be devised by those of skill in the art. For example, anti-TGF-beta binding-protein antibodies, obtained as described below, can be used to isolate large quantities of protein by immunoaffinity purification.

5. Production of Antibodies to TGF-beta binding-proteins

Antibodies to TGF-beta binding-protein can be obtained, for example, using the product of an expression vector as an antigen. Particularly useful anti-TGF-beta binding-protein antibodies "bind specifically" with TGF-beta binding-protein of Sequence ID Nos. 2, 6, 10, 12, 14, or 16, but not to other TGF-beta binding-proteins such as Dan, Cerberus, SCGF, or Gremlin. Antibodies of the present invention (including fragments and derivatives thereof) may be a polyclonal or, especially a monoclonal antibody. The antibody may belong to any immunoglobulin class, and may be for example an IgG, for example IgG₁, IgG₂, IgG₃, IgG₄; IgE; IgM; or IgA antibody. It may be of animal, for example mammalian origin, and may be for example a murine, rat, human or other primate antibody. Where desired the antibody may be an internalising antibody.

Polyclonal antibodies to recombinant TGF-beta binding-protein can be prepared using methods well-known to those of skill in the art (see, for example, Green et al., "Production of Polyclonal Antisera," in *Immunochemical Protocols* (Manson, ed.), pages 1-5 (Humana Press 1992); Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), page 15 (Oxford University Press 1995)). Although polyclonal antibodies are typically raised in animals such as rats, mice, rabbits, goats, or sheep, an anti-TGF-beta binding-protein antibody of the present invention may also be derived from a subhuman primate antibody. General techniques for raising diagnostically and therapeutically useful antibodies in baboons may be found, for example, in Goldenberg et al., international patent publication No. WO 91/11465 (1991), and in Losman et al., *Int. J. Cancer* 46:310,

1990.

The antibody should comprise at least a variable region domain. The variable region domain may be of any size or amino acid composition and will generally comprise at least one hypervariable amino acid sequence responsible for antigen binding embedded in a framework sequence. In general terms the variable (V) region domain may be any suitable arrangement of immunoglobulin heavy (V_H) and/or light (V_L) chain variable domains. Thus for example the V region domain may be monomeric and be a V_H or V_L domain where these are capable of independently binding antigen with acceptable affinity. Alternatively the V region domain may be dimeric and contain V_H - V_H , V_H - V_L , or V_L - V_L dimers in which the V_H and V_L chains are non-covalently associated (abbreviated hereinafter as F_v). Where desired, however, the chains may be covalently coupled either directly, for example via a disulphide bond between the two variable domains, or through a linker, for example a peptide linker, to form a single chain domain (abbreviated hereinafter as scF_v).

The variable region domain may be any naturally occurring variable domain or an engineered version thereof. By engineered version is meant a variable region domain which has been created using recombinant DNA engineering techniques. Such engineered versions include those created for example from natural antibody variable regions by insertions, deletions or changes in or to the amino acid sequences of the natural antibodies. Particular examples of this type include those engineered variable region domains containing at least one CDR and optionally one or more framework amino acids from one antibody and the remainder of the variable region domain from a second antibody.

The variable region domain may be covalently attached at a C-terminal amino acid to at least one other antibody domain or a fragment thereof. Thus, for example where a V_H domain is present in the variable region domain this may be linked to an immunoglobulin C_H1 domain or a fragment thereof. Similarly a V_L domain may be

linked to a C_K domain or a fragment thereof. In this way for example the antibody may be a Fab fragment wherein the antigen binding domain contains associated V_H and V_L domains covalently linked at their C-termini to a CH1 and C_K domain respectively. The CH1 domain may be extended with further amino acids, for example to provide a hinge region domain as found in a Fab' fragment, or to provide further domains, such as antibody CH2 and CH3 domains.

Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells (see, for example, Larrick et al., *Methods: A Companion to Methods in Enzymology* 2:106, 1991; Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies," in *Monoclonal Antibodies: Production, Engineering and Clinical Application*, Ritter et al. (eds.), page 166 (Cambridge University Press 1995); and Ward et al., "Genetic Manipulation and Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, Birch et al., (eds.), page 137 (Wiley-Liss, Inc. 1995)).

Antibodies for use in the invention may in general be monoclonal (prepared by conventional immunisation and cell fusion procedures) or in the case of fragments, derived therefrom using any suitable standard chemical e.g. reduction or enzymatic cleavage and/or digestion techniques, for example by treatment with pepsin.

More specifically, monoclonal anti-TGF-beta binding-protein antibodies can be generated utilizing a variety of techniques. Rodent monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art (see, for example, Kohler et al., *Nature* 256:495, 1975; and Coligan et al. (eds.), *Current Protocols in Immunology*, 1:2.5.1-2.6.7 (John Wiley & Sons 1991) ["Coligan"]; Picksley et al., "Production of monoclonal antibodies against proteins expressed in *E. coli*," in *DNA Cloning 2: Expression Systems, 2nd Edition*, Glover et al. (eds.), page 93 (Oxford University Press 1995)).

Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising a TGF-beta binding-protein gene product, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce
 5 hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

In addition, an anti-TGF-beta binding-protein antibody of the present invention may be derived from a human monoclonal antibody. Human monoclonal
 10 antibodies are obtained from transgenic mice that have been engineered to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for
 15 human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described, for example, by Green et al., *Nature Genet.* 7:13, 1994; Lonberg et al., *Nature* 368:856, 1994; and Taylor et al., *Int. Immun.* 6:579, 1994.

Monoclonal antibodies can be isolated and purified from hybridoma
 20 cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography (see, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3; Baines et al., "Purification of Immunoglobulin G (IgG)," in *Methods in Molecular Biology, Vol. 10*, pages 79-104 (The Humana Press, Inc. 1992)).

25 For particular uses, it may be desirable to prepare fragments of anti-TGF-beta binding-protein antibodies. Such antibody fragments can be obtained, for example, by proteolytic hydrolysis of the antibody. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. As an illustration, antibody fragments can be produced by enzymatic cleavage of
 30 antibodies with pepsin to provide a 5S fragment denoted F(ab')₂. This fragment can be

further cleaved using a thiol reducing agent to produce 3.5S Fab' monovalent fragments. Optionally, the cleavage reaction can be performed using a blocking group for the sulfhydryl groups that result from cleavage of disulfide linkages. As an alternative, an enzymatic cleavage using pepsin produces two monovalent Fab
 5 fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patent No. 4,331,647, Nisonoff et al., *Arch Biochem. Biophys.* 89:230, 1960, Porter, *Biochem. J.* 73:119, 1959, Edelman et al., in *Methods in Enzymology* 1:422 (Academic Press 1967), and by Coligan at pages 2.8.1-2.8.10 and 2.10.-2.10.4.

Other methods of cleaving antibodies, such as separation of heavy chains
 10 to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

Alternatively, the antibody may be a recombinant or engineered antibody obtained by the use of recombinant DNA techniques involving the manipulation and re-
 15 expression of DNA encoding antibody variable and/or constant regions. Such DNA is known and/or is readily available from DNA libraries including for example phage-antibody libraries (see Chiswell, D J and McCafferty, J. *Tibtech.* 10 80-84 (1992)) or where desired can be synthesised. Standard molecular biology and/or chemistry procedures may be used to sequence and manipulate the DNA, for example, to introduce
 20 codons to create cysteine residues, to modify, add or delete other amino acids or domains as desired.

From here, one or more replicable expression vectors containing the DNA may be prepared and used to transform an appropriate cell line, e.g. a non-producing myeloma cell line, such as a mouse NSO line or a bacterial, e.g. *E.coli* line, in which
 25 production of the antibody will occur. In order to obtain efficient transcription and translation, the DNA sequence in each vector should include appropriate regulatory sequences, particularly a promoter and leader sequence operably linked to the variable domain sequence. Particular methods for producing antibodies in this way are generally well known and routinely used. For example, basic molecular biology procedures are
 30 described by Maniatis *et al* (Molecular Cloning, Cold Spring Harbor Laboratory, New

York, 1989); DNA sequencing can be performed as described in Sanger *et al* (PNAS 74, 5463, (1977)) and the Amersham International plc sequencing handbook; and site directed mutagenesis can be carried out according to the method of Kramer *et al* (Nucl. Acids Res. 12, 9441, (1984)) and the Anglian-Biotechnology Ltd handbook. Additionally, there are numerous publications, detailing techniques suitable for the preparation of antibodies by manipulation of DNA, creation of expression vectors and transformation of appropriate cells, for example as reviewed by Mountain A and Adair, J R in Biotechnology and Genetic Engineering Reviews (ed. Tombs, M P, 10, Chapter 1, 1992, Intercept, Andover, UK) and in International Patent Specification No. WO 91/09967.

Where desired, the antibody according to the invention may have one or more effector or reporter molecules attached to it and the invention extends to such modified proteins. The effector or reporter molecules may be attached to the antibody through any available amino acid side-chain, terminal amino acid or, where present carbohydrate functional group located in the antibody, always provided of course that this does not adversely affect the binding properties and eventual usefulness of the molecule. Particular functional groups include, for example any free amino, imino, thiol, hydroxyl, carboxyl or aldehyde group. Attachment of the antibody and the effector and/or reporter molecule(s) may be achieved via such groups and an appropriate functional group in the effector or reporter molecules. The linkage may be direct or indirect, through spacing or bridging groups.

Effector molecules include, for example, antineoplastic agents, toxins (such as enzymatically active toxins of bacterial or plant origin and fragments thereof e.g. ricin and fragments thereof) biologically active proteins, for example enzymes, nucleic acids and fragments thereof, e.g. DNA, RNA and fragments thereof, naturally occurring and synthetic polymers e.g. polysaccharides and polyalkylene polymers such as poly(ethylene glycol) and derivatives thereof, radionuclides, particularly radioiodide, and chelated metals. Suitable reporter groups include chelated metals, fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.

Particular antineoplastic agents include cytotoxic and cytostatic agents, for example alkylating agents, such as nitrogen mustards (e.g. chlorambucil, melphalan,

mechlorethamine, cyclophosphamide, or uracil mustard) and derivatives thereof, triethylenephosphoramide, triethylenethiophosphoramide, busulphan, or cisplatin; antimetabolites, such as methotrexate, fluorouracil, floxuridine, cytarabine, mercaptopurine, thioguanine, fluoroacetic acid or fluorocitric acid, antibiotics, such as
 5 bleomycins (e.g. bleomycin sulphate), doxorubicin, daunorubicin, mitomycins (e.g. mitomycin C), actinomycins (e.g. dactinomycin) plicamycin, calichaemicin and derivatives thereof, or esperamicin and derivatives thereof; mitotic inhibitors, such as etoposide, vincristine or vinblastine and derivatives thereof; alkaloids, such as ellipticine; polyols such as taxicin-I or taxicin-II; hormones, such as androgens (e.g. dromostanolone
 10 or testolactone), progestins (e.g. megestrol acetate or medroxyprogesterone acetate), estrogens (e.g. dimethylstilbestrol diphosphate, polyestradiol phosphate or estramustine phosphate) or antiestrogens (e.g. tamoxifen); anthraquinones, such as mitoxantrone, ureas, such as hydroxyurea; hydrazines, such as procarbazine; or imidazoles, such as dacarbazine.

15 Particularly useful effector groups are calichaemicin and derivatives thereof (see for example South African Patent Specifications Nos. 85/8794, 88/8127 and 90/2839).

Chelated metals include chelates of di- or tripositive metals having a coordination number from 2 to 8 inclusive. Particular examples of such metals include
 20 technetium (Tc), rhenium (Re), cobalt (Co), copper (Cu), gold (Au), silver (Ag), lead (Pb), bismuth (Bi), indium (In), gallium (Ga), yttrium (Y), terbium (Tb), gadolinium (Gd), and scandium (Sc). In general the metal is preferably a radionuclide. Particular radionuclides include ^{99m}Tc , ^{186}Re , ^{188}Re , ^{58}Co , ^{60}Co , ^{67}Cu , ^{195}Au , ^{199}Au , ^{110}Ag , ^{203}Pb , ^{206}Bi , ^{207}Bi , ^{111}In , ^{67}Ga , ^{68}Ga , ^{88}Y , ^{90}Y , ^{160}Tb , ^{153}Gd and ^{47}Sc .

25 The chelated metal may be for example one of the above types of metal chelated with any suitable polydentate chelating agent, for example acyclic or cyclic polyamines, polyethers, (e.g. crown ethers and derivatives thereof); polyamides; porphyrins; and carbocyclic derivatives.

In general, the type of chelating agent will depend on the metal in use.
 30 One particularly useful group of chelating agents in conjugates according to the invention,

however, are acyclic and cyclic polyamines, especially polyaminocarboxylic acids, for example diethylenetriaminepentaacetic acid and derivatives thereof, and macrocyclic amines, e.g. cyclic tri-aza and tetra-aza derivatives (for example as described in International Patent Specification No. WO 92/22583); and polyamides, especially
 5 desferrioxamine and derivatives thereof.

Thus for example when it is desired to use a thiol group in the antibody as the point of attachment this may be achieved through reaction with a thiol reactive group present in the effector or reporter molecule. Examples of such groups include an α -halocarboxylic acid or ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl
 10 sulphone, or a disulphide. These and other suitable linking procedures are generally and more particularly described in International Patent Specifications Nos. WO 93/06231, WO 92/22583, WO 90/091195 and WO 89/01476.

ASSAYS FOR SELECTING MOLECULES WHICH INCREASE BONE DENSITY

As discussed above, the present invention provides methods for selecting
 15 and/or isolating compounds which are capable of increasing bone density. For example, within one aspect of the present invention methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) mixing a selected molecule with TGF-beta binding protein and a selected member of the TGF-beta family of proteins, (b) determining whether the
 20 selected molecule stimulates signaling by the TGF-beta family of proteins, or inhibits the binding of the TGF-beta binding protein to the TGF-beta family of proteins. Within certain embodiments, the molecule enhances the ability of TGF-beta to function as a positive regulator of mesenchymal cell differentiation.

Within other aspects of the invention, methods are provided for
 25 determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) exposing a selected molecule to cells which express TGF-beta binding-protein and (b) determining whether the expression (or activity) of TGF-beta binding-protein from said exposed cells decreases, and therefrom determining whether the compound is capable of increasing bone mineral content. Within one
 30 embodiment, the cells are selected from the group consisting of the spontaneously

transformed or untransformed normal human bone from bone biopsies and rat parietal bone osteoblasts. Such methods may be accomplished in a wide variety of assay formats including, for example, Countercurrent Immuno-Electrophoresis (CIEP), Radioimmunoassays, Radioimmunoprecipitations, Enzyme-Linked Immuno-Sorbent Assays (ELISA), Dot Blot assays, Inhibition or Competition assays, and sandwich assays (see U.S. Patent Nos. 4,376,110 and 4,486,530; see also *Antibodies: A Laboratory Manual, supra*).

Representative embodiments of such assays are provided below in Examples 5 and 6. Briefly, a family member of the TGF-beta super-family or a TGF-beta binding protein is first bound to a solid phase, followed by addition of a candidate molecule. The labeled family member of the TGF-beta super-family or a TGF-beta binding protein is then added to the assay, the solid phase washed, and the quantity of bound or labeled TGF-beta super-family member or TGF-beta binding protein on the solid support determined. Molecules which are suitable for use in increasing bone mineral content as described herein are those molecules which decrease the binding of TGF-beta binding protein to a member or members of the TGF-beta super-family in a statistically significant manner. Obviously, assays suitable for use within the present invention should not be limited to the embodiments described within Examples 2 and 3. In particular, numerous parameters may be altered, such as by binding TGF-beta to a solid phase, or by elimination of a solid phase entirely.

Within other aspects of the invention, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) exposing a selected molecule to cells which express TGF-beta and (b) determining whether the activity of TGF-beta from said exposed cells is altered, and therefrom determining whether the compound is capable of increasing bone mineral content. Similar to the above described methods, a wide variety of methods may be utilized to assess the changes of TGF-beta binding-protein expression due to a selected test compound.

For example, within one aspect of the present invention methods are provided for determining whether a selected molecule is capable of increasing bone

mineral content, comprising the steps of (a) mixing a selected molecule with TGF-beta-binding-protein and a selected member of the TGF-beta family of proteins, (b) determining whether the selected molecule up-regulates the signaling of the TGF-beta family of proteins, or inhibits the binding of the TGF-beta binding-protein to the

5 TGF-beta family of proteins. Within certain embodiments, the molecule enhances the ability of TGF-beta to function as a positive regulator of mechanochemical cell differentiation.

Similar to the above described methods, a wide variety of methods may be utilized to assess stimulation of TGF-beta due to a selected test compound. One

10 such representative method is provided below in Example 6 (see also Durham et al., *Endo.* 136:1374-1380).

Within yet other aspects of the present invention, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the step of determining whether a selected molecule inhibits the

15 binding of TGF-beta binding-protein to bone, or an analogue thereof. As utilized herein, it should be understood that bone or analogues thereof refers to hydroxyapatite, or a surface composed of a powdered form of bone, crushed bone or intact bone. Similar to the above described methods, a wide variety of methods may be utilized to assess the inhibition of TGF-beta binding-protein localization to bone matrix. One such

20 representative method is provided below in Example 7.

It should be noted that while the methods recited herein may refer to the analysis of an individual test molecule, that the present invention should not be so limited. In particular, the selected molecule may be contained within a mixture of compounds. Hence, the recited methods may further comprise the step of isolating a

25 molecule which inhibits the binding of TGF-beta binding-protein to a TGF-beta family member.

CANDIDATE MOLECULES

A wide variety of molecules may be assayed for their ability to inhibit the binding of TGF-beta binding-protein to a TGF-beta family member. Representative

30 examples which are discussed in more detail below include organic molecules, proteins

or peptides, and nucleic acid molecules. Although it should be evident from the discussion below that the candidate molecules described herein may be utilized in the assays described herein, it should also be readily apparent that such molecules can also be utilized in a variety of diagnostic and therapeutic settings.

5 1. Organic Molecules

Numerous organic molecules may be assayed for their ability to inhibit the binding of TGF-beta binding-protein to a TGF-beta family member.

For example, within one embodiment of the invention suitable organic molecules may be selected from either a chemical library, wherein chemicals are
10 assayed individually, or from combinatorial chemical libraries where multiple compounds are assayed at once, then deconvoluted to determine and isolate the most active compounds.

Representative examples of such combinatorial chemical libraries include those described by Agrafiotis et al., "System and method of automatically
15 generating chemical compounds with desired properties," U.S. Patent No. 5,463,564; Armstrong, R. W., "Synthesis of combinatorial arrays of organic compounds through the use of multiple component combinatorial array syntheses," WO 95/02566; Baldwin, J.J. et al., "Sulfonamide derivatives and their use," WO 95/24186; Baldwin, J.J. et al., "Combinatorial dihydrobenzopyran library," WO 95/30642; Brenner, S., "New kit for
20 preparing combinatorial libraries," WO 95/16918; Chenera, B. et al., "Preparation of library of resin-bound aromatic carbocyclic compounds," WO 95/16712; Ellman, J.A., "Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support," U.S. Patent No. 5,288,514; Felder, E. et al., "Novel combinatorial compound libraries," WO 95/16209; Lerner, R. et al., "Encoded combinatorial chemical libraries,"
25 WO 93/20242; Pavia, M.R. et al., "A method for preparing and selecting pharmaceutically useful non-peptide compounds from a structurally diverse universal library," WO 95/04277; Summerton, J.E. and D.D. Weller, "Morpholino-subunit combinatorial library and method," U.S. Patent No. 5,506,337; Holmes, C., "Methods for the Solid Phase Synthesis of Thiazolidinones, Metathiazanones, and Derivatives

thereof," WO 96/00148; Phillips, G.B. and G.P. Wei, "Solid-phase Synthesis of Benzimidazoles," *Tet. Letters* 37:4887-90, 1996; Ruhland, B. et al., "Solid-supported Combinatorial Synthesis of Structurally Diverse β -Lactams," *J. Amer. Chem. Soc.* 111:253-4, 1996; Look, G.C. et al., "The Identification of Cyclooxygenase-1
5 Inhibitors from 4-Thiazolidinone Combinatorial Libraries," *Bioorg and Med. Chem. Letters* 6:707-12, 1996.

2. Proteins and Peptides

A wide range of proteins and peptides may likewise be utilized as candidate molecules for inhibitors of the binding of TGF-beta binding-protein to a
10 TGF-beta family member.

a. Combinatorial Peptide Libraries

Peptide molecules which are putative inhibitors of the binding of TGF-beta binding-protein to a TGF-beta family member may be obtained through the screening of combinatorial peptide libraries. Such libraries may either be prepared by
15 one of skill in the art (*see e.g.*, U.S. Patent Nos. 4,528,266 and 4,359,535, and Patent Cooperation Treaty Publication Nos. WO 92/15679, WO 92/15677, WO 90/07862, WO 90/02809, or purchased from commercially available sources (*e.g.*, New England Biolabs Ph.D.TM Phage Display Peptide Library Kit).

b. Antibodies

20 Antibodies which inhibit the binding of TGF-beta binding-protein to a TGF-beta family member may readily be prepared given the disclosure provided herein. Within the context of the present invention, antibodies are understood to include monoclonal antibodies, polyclonal antibodies, anti-idiotypic antibodies, antibody fragments (*e.g.*, Fab, and F(ab')₂, F_v variable regions, or complementarity determining
25 regions). As discussed above, antibodies are understood to be specific against TGF-beta binding-protein, or against a specific TGF-beta family member, if they bind with a K_a of greater than or equal to 10⁷M, preferably greater than or equal to 10⁸M, and do not bind to other TGF-beta binding-proteins, or, bind with a K_a of less than or equal to

10⁶M. Furthermore, antibodies of the present invention should block or inhibit the binding of TGF-beta binding-protein to a TGF-beta family member.

The affinity of a monoclonal antibody or binding partner, as well as inhibition of binding can be readily determined by one of ordinary skill in the art (*see* 5 Scatchard, *Ann. N.Y. Acad. Sci.* 51:660-672, 1949).

Briefly, polyclonal antibodies may be readily generated by one of ordinary skill in the art from a variety of warm-blooded animals such as horses, cows, various fowl, rabbits, mice, or rats. Typically, the TGF-beta binding-protein or unique peptide thereof of 13-20 amino acids (preferably conjugated to keyhole limpet 10 hemocyanin by cross-linking with glutaraldehyde) is utilized to immunize the animal through intraperitoneal, intramuscular, intraocular, or subcutaneous injections, along with an adjuvant such as Freund's complete or incomplete adjuvant. Following several booster immunizations, samples of serum are collected and tested for reactivity to the protein or peptide. Particularly preferred polyclonal antisera will give a signal on one 15 of these assays that is at least three times greater than background. Once the titer of the animal has reached a plateau in terms of its reactivity to the protein, larger quantities of antisera may be readily obtained either by weekly bleedings, or by exsanguinating the animal.

Monoclonal antibodies may also be readily generated using conventional 20 techniques (*see* U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993 which are incorporated herein by reference; *see also Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980, and *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988, which are also incorporated 25 herein by reference).

Briefly, within one embodiment a subject animal such as a rat or mouse is immunized with TGF-beta binding-protein or portion thereof as described above. The protein may be admixed with an adjuvant such as Freund's complete or incomplete adjuvant in order to increase the resultant immune response. Between one and three 30 weeks after the initial immunization the animal may be reimmunized with another

booster immunization, and tested for reactivity to the protein utilizing assays described above. Once the animal has reached a plateau in its reactivity to the injected protein, it is sacrificed, and organs which contain large numbers of B cells such as the spleen and lymph nodes are harvested.

5 Cells which are obtained from the immunized animal may be immortalized by infection with a virus such as the Epstein-Barr virus (EBV) (see Glasky and Reading, *Hybridoma* 8(4):377-389, 1989). Alternatively, within a preferred embodiment, the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal
10 antibody. Suitable myeloma lines include, for example, NS-1 (ATCC No. TIB 18), and P3X63 - Ag 8.653 (ATCC No. CRL 1580).

Following the fusion, the cells may be placed into culture plates containing a suitable medium, such as RPMI 1640, or DMEM (Dulbecco's Modified Eagles Medium) (JRH Biosciences, Lenexa, Kansas), as well as additional ingredients,
15 such as fetal bovine serum (FBS, *i.e.*, from Hyclone, Logan, Utah, or JRH Biosciences). Additionally, the medium should contain a reagent which selectively allows for the growth of fused spleen and myeloma cells such as HAT (hypoxanthine, aminopterin, and thymidine) (Sigma Chemical Co., St. Louis, Missouri). After about seven days, the resulting fused cells or hybridomas may be screened in order to determine the presence
20 of antibodies which are reactive against TGF-beta binding-protein (depending on the antigen used), and which block or inhibit the binding of TGF-beta binding-protein to a TGF-beta family member.

A wide variety of assays may be utilized to determine the presence of antibodies which are reactive against the proteins of the present invention, including for
25 example countercurrent immuno-electrophoresis, radioimmunoassays, radioimmunoprecipitations, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, western blots, immunoprecipitation, inhibition or competition assays, and sandwich assays (see U.S. Patent Nos. 4,376,110 and 4,486,530; see also *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press,

1988). Following several clonal dilutions and reassays, a hybridoma producing antibodies reactive against the desired protein may be isolated.

Other techniques may also be utilized to construct monoclonal antibodies (see William D. Huse et al., "Generation of a Large Combinational Library of the Immunoglobulin Repertoire in Phage Lambda," *Science* 246:1275-1281, December 1989; see also L. Sastry et al., "Cloning of the Immunological Repertoire in *Escherichia coli* for Generation of Monoclonal Catalytic Antibodies: Construction of a Heavy Chain Variable Region-Specific cDNA Library," *Proc. Natl. Acad. Sci. USA* 86:5728-5732, August 1989; see also Michelle Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas," *Strategies in Molecular Biology* 3:1-9, January 1990). These references describe a commercial system available from Stratagene (La Jolla, California) which enables the production of antibodies through recombinant techniques. Briefly, mRNA is isolated from a B cell population, and utilized to create heavy and light chain immunoglobulin cDNA expression libraries in the λ ImmunoZap(H) and λ ImmunoZap(L) vectors. These vectors may be screened individually or co-expressed to form Fab fragments or antibodies (see Huse et al., *supra*; see also Sastry et al., *supra*). Positive plaques may subsequently be converted to a non-lytic plasmid which allows high level expression of monoclonal antibody fragments from *E. coli*.

Similarly, portions or fragments, such as Fab and Fv fragments, of antibodies may also be constructed utilizing conventional enzymatic digestion or recombinant DNA techniques to incorporate the variable regions of a gene which encodes a specifically binding antibody. Within one embodiment, the genes which encode the variable region from a hybridoma producing a monoclonal antibody of interest are amplified using nucleotide primers for the variable region. These primers may be synthesized by one of ordinary skill in the art, or may be purchased from commercially available sources. Stratagene (La Jolla, California) sells primers for mouse and human variable regions including, among others, primers for V_{Ha} , V_{Hb} , V_{Hc} , V_{Hd} , C_{H1} , V_L and C_L regions. These primers may be utilized to amplify heavy or light chain variable regions, which may then be inserted into vectors such as

ImmunoZAP™ H or ImmunoZAP™ L (Stratagene), respectively. These vectors may then be introduced into *E. coli*, yeast, or mammalian-based systems for expression. Utilizing these techniques, large amounts of a single-chain protein containing a fusion of the V_H and V_L domains may be produced (see Bird et al., *Science* 242:423-426, 5 1988). In addition, such techniques may be utilized to change a "murine" antibody to a "human" antibody, without altering the binding specificity of the antibody.

Once suitable antibodies have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (see *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor 10 Laboratory Press, 1988). Suitable techniques include peptide or protein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques.

c. Mutant TGF-beta binding-proteins

As described herein and below in the Examples (e.g., Examples 8 and 9), 15 altered versions of TGF-beta binding-protein which compete with native TGF-beta binding-protein's ability to block the activity of a particular TGF-beta family member should lead to increased bone density. Thus, mutants of TGF-beta binding-protein which bind to the TGF-beta family member but do not inhibit the function of the TGF-beta family member would meet the criteria. The mutant versions must effectively 20 compete with the endogenous inhibitory functions of TGF-beta binding-protein.

d. Production of proteins

Although various genes (or portions thereof) have been provided herein, it should be understood that within the context of the present invention, reference to one or more of these genes includes derivatives of the genes that are substantially similar to 25 the genes (and, where appropriate, the proteins (including peptides and polypeptides) that are encoded by the genes and their derivatives). As used herein, a nucleotide sequence is deemed to be "substantially similar" if: (a) the nucleotide sequence is derived from the coding region of the above-described genes and includes, for example, portions of the sequence or allelic variations of the sequences discussed above, or

alternatively, encodes a molecule which inhibits the binding of TGF-beta binding-protein to a member of the TGF-beta family, (b) the nucleotide sequence is capable of hybridization to nucleotide sequences of the present invention under moderate, high or very high stringency (*see* Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 5 2nd ed., Cold Spring Harbor Laboratory Press, NY, 1989); or (c) the DNA sequences are degenerate as a result of the genetic code to the DNA sequences defined in (a) or (b). Further, the nucleic acid molecule disclosed herein includes both complementary and non-complementary sequences, provided the sequences otherwise meet the criteria set forth herein. Within the context of the present invention, high stringency means 10 standard hybridization conditions (*e.g.*, 5XSSPE, 0.5% SDS at 65°C, or the equivalent).

The structure of the proteins encoded by the nucleic acid molecules described herein may be predicted from the primary translation products using the hydrophobicity plot function of, for example, P/C Gene or Intelligenetics Suite (Intelligenetics, Mountain View, California), or according to the methods described by 15 Kyte and Doolittle (*J. Mol. Biol.* 157:105-132, 1982).

Proteins of the present invention may be prepared in the form of acidic or basic salts, or in neutral form. In addition, individual amino acid residues may be modified by oxidation or reduction. Furthermore, various substitutions, deletions, or additions may be made to the amino acid or nucleic acid sequences, the net effect of 20 which is to retain or further enhance or decrease the biological activity of the mutant or wild-type protein. Moreover, due to degeneracy in the genetic code, for example, there may be considerable variation in nucleotide sequences encoding the same amino acid sequence.

Other derivatives of the proteins disclosed herein include conjugates of 25 the proteins along with other proteins or polypeptides. This may be accomplished, for example, by the synthesis of N-terminal or C-terminal fusion proteins which may be added to facilitate purification or identification of proteins (*see* U.S. Patent No. 4,851,341, *see also*, Hopp et al., *Bio/Technology* 6:1204, 1988.) Alternatively, fusion proteins such as Flag/TGF-beta binding-protein be constructed in order to assist in the 30 identification, expression, and analysis of the protein.

Proteins of the present invention may be constructed using a wide variety of techniques described herein. Further, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the
5 resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

Alternatively, oligonucleotide-directed site-specific (or segment specific) mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Exemplary
10 methods of making the alterations set forth above are disclosed by Walder et al. (*Gene* 42:133, 1986); Bauer et al. (*Gene* 37:73, 1985); Craik (*BioTechniques*, January 1985, 12-19); Smith et al. (*Genetic Engineering: Principles and Methods*, Plenum Press, 1981); and Sambrook et al. (*supra*). Deletion or truncation derivatives of proteins (e.g., a soluble extracellular portion) may also be constructed by utilizing convenient
15 restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in, and the DNA religated. Exemplary methods of making the alterations set forth above are disclosed by Sambrook et al. (*Molecular Cloning: A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, 1989).

Mutations which are made in the nucleic acid molecules of the present
20 invention preferably preserve the reading frame of the coding sequences. Furthermore, the mutations will preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, that would adversely affect translation of the mRNA. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation *per se* be predetermined. For example, in
25 order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed mutants screened for indicative biological activity. Alternatively, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following

ligation, the resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

Nucleic acid molecules which encode proteins of the present invention may also be constructed utilizing techniques of PCR mutagenesis, chemical
5 mutagenesis (Drinkwater and Klinedinst, *PNAS* 83:3402-3406, 1986), by forced nucleotide misincorporation (*e.g.*, Liao and Wise *Gene* 88:107-111, 1990), or by use of randomly mutagenized oligonucleotides (Horwitz et al., *Genome* 3:112-117, 1989).

The present invention also provides for the manipulation and expression of the above described genes by culturing host cells containing a vector capable of
10 expressing the above-described genes. Such vectors or vector constructs include either synthetic or cDNA-derived nucleic acid molecules encoding the desired protein, which are operably linked to suitable transcriptional or translational regulatory elements. Suitable regulatory elements may be derived from a variety of sources, including bacterial, fungal, viral, mammalian, insect, or plant genes. Selection of appropriate
15 regulatory elements is dependent on the host cell chosen and may be readily accomplished by one of ordinary skill in the art. Examples of regulatory elements include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a transcriptional terminator, and a ribosomal binding sequence, including a translation initiation signal.

20 Nucleic acid molecules that encode any of the proteins described above may be readily expressed by a wide variety of prokaryotic and eukaryotic host cells, including bacterial, mammalian, yeast or other fungi, viral, insect, or plant cells. Methods for transforming or transfecting such cells to express foreign DNA are well known in the art (see, *e.g.*, Itakura et al., U.S. Patent No. 4,704,362; Hinnen et al., *Proc.*
25 *Natl. Acad. Sci. USA* 75:1929-1933, 1978; Murray et al., U.S. Patent No. 4,801,542; Upshall et al., U.S. Patent No. 4,935,349; Hagen et al., U.S. Patent No. 4,784,950; Axel et al., U.S. Patent No. 4,399,216; Goeddel et al., U.S. Patent No. 4,766,075; and Sambrook et al. *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, 1989; for plant cells see Czako and Marton, *Plant Physiol.*
30 104:1067-1071, 1994; and Paszkowski et al., *Biotech.* 24:387-392, 1992).

Bacterial host cells suitable for carrying out the present invention include *E. coli*, *B. subtilis*, *Salmonella typhimurium*, and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, as well as many other bacterial species well known to one of ordinary skill in the art. Representative examples of
 5 bacterial host cells include DH5 α (Stratagene, LaJolla, California).

Bacterial expression vectors preferably comprise a promoter which functions in the host cell, one or more selectable phenotypic markers, and a bacterial origin of replication. Representative promoters include the β -lactamase (penicillinase) and lactose promoter system (see Chang et al., *Nature* 275:615, 1978), the T7 RNA
 10 polymerase promoter (Studier et al., *Meth. Enzymol.* 185:60-89, 1990), the lambda promoter (Elvin et al., *Gene* 87:123-126, 1990), the *trp* promoter (Nichols and Yanofsky, *Meth. in Enzymology* 101:155, 1983) and the *tac* promoter (Russell et al., *Gene* 20:231, 1982). Representative selectable markers include various antibiotic resistance markers such as the kanamycin or ampicillin resistance genes. Many
 15 plasmids suitable for transforming host cells are well known in the art, including among others, pBR322 (see Bolivar et al., *Gene* 2:95, 1977), the pUC plasmids pUC18, pUC19, pUC118, pUC119 (see Messing, *Meth. in Enzymology* 101:20-77, 1983 and Vieira and Messing, *Gene* 19:259-268, 1982), and pNH8A, pNH16a, pNH18a, and Bluescript M13 (Stratagene, La Jolla, California).

20 Yeast and fungi host cells suitable for carrying out the present invention include, among others, *Saccharomyces pombe*, *Saccharomyces cerevisiae*, the genera *Pichia* or *Kluyveromyces* and various species of the genus *Aspergillus* (McKnight et al., U.S. Patent No. 4,935,349). Suitable expression vectors for yeast and fungi include, among others, YCp50 (ATCC No. 37419) for yeast, and the amdS cloning vector pV3
 25 (Turnbull, *Bio/Technology* 7:169, 1989), YRp7 (Struhl et al., *Proc. Natl. Acad. Sci. USA* 76:1035-1039, 1978), YEp13 (Broach et al., *Gene* 8:121-133, 1979), pJDB249 and pJDB219 (Beggs, *Nature* 275:104-108, 1978) and derivatives thereof.

Preferred promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman et al., *J. Biol. Chem.* 255:12073-12080, 1980; Alber and
 30 Kawasaki, *J. Mol. Appl. Genet.* 1:419-434, 1982) or alcohol dehydrogenase genes

(Young et al., in *Genetic Engineering of Microorganisms for Chemicals*, Hollaender et al. (eds.), p. 355, Plenum, New York, 1982; Ammerer, *Meth. Enzymol.* 101:192-201, 1983). Examples of useful promoters for fungi vectors include those derived from *Aspergillus nidulans* glycolytic genes, such as the *adh3* promoter (McKnight et al.,
 5 *EMBO J.* 4:2093-2099, 1985). The expression units may also include a transcriptional terminator. An example of a suitable terminator is the *adh3* terminator (McKnight et al., *ibid.*, 1985).

As with bacterial vectors, the yeast vectors will generally include a selectable marker, which may be one of any number of genes that exhibit a dominant
 10 phenotype for which a phenotypic assay exists to enable transformants to be selected. Preferred selectable markers are those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include *leu2* (Broach et al., *ibid.*), *ura3* (Botstein et al., *Gene* 8:17, 1979), or *his3* (Struhl et al., *ibid.*). Another suitable selectable marker is the *cat* gene, which confers
 15 chloramphenicol resistance on yeast cells.

Techniques for transforming fungi are well known in the literature, and have been described, for instance, by Beggs (*ibid.*), Hinnen et al. (*Proc. Natl. Acad. Sci. USA* 75:1929-1933, 1978), Yelton et al. (*Proc. Natl. Acad. Sci. USA* 81:1740-1747, 1984), and Russell (*Nature* 301:167-169, 1983). The genotype of the host cell may
 20 contain a genetic defect that is complemented by the selectable marker present on the expression vector. Choice of a particular host and selectable marker is well within the level of ordinary skill in the art.

Protocols for the transformation of yeast are also well known to those of ordinary skill in the art. For example, transformation may be readily accomplished
 25 either by preparation of spheroplasts of yeast with DNA (see Hinnen et al., *PNAS USA* 75:1929, 1978) or by treatment with alkaline salts such as LiCl (see Itoh et al., *J. Bacteriology* 153:163, 1983). Transformation of fungi may also be carried out using polyethylene glycol as described by Cullen et al. (*Bio/Technology* 5:369, 1987).

Viral vectors include those which comprise a promoter that directs the
 30 expression of an isolated nucleic acid molecule that encodes a desired protein as

described above. A wide variety of promoters may be utilized within the context of the present invention, including for example, promoters such as MoMLV LTR, RSV LTR, Friend MuLV LTR, adenoviral promoter (Ohno et al., *Science* 265:781-784, 1994), neomycin phosphotransferase promoter/enhancer, late parvovirus promoter (Koering et al., *Hum. Gene Therap.* 5:457-463, 1994), Herpes TK promoter, SV40 promoter, metallothionein IIa gene enhancer/promoter, cytomegalovirus immediate early promoter, and the cytomegalovirus immediate late promoter. Within particularly preferred embodiments of the invention, the promoter is a tissue-specific promoter (see e.g., WO 91/02805; EP 0,415,731; and WO 90/07936). Representative examples of suitable tissue specific promoters include neural specific enolase promoter, platelet derived growth factor beta promoter, bone morphogenic protein promoter, human alpha1-chimaerin promoter, synapsin I promoter and synapsin II promoter. In addition to the above-noted promoters, other viral-specific promoters (e.g., retroviral promoters (including those noted above, as well as others such as HIV promoters), hepatitis, herpes (e.g., EBV), and bacterial, fungal or parasitic (e.g., malarial) -specific promoters may be utilized in order to target a specific cell or tissue which is infected with a virus, bacteria, fungus or parasite.

Mammalian cells suitable for carrying out the present invention include, among others COS, CHO, SaOS, osteosarcomas, KS483, MG-63, primary osteoblasts, and human or mammalian bone marrow stroma. Mammalian expression vectors for use in carrying out the present invention will include a promoter capable of directing the transcription of a cloned gene or cDNA. Preferred promoters include viral promoters and cellular promoters. Bone specific promoters include the bone sialo-protein and the promoter for osteocalcin. Viral promoters include the cytomegalovirus immediate early promoter (Boshart et al., *Cell* 41:521-530, 1985), cytomegalovirus immediate late promoter, SV40 promoter (Subramani et al., *Mol. Cell. Biol.* 1:854-864, 1981), MMTV LTR, RSV LTR, metallothionein-1, adenovirus E1a. Cellular promoters include the mouse metallothionein-1 promoter (Palmiter et al., U.S. Patent No. 4,579,821), a mouse V_K promoter (Bergman et al., *Proc. Natl. Acad. Sci. USA* 81:7041-7045, 1983; Grant et al., *Nucl. Acids Res.* 15:5496, 1987) and a mouse V_H promoter (Loh et al., *Cell*

33:85-93, 1983). The choice of promoter will depend, at least in part, upon the level of expression desired or the recipient cell line to be transfected.

Such expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest. Preferred RNA splice sites may be obtained from adenovirus and/or immunoglobulin genes. Also contained in the expression vectors is a polyadenylation signal located downstream of the coding sequence of interest. Suitable polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Sharp, *ibid.*), the polyadenylation signal from the Adenovirus 5 E1B region and the human growth hormone gene terminator (DeNoto et al., *Nuc. Acids Res.* 9:3719-3730, 1981). The expression vectors may include a noncoding viral leader sequence, such as the Adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites. Preferred vectors may also include enhancer sequences, such as the SV40 enhancer. Expression vectors may also include sequences encoding the adenovirus VA RNAs. Suitable expression vectors can be obtained from commercial sources (e.g., Stratagene, La Jolla, California).

Vector constructs comprising cloned DNA sequences can be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., *Cell* 14:725, 1978; Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456, 1973), electroporation (Neumann et al., *EMBO J.* 1:841-845, 1982), or DEAE-dextran mediated transfection (Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc., NY, 1987). To identify cells that have stably integrated the cloned DNA, a selectable marker is generally introduced into the cells along with the gene or cDNA of interest. Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. The selectable marker may be an amplifiable selectable marker. Preferred amplifiable selectable markers are the DHFR gene and the neomycin resistance gene. Selectable markers are reviewed by Thilly (*Mammalian Cell Technology*, Butterworth Publishers, Stoneham, Massachusetts, which is incorporated herein by reference).

Mammalian cells containing a suitable vector are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest. Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion. For cells that have been transfected with an amplifiable, selectable marker the drug concentration may be increased in a stepwise manner to select for increased copy number of the cloned sequences, thereby increasing expression levels. Cells expressing the introduced sequences are selected and screened for production of the protein of interest in the desired form or at the desired level. Cells that satisfy these criteria can then be cloned and scaled up for production.

10 Protocols for the transfection of mammalian cells are well known to those of ordinary skill in the art. Representative methods include calcium phosphate mediated transfection, electroporation, lipofection, retroviral, adenoviral and protoplast fusion-mediated transfection (*see* Sambrook et al., *supra*). Naked vector constructs can also be taken up by muscular cells or other suitable cells subsequent to injection into the muscle of a mammal (or other animals).

Numerous insect host cells known in the art can also be useful within the present invention, in light of the subject specification. For example, the use of baculoviruses as vectors for expressing heterologous DNA sequences in insect cells has been reviewed by Atkinson et al. (*Pestic. Sci.* 28:215-224, 1990).

20 Numerous plant host cells known in the art can also be useful within the present invention, in light of the subject specification. For example, the use of *Agrobacterium rhizogenes* as vectors for expressing genes in plant cells has been reviewed by Sinkar et al. (*J. Biosci. (Bangalore)* 11:47-58, 1987).

Within related aspects of the present invention, proteins of the present invention may be expressed in a transgenic animal whose germ cells and somatic cells contain a gene which encodes the desired protein and which is operably linked to a promoter effective for the expression of the gene. Alternatively, in a similar manner transgenic animals may be prepared that lack the desired gene (*e.g.*, "knock-out" mice). Such transgenics may be prepared in a variety of non-human animals, including mice, rats, rabbits, sheep, dogs, goats and pigs (*see* Hammer et al., *Nature* 315:680-683, 1985,

Palmiter et al., *Science* 222:809-814, 1983, Brinster et al., *Proc. Natl. Acad. Sci. USA* 82:4438-4442, 1985, Palmiter and Brinster, *Cell* 41:343-345, 1985, and U.S. Patent Nos. 5,175,383, 5,087,571, 4,736,866, 5,387,742, 5,347,075, 5,221,778, and 5,175,384). Briefly, an expression vector, including a nucleic acid molecule to be
5 expressed together with appropriately positioned expression control sequences, is introduced into pronuclei of fertilized eggs, for example, by microinjection. Integration of the injected DNA is detected by blot analysis of DNA from tissue samples. It is preferred that the introduced DNA be incorporated into the germ line of the animal so that it is passed on to the animal's progeny. Tissue-specific expression may be
10 achieved through the use of a tissue-specific promoter, or through the use of an inducible promoter, such as the metallothionein gene promoter (Palmiter et al., 1983, *ibid*), which allows regulated expression of the transgene.

Proteins can be isolated by, among other methods, culturing suitable host and vector systems to produce the recombinant translation products of the present
15 invention. Supernatants from such cell lines, or protein inclusions or whole cells where the protein is not excreted into the supernatant, can then be treated by a variety of purification procedures in order to isolate the desired proteins. For example, the supernatant may be first concentrated using commercially available protein concentration filters, such as an Amicon or Millipore Pellicon ultrafiltration unit.
20 Following concentration, the concentrate may be applied to a suitable purification matrix such as, for example, an anti-protein antibody bound to a suitable support. Alternatively, anion or cation exchange resins may be employed in order to purify the protein. As a further alternative, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps may be employed to further purify the protein.
25 Other methods of isolating the proteins of the present invention are well known in the skill of the art.

A protein is deemed to be "isolated" within the context of the present invention if no other (undesired) protein is detected pursuant to SDS-PAGE analysis followed by Coomassie blue staining. Within other embodiments, the desired protein

can be isolated such that no other (undesired) protein is detected pursuant to SDS-PAGE analysis followed by silver staining.

3. Nucleic Acid Molecules

Within other aspects of the invention, nucleic acid molecules are provided which are capable of inhibiting TGF-beta binding-protein binding to a member of the TGF-beta family. For example, within one embodiment antisense oligonucleotide molecules are provided which specifically inhibit expression of TGF-beta binding-protein nucleic acid sequences (*see generally*, Hirashima et al. in *Molecular Biology of RNA: New Perspectives* (M. Inouye and B. S. Dudock, eds., 1987 Academic Press, San Diego, p. 401); *Oligonucleotides: Antisense Inhibitors of Gene Expression* (J.S. Cohen, ed., 1989 MacMillan Press, London); Stein and Cheng, *Science* 261:1004-1012, 1993; WO 95/10607; U.S. Patent No. 5,359,051; WO 92/06693; and EP-A2-612844). Briefly, such molecules are constructed such that they are complementary to, and able to form Watson-Crick base pairs with, a region of transcribed TGF-beta binding-protein mRNA sequence. The resultant double-stranded nucleic acid interferes with subsequent processing of the mRNA, thereby preventing protein synthesis (see Example 10).

Within other aspects of the invention, ribozymes are provided which are capable of inhibiting the TGF-beta binding-protein binding to a member of the TGF-beta family. As used herein, "ribozymes" are intended to include RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity. The catalytic strand cleaves a specific site in a target RNA at greater than stoichiometric concentration. A wide variety of ribozymes may be utilized within the context of the present invention, including for example, the hammerhead ribozyme (for example, as described by Forster and Symons, *Cell* 48:211-220, 1987; Haseloff and Gerlach, *Nature* 328:596-600, 1988; Walbot and Bruening, *Nature* 334:196, 1988; Haseloff and Gerlach, *Nature* 334:585, 1988); the hairpin ribozyme (for example, as described by Haseloff et al., U.S. Patent No. 5,254,678, issued October 19, 1993 and Hempel et al., European Patent Publication No. 0 360 257, published March 26, 1990);

and *Tetrahymena* ribosomal RNA-based ribozymes (see Cech et al., U.S. Patent No. 4,987,071). Ribozymes of the present invention typically consist of RNA, but may also be composed of DNA, nucleic acid analogs (e.g., phosphorothioates), or chimerics thereof (e.g., DNA/RNA/RNA).

5 4. Labels

The gene product or any of the candidate molecules described above and below, may be labeled with a variety of compounds, including for example, fluorescent molecules, toxins, and radionuclides. Representative examples of fluorescent molecules include fluorescein, *Phycobili* proteins, such as phycoerythrin, rhodamine, Texas red
10 and luciferase. Representative examples of toxins include ricin, abrin diphtheria toxin, cholera toxin, gelonin, pokeweed antiviral protein, tritin, *Shigella* toxin, and *Pseudomonas* exotoxin A. Representative examples of radionuclides include Cu-64, Ga-67, Ga-68, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-111, I-123, I-125, I-131, Re-186, Re-188, Au-198, Au-199, Pb-203, At-211, Pb-212 and Bi-212. In addition, the
15 antibodies described above may also be labeled or conjugated to one partner of a ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein.

Methods for conjugating or labeling the molecules described herein with the representative labels set forth above may be readily accomplished by one of
20 ordinary skill in the art (see Trichothecene Antibody Conjugate, U.S. Patent No. 4,744,981; Antibody Conjugate, U.S. Patent No. 5,106,951; Fluorogenic Materials and Labeling Techniques, U.S. Patent No. 4,018,884; Metal Radionuclide Labeled Proteins for Diagnosis and Therapy, U.S. Patent No. 4,897,255; and Metal Radionuclide Chelating Compounds for Improved Chelation Kinetics, U.S. Patent No. 4,988,496; see
25 also Inman, *Methods In Enzymology*, Vol. 34, *Affinity Techniques, Enzyme Purification: Part B*, Jakoby and Wilchek (eds.), Academic Press, New York, p. 30, 1974; see also Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," *Anal. Biochem.* 171:1-32, 1988).

PHARMACEUTICAL COMPOSITIONS

As noted above, the present invention also provides a variety of pharmaceutical compositions, comprising one of the above-described molecules which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family along with a pharmaceutically or physiologically acceptable carrier, excipients or diluents. Generally, such carriers should be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the therapeutic agent with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with nonspecific serum albumin are exemplary appropriate diluents.

In addition, the pharmaceutical compositions of the present invention may be prepared for administration by a variety of different routes. In addition, pharmaceutical compositions of the present invention may be placed within containers, along with packaging material which provides instructions regarding the use of such pharmaceutical compositions. Generally, such instructions will include a tangible expression describing the reagent concentration, as well as within certain embodiments, relative amounts of excipient ingredients or diluents (*e.g.*, water, saline or PBS) which may be necessary to reconstitute the pharmaceutical composition.

METHODS OF TREATMENT

The present invention also provides methods for increasing the mineral content and mineral density of bone. Briefly, numerous conditions result in the loss of bone mineral content, including for example, disease, genetic predisposition, accidents which result in the lack of use of bone (*e.g.*, due to fracture), therapeutics which effect bone resorption, or which kill bone forming cells and normal aging. Through use of the molecules described herein which inhibit the TGF-beta binding-protein binding to a TGF-beta family member such conditions may be treated or prevented. As utilized herein, it should be understood that bone mineral content has been increased, if bone

mineral content has been increased in a statistically significant manner (e.g., greater than one-half standard deviation), at a selected site.

A wide variety of conditions which result in loss of bone mineral content may be treated with the molecules described herein. Patients with such conditions may
5 be identified through clinical diagnosis utilizing well known techniques (see, e.g., Harrison's Principles of Internal Medicine, McGraw-Hill, Inc.). Representative examples of diseases that may be treated included dysplasias, wherein there is abnormal growth or development of bone. Representative examples of such conditions include
10 achondroplasia, cleidocranial dysostosis, enchondromatosis, fibrous dysplasia, Gaucher's, hypophosphatemic rickets, Marfan's, multiple hereditary exotoses, neurofibromatosis, osteogenesis imperfecta, osteopetrosis, osteopoikilosis, sclerotic lesions, fractures, periodontal disease, pseudoarthrosis and pyogenic osteomyelitis.

Other conditions which may be treated or prevented include a wide variety of causes of osteopenia (i.e., a condition that causes greater than one standard
15 deviation of bone mineral content or density below peak skeletal mineral content at youth). Representative examples of such conditions include anemic states, conditions caused steroids, conditions caused by heparin, bone marrow disorders, scurvy, malnutrition, calcium deficiency, idiopathic osteoporosis, congenital osteopenia or osteoporosis, alcoholism, chronic liver disease, senility, postmenopausal state,
20 oligomenorrhea, amenorrhea, pregnancy, diabetes mellitus, hyperthyroidism, Cushing's disease, acromegaly, hypogonadism, immobilization or disuse, reflex sympathetic dystrophy syndrome, transient regional osteoporosis and osteomalacia.

Within one aspect of the present invention, bone mineral content or density may be increased by administering to a warm-blooded animal a therapeutically
25 effective amount of a molecule which inhibits the TGF-beta binding-protein binding to a TGF-beta family member. Examples of warm-blooded animals that may be treated include both vertebrates and mammals, including for example horses, cows, pigs, sheep, dogs, cats, rats and mice. Representative examples of therapeutic molecules include ribozymes, ribozyme genes, antisense oligonucleotides and antibodies (e.g., humanized
30 antibodies).

Within other aspects of the present invention, methods are provided for increasing bone density, comprising the step of introducing into cells which home to bone a vector which directs the expression of a molecule which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family, and administering the
 5 vector containing cells to a warm-blooded animal. Briefly, cells which home to bone may be obtained directly from the bone of patients (*e.g.*, cells obtained from the bone marrow such as CD34+, osteoblasts, osteocytes, and the like), from peripheral blood, or from cultures.

A vector which directs the expression of a molecule that inhibits the
 10 TGF-beta binding-protein binding to a member of the TGF-beta family is introduced into the cells. Representative examples of suitable vectors include viral vectors such as herpes viral vectors (*e.g.*, U.S. Patent No. 5,288,641), adenoviral vectors (*e.g.*, WO 94/26914, WO 93/9191; Kolls et al., *PNAS* 91(1):215-219, 1994; Kass-Eisler et al., *PNAS* 90(24):11498-502, 1993; Guzman et al., *Circulation* 88(6):2838-48, 1993;
 15 Guzman et al., *Cir. Res.* 73(6):1202-1207, 1993; Zabner et al., *Cell* 75(2):207-216, 1993; Li et al., *Hum Gene Ther.* 4(4):403-409, 1993; Caillaud et al., *Eur. J. Neurosci.* 5(10):1287-1291, 1993; Vincent et al., *Nat. Genet.* 5(2):130-134, 1993; Jaffe et al., *Nat. Genet.* 1(5):372-378, 1992; and Levrero et al., *Gene* 101(2):195-202, 1991), adeno-associated viral vectors (WO 95/13365; Flotte et al., *PNAS* 90(22):10613-10617, 1993),
 20 baculovirus vectors, parvovirus vectors (Koering et al., *Hum. Gene Therap.* 5:457-463, 1994), pox virus vectors (Panicali and Paoletti, *PNAS* 79:4927-4931, 1982; and Ozaki et al., *Biochem. Biophys. Res. Comm.* 193(2):653-660, 1993), and retroviruses (*e.g.*, EP 0,415,731; WO 90/07936; WO 91/0285, WO 94/03622; WO 93/25698; WO 93/25234; U.S. Patent No. 5,219,740; WO 93/11230; WO 93/10218). Viral
 25 vectors may likewise be constructed which contain a mixture of different elements (*e.g.*, promoters, envelope sequences and the like) from different viruses, or non-viral sources. Within various embodiments, either the viral vector itself, or a viral particle which contains the viral vector may be utilized in the methods and compositions described below.

Within other embodiments of the invention, nucleic acid molecules which encode a molecule which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family themselves may be administered by a variety of techniques, including, for example, administration of asialosomucoid (ASOR) conjugated with poly-L-lysine DNA complexes (Cristano et al., *PNAS* 92:122-92126, 1993), DNA linked to killed adenovirus (Curiel et al., *Hum. Gene Ther.* 3(2):147-154, 1992), cytofectin-mediated introduction (DMRIE-DOPE, Vical, California), direct DNA injection (Acsadi et al., *Nature* 352:815-818, 1991); DNA ligand (Wu et al., *J. of Biol. Chem.* 264:16985-16987, 1989); lipofection (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417, 1989); liposomes (Pickering et al., *Circ.* 89(1):13-21, 1994; and Wang et al., *PNAS* 84:7851-7855, 1987); microprojectile bombardment (Williams et al., *PNAS* 88:2726-2730, 1991); and direct delivery of nucleic acids which encode the protein itself either alone (Vile and Hart, *Cancer Res.* 53: 3860-3864, 1993), or utilizing PEG-nucleic acid complexes.

Representative examples of molecules which may be expressed by the vectors of present invention include ribozymes and antisense molecules, each of which are discussed in more detail above.

Determination of increased bone mineral content may be determined directly through the use of X-rays (e.g., Dual Energy X-ray Absorptometry or "DEXA"), or by inference through bone turnover markers (osteoblast specific alkaline phosphatase, osteocalcin, type 1 procollagen C' propeptide (PICP), and total alkaline phosphatase; see Comier, C., *Curr. Opin. in Rheu.* 7:243, 1995), or markers of bone resorption (pyridinoline, deoxypyridinoline, N-telopeptide, urinary hydroxyproline, plasma tartrate-resistant acid phosphatases and galactosyl hydroxylysine; see Comier, *supra*). The amount of bone mass may also be calculated from body weights, or utilizing other methods (see Guinness-Hey, *Metab. Bone Dis. and Rel. Res.* 5:177-181, 1984).

As will be evident to one of skill in the art, the amount and frequency of administration will depend, of course, on such factors as the nature and severity of the indication being treated, the desired response, the condition of the patient, and so forth.

Typically, the compositions may be administered by a variety of techniques, as noted above.

The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLES

EXAMPLE 1

SCLEROSTEOSIS MAPS TO THE LONG ARM OF HUMAN CHROMOSOME 17

Genetic mapping of the defect responsible for sclerosteosis in humans localized the gene responsible for this disorder to the region of human chromosome 17 that encodes a novel TGF-beta binding-protein family member. In sclerosteosis, skeletal bone displays a substantial increase in mineral density relative to that of unaffected individuals. Bone in the head displays overgrowth as well. Sclerosteosis patients are generally healthy although they may exhibit variable degrees of syndactyly at birth and variable degrees of cranial compression and nerve compression in the skull.

Linkage analysis of the gene defect associated with sclerosteosis was conducted by applying the homozygosity mapping method to DNA samples collected from 24 South African Afrikaaner families in which the disease occurred. (Sheffield et al., 1994, *Human Molecular Genetics* 3:1331-1335. "Identification of a Bardet-Biedl syndrome locus on chromosome 3 and evaluation of an efficient approach to homozygosity mapping"). The Afrikaaner population of South Africa is genetically homogeneous; the population is descended from a small number of founders who colonized the area several centuries ago, and it has been isolated by geographic and social barriers since the founding. Sclerosteosis is rare everywhere in the world outside the Afrikaaner community, which suggests that a mutation in the gene was present in the founding population and has since increased in numbers along with the increase in the population. The use of homozygosity mapping is based on the assumption that DNA mapping markers adjacent to a recessive mutation are likely to be homozygous in affected individuals from consanguineous families and isolated populations.

A set of 371 microsatellite markers (Research Genetics, Set 6) from the autosomal chromosomes was selected to type pools of DNA from sclerosteosis patient samples. The DNA samples for this analysis came from 29 sclerosteosis patients in 24 families, 59 unaffected family members and a set of unrelated control individuals from the same population. The pools consisted of 4-6 individuals, either affected individuals, affected individuals from consanguineous families, parents and unaffected siblings, or

unrelated controls. In the pools of unrelated individuals and in most of the pools with affected individuals or family members analysis of the markers showed several allele sizes for each marker. One marker, D17S1299, showed an indication of homozygosity: one band in several of the pools of affected individuals.

5 All 24 sclerosteosis families were typed with a total of 19 markers in the region of D17S1299 (at 17q12-q21). Affected individuals from every family were shown to be homozygous in this region, and 25 of the 29 individuals were homozygous for a core haplotype; they each had the same alleles between D17S1787 and D17S930. The other four individuals had one chromosome which matched this haplotype and a
10 second which did not. In sum, the data compellingly suggested that this 3 megabase region contained the sclerosteosis mutation. Sequence analysis of most of the exons in this 3 megabase region identified a nonsense mutation in the novel TGF-beta binding-protein coding sequence (C>T mutation at position 117 of Sequence ID No. 1 results in a stop codon). This mutation was shown to be unique to sclerosteosis patients and
15 carriers of Afrikaaner descent. The identity of the gene was further confirmed by identifying a mutation in its intron (A>T mutation at position +3 of the intron) which results in improper mRNA processing in a single, unrelated patient with diagnosed sclerosteosis.

20

EXAMPLE 2

TISSUE-SPECIFICITY OF TGF-BETA BINDING-PROTEIN GENE EXPRESSION

A. Human Bone Gene Expression by RT-PCR:

First-strand cDNA was prepared from the following total RNA samples
25 using a commercially available kit ("Superscript Preamplification System for First-Strand cDNA Synthesis", Life Technologies, Rockville, MD): human brain, human liver, human spleen, human thymus, human placenta, human skeletal muscle, human thyroid, human pituitary, human osteoblast (NHOst from Clonetics Corp., San Diego, CA), human osteosarcoma cell line (Saos-2, ATCC# HTB-85), human bone, human
30 bone marrow, human cartilage, vervet monkey bone, *saccharomyces cerevisiae*, and

human peripheral blood monocytes. All RNA samples were purchased from a commercial source (Clontech, Palo Alto, CA), except the following which were prepared in-house: human osteoblast, human osteosarcoma cell line, human bone, human cartilage and vervet monkey bone. These in-house RNA samples were prepared
 5 using a commercially available kit ("TRI Reagent", Molecular Research Center, Inc., Cincinnati, OH).

PCR was performed on these samples, and additionally on a human genomic sample as a control. The sense *Beer* oligonucleotide primer had the sequence 5'-CCGGAGCTGGAGAACAACAAG-3' (SEQ ID NO:19). The antisense *Beer*
 10 oligonucleotide primer had the sequence 5'-GCACTGGCCGGAGCACACC-3' (SEQ ID NO:20). In addition, PCR was performed using primers for the human beta-actin gene, as a control. The sense beta-actin oligonucleotide primer had the sequence 5'-AGGCCAACCGCGAGAAGATGA CC -3' (SEQ ID NO:21). The antisense beta-actin
 15 oligonucleotide primer had the sequence 5'-GAAGT CCAGGGCGACGTAGCA-3' (SEQ ID NO:22). PCR was performed using standard conditions in 25 ul reactions, with an annealing temperature of 61 degrees Celsius. Thirty-two cycles of PCR were performed with the *Beer* primers and twenty-four cycles were performed with the beta-actin primers.

Following amplification, 12 ul from each reaction were analyzed by
 20 agarose gel electrophoresis and ethidium bromide staining. See Figure 2A.

B. RNA In-situ Hybridization of Mouse Embryo Sections:

The full length mouse *Beer* cDNA (Sequence ID No. 11) was cloned into the pCR2.1 vector (Invitrogen, Carlsbad, CA) in the antisense and sense direction using
 25 the manufacturer's protocol. ³⁵S-alpha-GTP-labeled cRNA sense and antisense transcripts were synthesized using in-vitro transcription reagents supplied by Ambion, Inc (Austin, TX). In-situ hybridization was performed according to the protocols of Lyons et al. (*J. Cell Biol.* 111:2427-2436, 1990).

The mouse *Beer* cRNA probe detected a specific message expressed in
 30 the neural tube, limb buds, blood vessels and ossifying cartilages of developing mouse

embryos. Panel A in Figure 3 shows expression in the apical ectodermal ridge (aer) of the limb (l) bud, blood vessels (bv) and the neural tube (nt). Panel B shows expression in the 4th ventricle of the brain (4). Panel C shows expression in the mandible (ma) cervical vertebrae (cv), occipital bone (oc), palate (pa) and a blood vessel (bv). Panel D shows expression in the ribs (r) and a heart valve (va). Panel A is a transverse section of 10.5 dpc embryo. Panel B is a sagittal section of 12.5 dpc embryo and panels C and D are sagittal sections of 15.5 dpc embryos.

ba=branchial arch, h=heart, te=telencephalon (forebrain), b=brain, f=frontonasal mass, g=gut, h=heart, j=jaw, li=liver, lu=lung, ot=otic vesicle, ao=, sc=spinal cord, skm=skeletal muscle, ns=nasal sinus, th=thymus, to=tongue, fl=forelimb, di=diaphragm

EXAMPLE 3

15 EXPRESSION AND PURIFICATION OF RECOMBINANT BEER PROTEIN

A. Expression in COS-1 Cells:

The DNA sequence encoding the full length human Beer protein was amplified using the following PCR oligonucleotide primers: The 5' oligonucleotide primer had the sequence 5'-AAGCTTGGTACCATGCAGCTCCCAC-3' (SEQ ID NO:23) and contained a HindIII restriction enzyme site (in bold) followed by 19 nucleotides of the *Beer* gene starting 6 base pairs prior to the presumed amino terminal start codon (ATG). The 3' oligonucleotide primer had the sequence 5'-AAGCTTCTACTTGTTCATCGTCGTCCT TGTAGTCGTAGGCGTTCTCCAGCT-3' (SEQ ID NO:24) and contained a HindIII restriction enzyme site (in bold) followed by a reverse complement stop codon (CTA) followed by the reverse complement of the FLAG epitope (underlined, Sigma-Aldrich Co., St. Louis, MO) flanked by the reverse complement of nucleotides coding for the carboxy terminal 5 amino acids of the Beer. The PCR product was TA cloned ("Original TA Cloning Kit", Invitrogen, Carlsbad, CA) and individual clones were screened by DNA sequencing. A sequence-verified clone was then digested by HindIII and purified on a 1.5% agarose gel using a

commercially available reagents ("QIAquick Gel Extraction Kit", Qiagen Inc., Valencia, CA). This fragment was then ligated to HindIII digested, phosphatase-treated pcDNA3.1 (Invitrogen, Carlsbad, CA) plasmid with T4 DNA ligase. DH10B *E. coli* were transformed and plated on LB, 100 µg/ml ampicillin plates. Colonies bearing the
 5 desired recombinant in the proper orientation were identified by a PCR-based screen, using a 5' primer corresponding to the T7 promoter/priming site in pcDNA3.1 and a 3' primer with the sequence 5'- GCACTGGCCGGAGCACACC-3' (SEQ ID NO:25) that corresponds to the reverse complement of internal BEER sequence. The sequence of the cloned fragment was confirmed by DNA sequencing.

10 COS-1 cells (ATCC# CRL-1650) were used for transfection. 50 µg of the expression plasmid pcDNA-Beer-Flag was transfected using a commercially available kit following protocols supplied by the manufacturer ("DEAE-Dextran Transfection Kit", Sigma Chemical Co., St. Louis, MO). The final media following transfection was DMEM (Life Technologies, Rockville, MD) containing 0.1% Fetal
 15 Bovine Serum. After 4 days in culture, the media was removed. Expression of recombinant BEER was analyzed by SDS-PAGE and Western Blot using anti-FLAG M2 monoclonal antibody (Sigma-Aldrich Co., St. Louis, MO). Purification of recombinant BEER protein was performed using an anti-FLAG M2 affinity column ("Mammalian Transient Expression System", Sigma-Aldrich Co., St. Louis, MO). The
 20 column profile was analyzed via SDS-PAGE and Western Blot using anti-FLAG M2 monoclonal antibody.

B. Expression in SF9 insect cells:

The human *Beer* gene sequence was amplified using PCR with standard
 25 conditions and the following primers:

Sense primer: 5'-GTCGTCGGATCCATGGGGTGGCAGGCGTTCAAGAATGAT-3'
 (SEQ ID NO:26)

Antisense primer: 5'-GTCGTCAAGCTTCTACTTGTCATCGTCCTTGTAAGTCGTA
 GCGTTCTCCAGCTCGGC-3' (SEQ ID NO:27)

30 The resulting cDNA contained the coding region of Beer with two

modifications. The N-terminal secretion signal was removed and a FLAG epitope tag (Sigma) was fused in frame to the C-terminal end of the insert. BamHI and HindIII cloning sites were added and the gene was subcloned into pMelBac vector (Invitrogen) for transfer into a baculoviral expression vector using standard methods.

5 Recombinant baculoviruses expressing Beer protein were made using the Bac-N-Blue transfection kit (Invitrogen) and purified according to the manufacturers instructions.

SF9 cells (Invitrogen) were maintained in TNM_FH media (Invitrogen) containing 10% fetal calf serum. For protein expression, SF9 cultures in spinner flasks
10 were infected at an MOI of greater than 10. Samples of the media and cells were taken daily for five days, and Beer expression monitored by western blot using an anti-FLAG M2 monoclonal antibody (Sigma) or an anti-Beer rabbit polyclonal antiserum.

After five days the baculovirus-infected SF9 cells were harvested by centrifugation and cell associated protein was extracted from the cell pellet using a high
15 salt extraction buffer (1.5 M NaCl, 50 mM Tris pH 7.5). The extract (20 ml per 300 ml culture) was clarified by centrifugation, dialyzed three times against four liters of Tris buffered saline (150 mM NaCl, 50 mM Tris pH 7.5), and clarified by centrifugation again. This high salt fraction was applied to Hitrap Heparin (Pharmacia; 5 ml bed volume), washed extensively with HEPES buffered saline (25 mM HEPES
20 7.5, 150 mM NaCl) and bound proteins were eluted with a gradient from 150 mM NaCl to 1200 mM NaCl. Beer elution was observed at approximately 800 mM NaCl. Beer containing fractions were supplemented to 10% glycerol and 1 mM DTT and frozen at -80 degrees C.

25

EXAMPLE 4

PREPARATION AND TESTING OF POLYCLONAL ANTIBODIES TO BEER, GREMLIN, AND DAN

A. Preparation of antigen:

The DNA sequences of Human *Beer*, Human *Gremlin*, and Human *Dan*

were amplified using standard PCR methods with the following oligonucleotide primers:

H. Beer

Sense: 5' -GACTTGGATCCCAGGGGTGGCAGGCGTTC- 3' (SEQ ID NO:28)

5 Antisense 5' -AGCATAAGCTTCTAGTAGGCGTTCTCCAG- 3' (SEQ ID NO:29)

H. Gremlin

Sense: 5' -GACTTGGATCCGAAGGGAAAAAGAAAGGG- 3' (SEQ ID NO:30)

Antisense: 5' -AGCATAAGCTTTTAATCCAAATCGATGGA- 3' (SEQ ID NO:31)

H. Dan

10 Sense: 5' -ACTACGAGCTCGGCCCCACCACCCATCAACAAG- 3' (SEQ ID NO:32)

Antisense: 5' -ACTTAGAAGCTTTCAGTCCTCAGCCCCCTCTTCC-3' (SEQ ID NO:33)

In each case the listed primers amplified the entire coding region minus the secretion signal sequence. These include restriction sites for subcloning into the bacterial expression vector pQE-30 (Qiagen Inc., Valencia, CA) at sites BamHI/HindIII for Beer and Gremlin, and sites SacI/HindIII for Dan. pQE30 contains a coding sequence for a 6x His tag at the 5' end of the cloning region. The completed constructs were transformed into *E. coli* strain M-15/pRep (Qiagen Inc) and individual clones verified by sequencing. Protein expression in M-15/pRep and purification (6xHis affinity tag binding to Ni-NTA coupled to Sepharose) were performed as described by the manufacturer (Qiagen, The QIAexpressionist).

The *E. coli*-derived Beer protein was recovered in significant quantity using solubilization in 6M guanidine and dialyzed to 2-4M to prevent precipitation during storage. Gremlin and Dan protein were recovered in higher quantity with solubilization in 6M guanidine and a post purification guanidine concentration of 0.5M.

B. Production and testing of polyclonal antibodies:

Polyclonal antibodies to each of the three antigens were produced in rabbit and in chicken hosts using standard protocols (R & R Antibody, Stanwood, WA; standard protocol for rabbit immunization and antisera recovery; Short Protocols in

Molecular Biology. 2nd edition. 1992. 11.37- 11.41. Contributors Helen M. Cooper and Yvonne Paterson; chicken antisera was generated with Strategic Biosolutions, Ramona, CA).

Rabbit antisera and chicken egg IgY fraction were screened for activity
 5 via Western blot. Each of the three antigens was separated by PAGE and transferred to 0.45um nitrocellulose (Novex, San Diego, CA). The membrane was cut into strips with each strip containing approximately 75 ng of antigen. The strips were blocked in 3% Blotting Grade Block (Bio-Rad Laboratories, Hercules, CA) and washed 3 times in 1X Tris buffer saline (TBS) /0.02% TWEEN buffer. The primary antibody
 10 (preimmunization bleeds, rabbit antisera or chicken egg IgY in dilutions ranging from 1:100 to 1:10,000 in blocking buffer) was incubated with the strips for one hour with gentle rocking. A second series of three washes 1X TBS/0.02%TWEEN was followed by an one hour incubation with the secondary antibody (peroxidase conjugated donkey anti-rabbit, Amersham Life Science, Piscataway, NJ; or peroxidase conjugated donkey
 15 anti-chicken, Jackson ImmunoResearch, West Grove, PA). A final cycle of 3X washes of 1X TBS/0.02%TWEEN was performed and the strips were developed with Lumi-Light Western Blotting Substrate (Roche Molecular Biochemicals, Mannheim, Germany).

20 C. Antibody cross-reactivity test:

Following the protocol described in the previous section, nitrocellulose strips of Beer, Gremlin or Dan were incubated with dilutions (1:5000 and 1:10,000) of their respective rabbit antisera or chicken egg IgY as well as to antisera or chicken egg IgY (dilutions 1:1000 and 1:5000) made to the remaining two antigens. The increased
 25 levels of nonmatching antibodies was performed to detect low affinity binding by those antibodies that may be seen only at increased concentration. The protocol and duration of development is the same for all three binding events using the protocol described above. There was no antigen cross-reactivity observed for any of the antigens tested.

EXAMPLE 5

INTERACTION OF BEER WITH TGF-BETA SUPER-FAMILY PROTEINS

The interaction of Beer with proteins from different phylogenetic arms of the TGF- β superfamily were studied using immunoprecipitation methods. Purified

5 TGF β -1, TGF β -2, TGF β -3, BMP-4, BMP-5, BMP-6 and GDNF were obtained from commercial sources (R&D systems; Minneapolis, MN). A representative protocol is as follows. Partially purified Beer was dialyzed into HEPES buffered saline (25 mM HEPES 7.5, 150 mM NaCl). Immunoprecipitations were done in 300 μ l of IP buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1mM EDTA, 1.4 mM β -mercaptoethanol, 0.5 %

10 triton X 100, and 10% glycerol). 30 ng recombinant human BMP-5 protein (R&D systems) was applied to 15 μ l of FLAG affinity matrix (Sigma; St Louis MO)) in the presence and absence of 500 ng FLAG epitope-tagged Beer. The proteins were incubated for 4 hours @ 4°C and then the affinity matrix-associated proteins were washed 5 times in IP buffer (1 ml per wash). The bound proteins were eluted from the

15 affinity matrix in 60 microliters of 1X SDS PAGE sample buffer. The proteins were resolved by SDS PAGE and Beer associated BMP-5 was detected by western blot using anti-BMP-5 antiserum (Research Diagnostics, Inc) (see Figure 5).

BEER Ligand Binding Assay:

20 FLAG-Beer protein (20 ng) is added to 100 μ l PBS/0.2% BSA and adsorbed into each well of 96 well microtiter plate previously coated with anti-FLAG monoclonal antibody (Sigma; St Louis MO) and blocked with 10% BSA in PBS. This is conducted at room temperature for 60 minutes. This protein solution is removed and the wells are washed to remove unbound protein. BMP-5 is added to each well in

25 concentrations ranging from 10 pM to 500 nM in PBS/0.2% BSA and incubated for 2 hours at room temperature. The binding solution is removed and the plate washed with three times with 200 μ l volumes of PBS/0.2% BSA. BMP-5 levels are then detected using BMP-5 anti-serum via ELISA (F.M. Ausubel et al (1998) Current Protocols in Mol Biol. Vol 2 11.2.1-11.2.22). Specific binding is calculated by subtracting non-

30 specific binding from total binding and analyzed by the LIGAND program (Munson

and Podbard, Anal. Biochem., 107, p220-239, (1980).

In a variation of this method, Beer is engineered and expressed as a human Fc fusion protein. Likewise the ligand BMP is engineered and expressed as mouse Fc fusion. These proteins are incubated together and the assay conducted as described by Mellor et al using homogeneous time resolved fluorescence detection (G.W. Mellor et al., *J of Biomol Screening*, 3(2) 91-99, 1998).

EXAMPLE 6

10

SCREENING ASSAY FOR INHIBITION OF TGF-BETA BINDING-PROTEIN

BINDING TO TGF-BETA FAMILY MEMBERS

The assay described above is replicated with two exceptions. First, BMP concentration is held fixed at the K_d determined previously. Second, a collection of antagonist candidates is added at a fixed concentration (20 μ M in the case of the small organic molecule collections and 1 μ M in antibody studies). These candidate molecules (antagonists) of TGF-beta binding-protein binding include organic compounds derived from commercial or internal collections representing diverse chemical structures. These compounds are prepared as stock solutions in DMSO and are added to assay wells at \leq 1% of final volume under the standard assay conditions. These are incubated for 2 hours at room temperature with the BMP and Beer, the solution removed and the bound BMP is quantitated as described. Agents that inhibit 40% of the BMP binding observed in the absence of compound or antibody are considered antagonists of this interaction. These are further evaluated as potential inhibitors based on titration studies to determine their inhibition constants and their influence on TGF-beta binding-protein binding affinity. Comparable specificity control assays may also be conducted to establish the selectivity profile for the identified antagonist through studies using assays dependent on the BMP ligand action (e.g. BMP/BMP receptor competition study).

EXAMPLE 7

INHIBITION OF TGF-BETA BINDING-PROTEIN LOCALIZATION TO BONE MATRIX

Evaluation of inhibition of localization to bone matrix (hydroxyapatite) is conducted using modifications to the method of Nicolas (Nicolas, V. *Calcif Tissue Int* 5 57:206, 1995). Briefly, ¹²⁵I-labelled TGF-beta binding-protein is prepared as described by Nicolas (*supra*). Hydroxyapatite is added to each well of a 96 well microtiter plate equipped with a polypropylene filtration membrane (Polyfiltroninc, Weymouth MA). TGF-beta binding-protein is added to 0.2% albumin in PBS buffer. The wells containing matrix are washed 3 times with this buffer. Adsorbed TGF-beta binding- 10 protein is eluted using 0.3M NaOH and quantitated.

Inhibitor identification is conducted via incubation of TGF-beta binding-protein with test molecules and applying the mixture to the matrix as described above. The matrix is washed 3 times with 0.2% albumin in PBS buffer. Adsorbed TGF-beta binding-protein is eluted using 0.3 M NaOH and quantitated. Agents that inhibit 40% 15 of the TGF-beta binding-protein binding observed in the absence of compound or antibody are considered bone localization inhibitors. These inhibitors are further characterized through dose response studies to determine their inhibition constants and their influence on TGF-beta binding-protein binding affinity.

20

EXAMPLE 8

CONSTRUCTION OF TGF-BETA BINDING-PROTEIN MUTANT

A. Mutagenesis:

A full-length TGF-beta binding-protein cDNA in pBluescript SK serves 25 as a template for mutagenesis. Briefly, appropriate primers (see the discussion provided above) are utilized to generate the DNA fragment by polymerase chain reaction using Vent DNA polymerase (New England Biolabs, Beverly, MA). The polymerase chain reaction is run for 23 cycles in buffers provided by the manufacturer using a 57°C annealing temperature. The product is then exposed to two restriction enzymes and 30 after isolation using agarose gel electrophoresis, ligated back into pRBP4-503 from

which the matching sequence has been removed by enzymatic digestion. Integrity of the mutant is verified by DNA sequencing.

B. Mammalian Cell Expression and Isolation of Mutant TGF-beta binding-protein:

5 The mutant TGF-beta binding-protein cDNAs are transferred into the pcDNA3.1 mammalian expression vector described in EXAMPLE 3. After verifying the sequence, the resultant constructs are transfected into COS-1 cells, and secreted protein is purified as described in EXAMPLE 3.

10

EXAMPLE 9

ANIMAL MODELS -I

GENERATION OF TRANSGENIC MICE OVEREXPRESSING THE *BEER* GENE

The ~200 kilobase (kb) BAC clone 15G5, isolated from the CITB mouse
 15 genomic DNA library (distributed by Research Genetics, Huntsville, AL) was used to determine the complete sequence of the mouse *Beer* gene and its 5' and 3' flanking regions. A 41 kb *Sall* fragment, containing the entire gene body, plus ~17 kb of 5' flanking and ~20 kb of 3' flanking sequence was sub-cloned into the *Bam*HI site of the SuperCosI cosmid vector (Stratagene, La Jolla, CA) and propagated in the *E. coli* strain
 20 DH10B. From this cosmid construct, a 35 kb *Mlu*I - *Avi*III restriction fragment (Sequence No. 6), including the entire mouse *Beer* gene, as well as 17 kb and 14 kb of 5' and 3' flanking sequence, respectively, was then gel purified, using conventional means, and used for microinjection of mouse zygotes (DNX Transgenics; US Patent No. 4,873,191). Founder animals in which the cloned DNA fragment was integrated
 25 randomly into the genome were obtained at a frequency of 5-30% of live-born pups. The presence of the transgene was ascertained by performing Southern blot analysis of genomic DNA extracted from a small amount of mouse tissue, such as the tip of a tail. DNA was extracted using the following protocol: tissue was digested overnight at 55°C in a lysis buffer containing 200 mM NaCl, 100 mM Tris pH8.5, 5 mM EDTA, 0.2%
 30 SDS and 0.5 mg/ml Proteinase K. The following day, the DNA was extracted once

with phenol/chloroform (50:50), once with chloroform/isoamylalcohol (24:1) and precipitated with ethanol. Upon resuspension in TE (10mM Tris pH7.5, 1 mM EDTA) 8-10 ug of each DNA sample were digested with a restriction endonuclease, such as EcoRI, subjected to gel electrophoresis and transferred to a charged nylon membrane, such as HyBondN+ (Amersham, Arlington Heights, IL). The resulting filter was then hybridized with a radioactively labelled fragment of DNA deriving from the mouse *Beer* gene locus, and able to recognize both a fragment from the endogenous gene locus and a fragment of a different size deriving from the transgene. Founder animals were bred to normal non-transgenic mice to generate sufficient numbers of transgenic and non-transgenic progeny in which to determine the effects of *Beer* gene overexpression. For these studies, animals at various ages (for example, 1 day, 3 weeks, 6 weeks, 4 months) are subjected to a number of different assays designed to ascertain gross skeletal formation, bone mineral density, bone mineral content, osteoclast and osteoblast activity, extent of endochondral ossification, cartilage formation, etc. The transcriptional activity from the transgene may be determined by extracting RNA from various tissues, and using an RT-PCR assay which takes advantage of single nucleotide polymorphisms between the mouse strain from which the transgene is derived (129Sv/J) and the strain of mice used for DNA microinjection [(C57BL5/J x SJL/J)F2].

ANIMAL MODELS – II

DISRUPTION OF THE MOUSE BEER GENE BY HOMOLOGOUS RECOMBINATION

Homologous recombination in embryonic stem (ES) cells can be used to inactivate the endogenous mouse *Beer* gene and subsequently generate animals carrying the loss-of-function mutation. A reporter gene, such as the *E. coli* β -galactosidase gene, was engineered into the targeting vector so that its expression is controlled by the endogenous *Beer* gene's promoter and translational initiation signal. In this way, the spatial and temporal patterns of *Beer* gene expression can be determined in animals carrying a targeted allele.

The targeting vector was constructed by first cloning the drug-selectable phosphoglycerate kinase (PGK) promoter driven *neomycin-resistance* gene (*neo*)

cassette from pGT-N29 (New England Biolabs, Beverly, MA) into the cloning vector pSP72 (Promega, -Madson, WI). PCR was used to flank the PGKneo cassette with bacteriophage P1 loxP sites, which are recognition sites for the P1 Cre recombinase (Hoess et al., PNAS USA, 79:3398, 1982). This allows subsequent removal of the neo-resistance marker in targeted ES cells or ES cell-derived animals (US Patent 4,959,317). The PCR primers were comprised of the 34 nucleotide (ntd) loxP sequence, 15-25 ntd complementary to the 5' and 3' ends of the PGKneo cassette, as well as restriction enzyme recognition sites (BamHI in the sense primer and EcoRI in the anti-sense primer) for cloning into pSP72. The sequence of the sense primer was 5'-AATCTGGATCCATAACTTCGTATAGCATACATTATACGAAGTTATCTGCAG . GATTCGAGGGCCCCCT-3' (SEQ ID NO:34); sequence of the anti-sense primer was 5'-AATCTGAATTCCACCGGTGTTAATTAATAACTTCGT ATAATGTATGCTATACGAAGTTATAGATCTAGAG TCAGCTTCTGA-3' (SEQ ID NO:35).

The next step was to clone a 3.6 kb XhoI-HindIII fragment, containing the *E. coli* β -galactosidase gene and SV40 polyadenylation signal from pSV β (Clontech, Palo Alto, CA) into the pSP72-PGKneo plasmid. The "short arm" of homology from the mouse *Beer* gene locus was generated by amplifying a 2.4 kb fragment from the BAC clone 15G5. The 3' end of the fragment coincided with the translational initiation site of the *Beer* gene, and the anti-sense primer used in the PCR also included 30 ntd complementary to the 5' end of the β -galactosidase gene so that its coding region could be fused to the Beer initiation site in-frame. The approach taken for introducing the "short arm" into the pSP72- β gal-PGKneo plasmid was to linearize the plasmid at a site upstream of the β -gal gene and then to co-transform this fragment with the "short arm" PCR product and to select for plasmids in which the PCR product was integrated by homologous recombination. The sense primer for the "short arm" amplification included 30 ntd complementary to the pSP72 vector to allow for this recombination event. The sequence of the sense primer was 5'-ATTAGGTGACACT ATAGAACTCGAGCAGCTGAAGCTTAACCACATGGTGGCTCACAACCAT-3' (SEQ ID NO:36) and the sequence of the anti-sense primer was 5'-

AACGACGGCCAGTGAATCCGTA

ATCATGGTCATGCTGCCAGGTGGAGGAGGGCA-3' (SEQ ID NO:37).

The "long arm" from the *Beer* gene locus was generated by amplifying a 6.1 kb fragment from BAC clone 15G5 with primers which also introduce the rare-cutting restriction enzyme sites SgrAI, FseI, AscI and PacI. Specifically, the sequence of the sense primer was 5'-ATTACCACCGGTGACACCCGCTTCCTGACAG-3' (SEQ ID NO:38); the sequence of the anti-sense primer was 5'-ATTACTTAATTAAACATGGCGCGCCAT ATGGCCGGCCCCCTAATTGCGGCGCATCGTTAATT-3' (SEQ ID NO:39). The resulting PCR product was cloned into the TA vector (Invitrogen, Carlsbad, CA) as an intermediate step.

The mouse *Beer* gene targeting construct also included a second selectable marker, the *herpes simplex virus 1 thymidine kinase* gene (HSVTK) under the control of rous sarcoma virus long terminal repeat element (RSV LTR). Expression of this gene renders mammalian cells sensitive (and inviable) to gancyclovir; it is therefore a convenient way to select against neomycin-resistant cells in which the construct has integrated by a non-homologous event (US Patent 5,464,764). The RSVLTR-HSVTK cassette was amplified from pPS1337 using primers that allow subsequent cloning into the FseI and AscI sites of the "long arm"-TA vector plasmid. For this PCR, the sequence of the sense primer was 5'-ATTACGGCCGGCCGCAAAGGAATTCAAGATCTGA-3' (SEQ ID NO:40); the sequence of the anti-sense primer was 5'-ATTACGGCGCGCCCCTC ACAGGCCGCGACCCAGCT-3' (SEQ ID NO:41).

The final step in the construction of the targeting vector involved cloning the 8.8 kb SgrAI-AscI fragment containing the "long arm" and RSVLTR-HSVTK gene into the SgrAI and AscI sites of the pSP72-"short arm"-βgal-PGKneo plasmid. This targeting vector was linearized by digestion with either AscI or PacI before electroporation into ES cells.

EXAMPLE 10

ANTISENSE-MEDIATED BEER INACTIVATION

17-nucleotide antisense oligonucleotides are prepared in an overlapping format, in such a way that the 5' end of the first oligonucleotide overlaps the translation
5 initiating AUG of the Beer transcript, and the 5' ends of successive oligonucleotides occur in 5 nucleotide increments moving in the 5' direction (up to 50 nucleotides away), relative to the Beer AUG. Corresponding control oligonucleotides are designed and prepared using equivalent base composition but redistributed in sequence to inhibit any significant hybridization to the coding mRNA. Reagent delivery to the test cellular
10 system is conducted through cationic lipid delivery (P.L. Felgner, *Proc. Natl. Acad. Sci. USA* 84:7413, 1987). 2 ug of antisense oligonucleotide is added to 100 ul of reduced serum media (Opti-MEM I reduced serum media; Life Technologies, Gaithersburg MD) and this is mixed with Lipofectin reagent (6 ul) (Life Technologies, Gaithersburg MD) in the 100 ul of reduced serum media. These are mixed, allowed to complex for 30
15 minutes at room temperature and the mixture is added to previously seeded MC3T3E21 or KS483 cells. These cells are cultured and the mRNA recovered. Beer mRNA is monitored using RT-PCR in conjunction with Beer specific primers. In addition, separate experimental wells are collected and protein levels characterized through western blot methods described in Example 4. The cells are harvested, resuspended in
20 lysis buffer (50 mM Tris pH 7.5, 20 mM NaCl, 1mM EDTA, 1% SDS) and the soluble protein collected. This material is applied to 10-20 % gradient denaturing SDS PAGE. The separated proteins are transferred to nitrocellulose and the western blot conducted as above using the antibody reagents described. In parallel, the control oligonucleotides are added to identical cultures and experimental operations are repeated. Decrease in
25 Beer mRNA or protein levels are considered significant if the treatment with the antisense oligonucleotide results in a 50% change in either instance compared to the control scrambled oligonucleotide. This methodology enables selective gene inactivation and subsequent phenotype characterization of the mineralized nodules in the tissue culture model.

SEQUENCES

Sequence ID No. 1: Human BEER cDNA (complete coding region plus 5' and 3' UTRs)

5 AGAGCCTGTGCTACTGGAAGGTGGCGTGCCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCGTCTGC
CTGCTGGTACACACAGCCTTCCTGTAGTGGAGGGCCAGGGGTGGCAGGCGTTCAAGAATGATGCCACGGAAATCATCCC
CGAGCTCGGAGAGTACCCCGAGCCTCCACCGAGCTGGAGAACAAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
10 CTCCCCACCACCCCTTTGAGACCAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACTTCACCCGCTACGTGACCGAT
GGGCGGTGCCGAGCGCCAAGCCGGTCAACGAGCTGGTGTGCTCCGGCCAGTGGCGCCCGCGCGCTGTGCCCCAACGC
CATCGGCCGCGCAAGTGGTGGCGACCTAGTGGGCCGACTTCCGCTGCATCCCCGACCGCTACCGCGCGCAGCGGTGC
AGCTGTGTGTCCCGGTGGTGGCGCGCGCGCGCAAGGTGCGCCTGGTGGCTCGTGAAGTGAAGCGCCTCACC
CGCTTCCACAACCAAGTGGAGCTCAAGGACTTCGGGACCGAGGCGGCTCGGCCGAGAGGGCCGGAAGCGCGGCCCG
15 CGCCCGGAGCGCAAGCCAAACAGGCGAGCTGGAGAACCCCTACTAGAGCCCGCCGCGCCCTCCCCACCGCGGGC
GCCCGGCCCTGAACCGCGCGCCACATTTCTGTCTCTGCGCGTGGTTTGATTGTTTATATTTCATTGTAATGCCTGC
AACCAGGGCAGGGGCTGAGACCTTCAGGCCCTGAGGAATCCCGGGCGCGGCAAGGCCCTCCAGCCGCGAGCTG
AGGGGTCCACGGGGCAGGGGAGGGAATTGAGAGTACAGACACTGAGCCACGCGAGCCCGCTCTGGGGCCGCTACCT
TTGCTGGTCCCACTTCAGAGGAGGAGAAATGAAGCATTTTCACCGCCTGGGGTTTAAAGGAGCGGTGTGGAGTGG
20 GAAAGTCCAGGAGTGGTTAAGAAAGTTGGATAAGATTCCCTTGCACCTCGCTGCCATCAGAAAGCCTGAGGCGTGC
CCAGAGCACAAAGACTGGGGGCAACTGTAGATGTGGTTTCTAGTCTGGCTGCGCACTAACTTGCTGTGTAACCTGAAC
TACACAATTCTCCTTCGGGACCTCAATTTCCACTTTGTAATAGAGGTGGAGTGGGAATAGGATCTCGAGGAGACTAT
TGGCATATGATTCCAAGGACTCCAGTGCCTTTTGAATGGGCGAGGTGAGAGAGAGAGAGAGAAAGAGAGAGAAATGAATG
CAGTTGCATTGATTCAAGTGCAGGTCACTTCCAGAATTCAGAGTGTGATGCTCTCTTCTGACAGCCAAAGATGAAAA
25 CAAACAGAAAAAAGTAAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAAGCTATGCTG
CTTCCAGCCTGGCTTCCCCGATGTTTGGCTACCTCCACCCCTCCATCTCAAGAAATAACATCATCATTGGGGTAGA
AAAGGAGAGGGTCCGAGGGTGGTGGGAGGATAGAAATCATCCGCCCACTTCCAAAGAGCAGCATCCCTCCCCCG
ACCCATAGCCATGTTTAAAGTCACTTCCGAAGAGAGTGAAGGTTCAAGGACACTGGCCTTGCAGGCGCGAGGGAGC
AGCCATCAAACTCACAGACAGACATCCCTTTGAGACACCGCTTCTGCCCACTACCGGACACATTTCTGCCT
AGAAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATTTACACTAAAAGATATTATTTGGGGAAAACTACAAGT
30 GTGTACATATGCTGAGAACTGCAGAGCATATAGCTGCCACCAAAATCTTTTGAATATCATTTCCAGACAACTC
TTACTTTCTGTGTAGTTTAAATGTTAAAAAAGAGTTTAAACAGAGCAGATGACATATGAAGCCCTGCGGACT
GGTGGTTTGGCAATTCTCCAGTGGGACTTGTCCACAGAAATGAAGTAGTGGTTTAAAGAGTTAAATTACAT
ATTTATTTCTCACTTAAGTTATTTATGCAAGTTTCTTGTAGAGAAATGCAATGTTAATATTGCTTTATGAATTAA
CAGTCTGTCTTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG
35

Sequence ID No. 2: Human BEER protein (complete sequence)

40 MQLPLALCLVCLLVHTAFRVVEGQGWQAFKNDATETIPELGEYPEPPPELENNKTMNRAENGRRPPHPFETKDVSEYSC
RELHFTRYVTDGPRCAKPVTELVCSGQCGPARLLPNAIGRKWWRPSGPDFRCIPDRYRQVRVQLLCPGGEAPRARKVR
LVASCKCKRLTRFHNQSELKDFGTEAARPQKGRKPRPRARSAKANQAELENAY

45 Sequence ID No. 3: Human Beer cDNA containing Sclerosteosis nonsense mutation

AGAGCCTGTGCTACTGGAAGGTGGCGTGCCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCGTCTGC
CTGCTGGTACACACAGCCTTCCTGTAGTGGAGGGCTAGGGGTGGCAGGCGTTCAAGAATGATGCCACGGAAATCATCC
50 CGAGCTCGGAGAGTACCCCGAGCCTCCACCGAGCTGGAGAACAAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
CTCCCCACCACCCCTTTGAGACCAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACTTCACCCGCTACGTGACCGAT
GGGCGGTGCCGAGCGCCAAGCCGGTCAACGAGCTGGTGTGCTCCGGCCAGTGGCGCCCGCGCGCTGTGCCCCAACGC
CATCGGCCGCGCAAGTGGTGGCGACCTAGTGGGCCGACTTCCGCTGCATCCCCGACCGCTACCGCGCGCAGCGGTGC
AGCTGTGTGTCCCGGTGGTGGCGCGCGCGCGCGCAAGGTGCGCCTGGTGGCTGTGCAAGTGAAGCGCCTCACC
55 CGCTTCCACAACCAAGTGGAGCTCAAGGACTTCGGGACCGAGGCGGCTCGGCCGAGAGGGCCGGAAGCCGCGGCCCG
CGCCCGGAGCGCAAGCCAAACAGGCGGAGCTGGAGAACCCCTACTAGAGCCCGCCGCGCCCTCCCCACCGCGGGC
GCCCCGGCCCTGAACCCGCGCCCAATTTCTGTCTCTGCGCGTGGTTTGATTGTTTATATTTCATTGTAATGCCTGC
AACCAGGGCAGGGGCTGAGACCTTCAGGCCCTGAGGAATCCCGGGCGCGGCAAGGCCCTCCAGCCCGCAGCTG
AGGGGTCCACGGGGCAGGGGAGGGAATTGAGAGTACAGACACTGAGCCACGCGAGCCCGCTCTGGGGCCGCTACCT
60 TTGCTGGTCCCACTTCAGAGGAGGAGAAATGAAGCATTTTCACCGCCTGGGGTTTAAAGGAGCGGTGTGGAGTGG
GAAAGTCCAGGAGTGGTTAAGAAAGTTGGATAAGATTCCCTTGCACCTCGCTGCCATCAGAAAGCCTGAGGCGTGC
CCAGAGCACAAAGACTGGGGGCAACTGTAGATGTGGTTTCTAGTCTGGCTGCGCACTAACTTGCTGTGTAACCTGAAC
TACACAATTCTCCTTCGGGACCTCAATTTCCACTTTGTAATAGAGGTGGAGTGGGAATAGGATCTCGAGGAGACTAT
TGGCATATGATTCCAAGGACTCCAGTGCCTTTTGAATGGGCGAGGTGAGAGAGAGAGAGAGAAAGAGAGAGAAATGAATG
65 CAGTTGCATTGATTCAAGTGCAGGTCACTTCCAGAATTCAGAGTGTGATGCTCTCTTCTGACAGCCAAAGATGAAAA

CAAACAGAAAAAAGTAAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAAGCTATGCTG
 CTTCCAGCCTGGCTTCCCGGATGTTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
 AAAGGAGAGGGTCCGAGGGTGGTGGGAGGATAGAAATCACATCCGCCCAACTTCCCAAAGAGCAGCATCCCTCCCCG
 ACCCATAGCCATGTTTAAAGTCACCTTCCGAAGAGAAGTGAAGGTTCAAGGACACTGGCCTTGACGGCCCGAGGGAGC
 5 AGCCATCACAACTCACAGACCAGCACATCCCTTTTGAGACACCGCCTTCTGCCACCCTCACGGACACATTTCTGCCT
 AGAAAAACAGCTTCTACTGCTCTTACATGTGATGGCATATCTTACACTAAAGAATATTATTGGGGGAAAAACTACAAGT
 GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAAATCTTTTGAAATCATTCCAGACACCTC
 TTACTTTCTGTGTAGTTTTTAATTGTTAAAAAAGTTTAAACAGAAGCACATGACATATGAAAGCCTGCAGGACT
 10 GGTGTTTTTTGGCAATTCTTCCAGTGGGACTTGTCCACAAGATGAAAGTAGTGGTTTTTAAAGAGTTAAGTTACAT
 ATTTATTTCTCACTTAAGTTATTATGCAAAAGTTTTCTTGTAGAGATGACAATGTTAATATTGCTTTATGAATTAA
 CAGTCTGTTCTTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG

Sequence ID No. 4: Truncated Human Beer protein from Sclerosteosis

15 MQLPLALCLVCLLVHTAFRVVEG*

20 Sequence ID No. 5: Human BEER cDNA encoding protein variant (V10I)

AGAGCCTGTGCTACTGGAAGGTGGCGTGCCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCATCTGC
 CTGCTGGTACACAGCCTTCCGTGTAGTGGAGGGCCAGGGTGGCAGGCCTTCAAGAATGATGCCACGGAATCATCCG
 CGAGCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGAACAACAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
 25 CTCCCCACCACTTCTTGGAGACCAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACCTTCAACCCGTACGTGACCGAT
 GGGCCGTGCGCAGCGCCAAGCCCGTCCCGAGTGTGTGCTCCGCGCAGTGCAGCCCGCGCGCTGTGCGCCAACGC
 CATCGGCGCGGCAAGTGGTGGCGACCTAGTGGGCGGACTTCCGCTGCATCCCGCAACGCTACCGCGCGCAGCGCGTGC
 AGCTGCTGTGTCCTGGTGGTGGAGCGCCGCGCGCAAGGTGCGCCTGGTGGCTCGTGCAAGTGAAGCGCCTCACC
 CGCTTCCACAACCACTGGAGCTCAAGGACTTCGGGACCGAGCGCTCGGCCGAGAAGGGCGGAGCGCGGCCCCG
 30 CGCCCGAGCGCCAAGGCCAACCAGGCGGAGCTGGAGAAGCCTACTAGAGCCCGCCCGCCCTCCACCGCGCGGGC
 GCGCCGCGCTGAACCCGCGCCCACTTCTGTCTCTGCGCTGGTGTGATTGTTTATTTATTGTTAAATGCCTGC
 AACCAGGGCAGGGGGCTGAGACCTTCCAGGCGCTGAGGAATCCCGGCGCGGCAAGGCCCTCCAGCCCGCCAGCTG
 AGGGGTCCCAAGGGGCGAGGGGAGGAATTGAGAGTCCAGACACTGAGCCACGCGAGCCCGCTCTGGGGCGCCTACCT
 TTGCTGGTCCCACTTCCAGAGGAGCAGAAATGGAAGCATTTTACCGCCCTGGGGTTTAAAGGAGCGGTGTGGAGTGG
 35 GAAAGTCCAGGAGCTGGTTAAGAAAGTTGGATAAGATTCCCGCTTGCACCTCGCTGCCCATCAGAAAGCCTGAGGCGTGC
 CCAGAGCACAAGACTGGGGCACTGTAGATGTGTTTCTAGTCTGGCTCTGCCACTAATTGTGTGTAACTTGAAC
 TACACAATTCTCCTTCCGGACCTCAATTTCACCTTGTAAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
 TGGCATATGATTCCAAGACTCCAGTGCCTTTGAATGGGCAGAGGTGAGAGAGAGAGAGAAGAGAGAGAATGAATG
 CAGTTGCATTGATTAGTGCCTAAGGTCACTTCCAGAATTGAGAGTTGTGTCTCTTCTGACAGCCAAAGATGAAAAA
 40 CAAACAGAAAAAAGTAAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAAGCTATGCTG
 CTTCCAGCCTGGCTTCCCGGATGTTTGGCTACCTCACCCTCCATCTCAAAGAAATAACATCATCTTGGGGTAGA
 AAAGGAGAGGGTCCGAGGGTGGTGGGAGGATAGAAATCACATCCGCCCAACTTCCCAAAGAGCAGCATCCCTCCCCG
 ACCCATAGCCATGTTTAAAGTCACCTTCCGAAGAGAAGTGAAGGTTCAAGGACACTGGCCTTGACGGCCCGAGGGAGC
 AGCCATCACAACTCACAGACCAGCACATCCCTTTTGAGACACCGCCTTCTGCCACCCTCACGGACACATTTCTGCCT
 45 AGAAAAACAGCTTCTACTGCTCTTACATGTGATGGCATATCTTACACTAAAGAATATTATTGGGGGAAAAACTACAAGT
 GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAAATCTTTTGAAATCATTCCAGACACCTC
 TTACTTTCTGTGTAGTTTTTAATTGTTAAAAAAGTTTAAACAGAAGCACATGACATATGAAAGCCTGCAGGACT
 GGTGTTTTTTGGCAATTCTTCCAGTGGGACTTGTCCACAAGATGAAAGTAGTGGTTTTTAAAGAGTTAAGTTACAT
 ATTTATTTCTCACTTAAGTTATTATGCAAAAGTTTTCTTGTAGAGATGACAATGTTAATATTGCTTTATGAATTAA
 50 CAGTCTGTTCTTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG

Sequence ID No. 6: Human BEER protein variant (V10I)

55 MQLPLALCLICLLVHTAFRVVEGQGWQAFKNDATETIIRELGEYPEPPPELENNKTMNRAENGRRPPHPFETKDVSEYSC
 RELHFTRYVTDGPCRSAPVTELVCSGQCGPARLLPNAIGRGKWRPSPGDFRCIPDRYRAQRVQLLCPGGEAPRARKVR
 LVASCKCKRLTRFHNQSELKDFGTEAARPQKGRKPRPRARSAKANQAELENAY

60 Sequence ID No. 7: Human Beer cDNA encoding protein variant (P38R)

AGAGCCTGTGCTACTGGAAGGTGGCGTGCCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCGTCTGC
 CTGCTGGTACACAGCCTTCCGTGTAGTGGAGGGCCAGGGTGGCAGGCCTTCAAGAATGATGCCACGGAATCATCCG
 65 CGAGCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGAACAACAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
 CTCCCCACCACTTGGAGACCAAGACGTGTCCGATACAGCTGCCGCGAGCTGCACCTTCAACCCGTACGTGACCGAT
 GGCCCGTCCCGCAGCGCCAAGCCGCTCACCGAGTGGTGTGCTCCGCGCAGTGCAGCCCGCGCGCTGTGCGCCAACGC

CATCGGCCGCGCAAGTGGTGGCGACCTAGTGGGCCCCGACTTCCGCTGCATCCCCGACCGCTACCGCGCGCAGCGCGTGC
 AGCTGCTGTGTCCCGGTGGTGAAGCGCGCGCGCGCAAGGTGCGCCTGGTGGCCTCGTGCAAGTGAAGCGCCTCACC
 CGCTTCCACAACCAGTCGGAGCTCAAGGACTTCGGGACCGAGGCCGCTCGGCCGCGAGAAGGGCCGGAAGCCGCGGCCCG
 CGCCCGGAGCGCCAAAGCCAACCAGGCCGAGCTGGAGAAGCGCCTACTAGAGCCGCGCCGCGCCCTCCCCACCGCGGGC
 5 GCCCCGGCCCTGAACCCGCGCCCCACATTCTGTCTCTGCGCGTGGTTTGATTGTTTATATTTTCATTGTAAATGCCTGC
 AACCAGGGCAGGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCCGGGCGCGGCAAGGCCCCCTCAGCCCGCCAGCTG
 AGGGGTCCACGGGGCAGGGGAGGGAATTGAGAGTCACAGACACTGAGCCACGACGCCCGCTCTGGGGCCGCTACCT
 TTGCTGGTCCCACTTCAGAGGAGGAGAAATGGAAGCATTTTACCGCCCTGGGGTTTAAAGGAGCGGTGTGGGAGTGG
 10 GAAAGTCCAGGACTGGTTAAGAAAGTTGGATAAGATTCCCCCTGCACCTCGCTGCCATCAGAAAGCCTGAGGCGTGC
 CCAGAGCACAAGACTGGGGGCACTGTAGATGTGGTTTCTAGTCTGGCTCTGCCACTAATTGCTGTGTAACTTGAAC
 TACACAATTCTCTTCGGGACCTCAATTTCEACTTTGTAATAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
 TGGCATATGATTCCAAGGACTCCAGTGCCCTTTGAATGGGCGAGAGTGAGAGAGAGAGAGAGAGAGAGAGAAATGAATG
 CAGTTGCATTGATTCAAGTCCCAAGGTCACTTCCAGAATTGAGAGTTGTGATGCTCTCTCTGACAGCCAAAGATGAAAA
 CAAACAGAAAAAAGTAAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAAACTCTCGGAAGAAGCTATGCTG
 15 CTTCCAGCCTGGCTTCCCGGATGTTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
 AAAGGAGAGGGTCCGAGGGTGGTGGGAGGATAGAAATCAGATCCGCCCCAACTTCCCAAGAGCAGCATCCCTCCCCCG
 ACCCATAGCCATGTTTAAAGTCACTTCCGAAGAGAAGTGAAGGTTCAAGGACACTGGCCTTGCAAGCCCGAGGGAGC
 AGCCATCAGAACTCAGACACAGCAGCATCCCTTTGAGACACCGCCTTCTGCCCACTCAGGACACATTTCTGCCT
 AGAAAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAAGAATATTATGGGGGAAAACTACAAGT
 20 GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAAATCTTTTGAAATCATTTCCAGACAACCTC
 TTACTTTCTGTAGTTTTTAATTGTTAAAAAAGTTTTAAACAGAGCAGCATGACATATGAAGCCCTGAGGACT
 GGTGTTTTTTGGCAATTCTTCCAGTGGGACTGTGCCACAAGAATGAAAGTAGTGGTTTTTAAAGAGTTAAGTTACAT
 ATTTATTTCTCACTAAGTTATTATGCAAAAGTTTTCTTGTAGAGAATGACAAATGTTAATATTGCTTTATGAATTAA
 CAGTCTGTTCTTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG
 25

Sequence ID No. 8: Human BEER protein variant (P38R)

30 MQLPLALCLVCLLVHATAFRVVEGQGWQAFKNDATETIIRELGEYPEPPPELENNKTMNRAENGRRPPHPFETKDVSEYSC
 RELHFTTRYVTDGPCRSAPVTELVCSSGQCGPARLLPNAIGRGKWWRPSPGDFRCIPDRYARQVQLLCPGGEAPRARKVR
 LVASCKCKRLTRFHNQSELKDFGTEAARPOKGRKPRPRARSAKANQAELENAY

35 Sequence ID No. 9: Vervet BEER cDNA (complete coding region)

ATGCAGCTCCCACTGGCCCTGTGTCTGTCTGCTGGTACACGACGCTTCCGTTGATGTGAGGGGCCAGGGGTGGCA
 GGCTTCAAGAATGATGCCACGGAATCATCCCGAGCTCGGAGAGTACCCGAGCCGCCACCGGAGCTGGAGAAACA
 AGACCATGAACCGGGCGGAGAATGGAGGGCGGCTCCCCACCAACCCCTTTGAGACCAAGACGTGTCCGAGTACAGCTGC
 40 CGAGAGTGCCTTACCCGCTACGTGACCGATGGGCGGTGCGCGAGCGCAAGCCAGTCACCGAGTTGGTGTGCTCCGG
 CCAGTGGCGCCCGGACGCTGTGCCCAACGCCATCGGCCGCGGCAAGTGGTGGCGCCGAGTGGGCCGACTTCCGCT
 GCATCCCGACCGCTACCGCGCGAGCGTGTGACGTGCTGTGTCGGTGGTGGCGCCGCGCGCGCAAGGTGCGC
 CTGGTGGCCTCGTGAAGTGAAGCGCTTCCACCGCTTCCACAACAGTCCGAGCTCAGGACTTCCGTTCCGAGGCGCG
 45 TCGGCCGAGAAAGGCCGAAGCCGCGCCCCGCGCCCGGGGGCCAAAGCCAATCAGGCCGAGCTGGAGAACGCTACT
 AG

Sequence ID No. 10: Vervet BEER protein (complete sequence)

50 MQLPLALCLVCLLVHAAFRVVEGQGWQAFKNDATETIIRELGEYPEPPPELENNKTMNRAENGRRPPHPFETKDVSEYSC
 RELHFTTRYVTDGPCRSAPVTELVCSSGQCGPARLLPNAIGRGKWWRPSPGDFRCIPDRYARQVQLLCPGGEAPRARKVR
 LVASCKCKRLTRFHNQSELKDFGPEAARPOKGRKPRPRARGAKANQAELENAY

55 Sequence ID No. 11: Mouse BEER cDNA (coding region only)

ATGCAGCCCTCACTAGCCCGTGCCTCATCTGCTACTTGTGCACGCTGCCTTCTGTGCTGTGAGGGGCCAGGGGTGGCA
 AGCCTTCAGGAATGATGCCACAGAGGTATCCAGGGCTTGGAGAGTACCCGAGCCTCTCTGAGAACCAACAGACCA
 60 TGAACCGGGCGGAGAATGGAGGAGACCTCCCAACCATCCCTATGACGCCAAAGGTGTGTCGAGTACAGCTGCCGCGAG
 CTGCACTACACCCGCTTCTGACAGACGGCCATGCCGACGCGCAAGCCGCTCACCAGTTGGTGTGCTCCGGCCAGTG
 CGGCCCGCGCGGCTGTGCCCAACGCCATCGGGCGGTGAAGTGGTGGCGCCGAAGCAGACCGGATTTCCGCTGCATCC
 CGGATCGTACCGCGCGCAGGGTGCAGCTGTGTCGCCCGGGGCGCGCGCGCGCTCGCGCAAGGTGCGTGTG
 GCCTCGTGCAAGTGAAGCGCTCACCCTTCCACAACAGTCCGAGCTCAAGGACTTCCGGCCGAGACCGCGCGGCC
 65 GCAGAAGGTCGCAAGCCGCGGCCCGCGCCCGGGGAGCCAAAGCCAACAGGCGGAGCTGGAGAACGCTACTAGAG

Sequence ID No. 12: Mouse BEER protein (complete sequence)

5 MQPSLAPCLICLLVHAAFCAVEGGQWQAFRNDATVPIPLGEYEPPEPPENNQTMNRAENGGRPPHPYDAKDVSEYSCRE
LHYTRFLTDGPCRSAPVTELVCSGQCGPARLLPNAIGRVKWWRPNGPDFRCIPDRYRAQRVQLLCPGGAAPRSRKVRLV
ASCKCKRLTRFHNQSELKDFGPETARPQKGRKPRPGARGAKANQAELENAY

10

Sequence ID No. 13: Rat BEER cDNA (complete coding region plus 5' UTR)

GAGGACCGAGTGCCCTTCTCTTCTGGCACCATGCAGCTCTCACTAGCCCCTTGCCTTGCCTGCCTGCTGTACATGCA
GCCTTCGTTGCTGTGGAGAGCCAGGGGTGGCAAGCCTTCAAGAATGATGCCACAGAAATCATCCCGGAGCTCAGAGAGTA
15 CCCAGAGCCTCCTCAGGAAGTACAGAAACCAACAGACCATGAACCGGGCCGAGAACGGAGGCAGACCCCCCACCATCCTT
ATGACACCAAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACTACACCCGCTTCGTGACCGACGGCCCGTGCCGAGT
GCCAAGCCCGTCAACGAGTTGGTGTCTCGGCGCAGTGCAGCCCGCGCGCTGTGCCAACGCCATCGGGCGCGTGAA
GTGGTGGCGCCGAAACGACCCGACTTCCGCTGCATCCCGGATCGCTACCGCGCGCAGCGGTGCAGTGTGTGCCCG
GCGGCGCGCGCGCGCTCGCGCAAGGTGCGTCTGGTGGCTCGTGCAAGTGCAGCGCCTCACCCGCTTCCACAACCAG
20 TCGGAGCTCAAGGACTTCGGACCTGAGACCGCGCGCGCAGAGGGTGCAGAGCCGCGGCCCGCGCCCGGGGAGCCAA
AGCCAACCGAGCGAGCTGGAGAACGCTACTAG

25

Sequence ID No. 14: Rat BEER protein (complete sequence)

MQLSLAPCLACLLVHAAFVAVESQGWQAFKNDATVPIPLREYEPPEQLENNQTMNRAENGGRPPHPYDTKDVSEYSC
RELHYTRFVTDGPCRSAPVTELVCSGQCGPARLLPNAIGRVKWWRPNGPDFRCIPDRYRAQRVQLLCPGGAAPRSRKVR
LVASCKCKRLTRFHNQSELKDFGPETARPQKGRKPRPRARGAKANQAELENAY

30

Sequence ID No. 15: Bovine BEER cDNA (partial coding sequence)

AGAATGATGCCACAGAAATCATCCCGAGCTGGGCGAGTACCCCGAGCCTCTGCCAGAGCTGAACAACAAGACCATGAAC
35 CGGGCGGAGAACGGAGGGAGACCTCCCCACACCCCTTTGAGACCAAGACGCCTCCGAGTACAGCTGCCGGGAGCTGCA
CTTCACCCGCTACGTGACGATGGGCGGTGCCGCGAGCGCAAGCCGGTCAACGAGCTGGTGTGCTCGGGCCAGTGCGGCC
CGGCGCGCTGCTGCCAACGCCATCGGCCGCGCAAGTGGTGGCGCCCAAGCGGGCCGACTTCCGCTGCATCCCCGAC
CGCTACCGCGCGCAGCGGGTGCAGCTGTGTCTGCGCGCGCGGCCGCGCGCGCAAGGTGCGCTGGTGGCCTC
40 GTGCAAGTGCAAGCGCCTCACTCGCTTCCACAACAGTCCGAGCTCAAGGACTTCGGGCCCGAGGCCGCGCGCGCCGCA
CGGGCCGAAGCTGCGGCCCGCGCCGGGACCAAGCCAGCCGGGCCA

45

Sequence ID No. 16: Bovine BEER protein (partial sequence -- missing signal sequence and last 6 residues)

NDATEIIPELGEYEPPLPELNNKTMNRAENGGRPPHPFETKDASEYSCRELHFTRYVTDGPCRSAPVTELVCSGQCGP
ARLLPNAIGRGKWWRPSPGPDFRCIPDRYRAQRVQLLCPGGAAPRARKVRLVASCKCKRLTRFHNQSELKDFGPEAARPQT
GRKLRPRARGTKASRA

50

Sequence ID No. 17: MluI - AviII restriction fragment used to make mouse Beer transgene

CGCGTTTTGGTGAGCAGCAATATTGCGCTTCGATGAGCCTTGGCGTTGAGATTGATACCTCTGCTGCACAAAAGGCAATC
GACCGAGCTGGACAGCGCATTCGTGACACCGTCTCCTTCGAACCTTATCGCAATGGAGTGTCTCATCAAGGACNGCC
TGATCGCAATGGTGTATCCACGAGCGGCAATCGAAAACCTCAGCCGGTGACCAATATCTACAACATCAGCCTTGGT
ATCTGCGTGATGAGCAGCGCAGAACAGGTAACCGTCAGTCCCGATAAGTTCAAAGTTAAACCTGGTGTGTATACCAA
CATTGAAACGTTGATCGAAAACGCGCTGAAAAACCTGCTGAATGTGCGGCGCTGGATGTCAAAAGCAAAATGGCAGCAG
60 ACAAGAAAGCGATGGATGAACCTGGCTTCTATGTCCGACGGCCATCATGATGGAATGTTCCCGGTGGTGTATCTGG
CAGCAGTCCGTCGATAGTATGCAATTGATAATTATTATCAATTGCGGGTCTTTCCGGCGATCCGCTTGTACGGGGC
GGCGACCTCGCGGGTTTTGCTATTTATGAAAATTTCCGGTTTAAGGCGTTTCCGTTCTTCTCGTCATACTTAATGT
TTTTATTTAAAATACCTCTGAAAAGAAAGGAAACGACAGGTGCTGAAAGCGAGCTTTTGGCCTCTGTCGTTTCTTCT
TCTGTTTTGTCCGTGGAATGAACAATGGAAGTCAACAAAAGCAGAGCTTATCGATGATAAGCGGTCAAACATGAGAAT

AATACTCTTAAATCTGGGTGGGAGAGTGGCTGCTGTAATCCCAGAACTCGGGAGGCGGAGACAGGGAATCATCAGA
 GCAAACCTGGCTAACCCAGAAATAGCAAAACACTGAGCTCTGGGCTCTGTGAGAGATCCTGCTTAAACATATAAGAGAGAGAA
 TAAACATTGAAGAAGACAGTAGATGCCAATTTTAAAGCCCCACATGCACATGGACAAGTGTGCGTTTGAACACACATAT
 5 GCACTCATGTGAACAGGCGATGCACACTCGGGCTTATCACACACATAATTGAAAGAGAGAGTGTAGAGAGGAGAGTGCAC
 ATTAGAGTTTACAGGAAAGTGTGAGTGAGCACACCCATGACACAGACATGTGTGCCAGGGAGTAGGAAAGGAGCCTGGG
 TTTGTGTATAAGAGGAGCCATCATGTGTTTCTAAGGAGGGCGTGTGAAGGAGGCGTTGTGTGGGCTGGAGCAT
 GGTGTGAACCTGAGCATGCTCCCTGTGGGAAACAGGAGGGTGGCCACCCTGCAGAGGGTCCCCTGTCCAGCGGGATCAGT
 AAAAGCCCCGTGTGAGAACTTTAGGTAATAGCCAGAGAGAGAAAGGTAGGAAAGTGGGGGACTCCCATCTCTGATGTAG
 10 GAGGATCTGGGCAAGTAGAGGTGCGTTTGAGGTAGAAAGAGGGGTGCAGAGGAGATGCTCTTAATCTGGGTGAGCAGTT
 TCTTTCCAAATATGCTGTGAGGAGGTGTAGGTGGGCCATTCACTCACTCAGCAGAGGATGATGATGCCCGGTGGA
 TGCTGGAATGGCCGAGCATCAACCTGGCTCTGGAAGAACTCCATCTTTGAGAAGGAGATGGATCTGTGTATGGCCAG
 CGGGGTACAGGTGCTTGGGGCCCCCTGGGGGACTCCTAGCACTGGGTGATGTTTATCGAGTCTCTGTGTGCCAGGCAC
 TGGCCTGGGGCTTTGTTCTGTCTCTGTTTGTTCGTTTGTGAGACAGACTCTGCTATGTATCCGTGTCAATCTTGG
 AATCTCACTGCATAGCCAGGCTGCGGAGAGAGGGGCAATAGGCCTGTGAAGCAAGGCACATCTCAGAGACTAGAC
 15 TCCACCCTGCGAATGATGACAGGTGAGAGCTGAGTTCGGAAGATTTTTTTTCCAGCTGCCAGGTGGAGTGTGAGTGGC
 AGCTAGCGGCAAGGGTAGAGGGCGAGCTCCCTGTGCAGGAGAAATGCAAGCAAGAGATGGCAAGCCAGTGAGTTAAGCAT
 TCTGTGTGGGAGCAGGTGGATGAAGAGAGAGGCTGGGCTTTCGCTCTGGGGGGGGGTGAGGGGTGGGGATGAGGTGA
 GAGGAGGGCAGCTCCCTGAGTGTGATGAGATTTTTCTGACAGTGACCTTTGGCCTCTCCCTCCCCACTTCCCTTCTT
 TCTTTTCTCCACCATTGCTTTCCTTGTCTTGGAGAAATCTGAGTTTCCACTTCACTGGTGATGAGCAGGAAACAGA
 20 AGCCGT
 GTATGT
 GTATGT
 TGT
 25 GT
 AACTGGAGTTGGAGGAGGTGTGAGTCCCTGACATGTTTGTGTGGAACTGAAACCCCGGTCTATGCAAGAGCAGGAAGT
 GCAGTTATCTGCTGAGCCATCTCTCCAGTCTGAAATCCATTCTCTTAAATACACGTGGCAGAGACATGATGGGATTTA
 CGTATGGATTAAATGTGGCGGTCTTAAGTTCCGGCACAGGCAAGCACCTGTAAAGCCATCACCAACCGAGGTGA
 ATGTGACCATCACCCCATGTTCTTCATGTCCCTGTCCCTCCATCTCCATCTCAAGCACCTCTTGCTCTGCTCTG
 TCGCTGGAGAACAGTGTGCATCTGCACACTCTTATGTGAGTGAAGTGCACAGCCTGCACCCCTTCTGCTGTGAGTATT
 30 TGGGTTCTGACTCTGCTATCACACACTACTGTACTGCATTCTCTGCTCTCTTTTTTAAACATATTTTTATTTGTTTGT
 GTGTATGCACATGTGTGCACATGTGTACAGATACTATGGAGGCCAGAAAGGCCATGGCCCTCTGAGAGCTGAGATA
 GGCAGCGTGTGAGCTCCCTGGTGTGGGTGCTGGGAACCAAACTTGAATCTAAGCAAGCACTTTTAACTCTGAGGCAGC
 TCTCAGTACCCCTTCTTCATTTCTCGCCTGGGTTCATTGTATGGACACATGTAGCTAGAATATCTTGCTTATCTAATTA
 TGTACATGTTTGTGCTAAGAGAGAGTAATGCTCTATAGCCTGAGCTGGCCTCAACCTTGGCCTCTCTGCTCAGCC
 35 TCTCCTCCTGAGTGTCTAGGATGACAGGCGAGTGTAACTTACATGGTTTCATGTTTGTGTCAGACTGAAGGATAACAT
 TCATACAGAGAAGGTCTGGGTACAAAGTGTGAGTTCATGTAATGGCAACACCCGTGATCAAGAAACAACTCAGGGG
 CTGGAGAGATGGCACTGACTGCTCTTCCAGAGGTCCGGAGTCAATTCCAGCAACACATGTTGGCTCACAGCCATCTA
 TAACGAGATCTGACGCCCTCTTCTGTTGTGTCTGAAGACAGETACAGTGTACTCACATAAAATAAATAAATCTTAAAAAC
 ACACACACACACAATAATCCACCCAGAAAGCCACTCCATGTCCCTCCACGCTCTGCTTACAGTACTCCAGGTT
 40 ACCACTGTTCAAGGCTTCTAACAACCTGGTTTACTTGGGCTCTTTCTGCTCTGTGGAGCCACACATCTGTGTGCTCAT
 ACAGTCTCTTTCTAGTAAGTGTATATTACTCTGCGTTTTTACATGTATTTATTATTGTAGTTGTGTGTGCGTGTGGG
 CCATGCTATGGCACAGTGTGTGGGGATGTGAGATATTGTGAACAGGGGACAGTCTCTTTCTCAATCATGTGGGTCCAG
 AGGTTGAACCTCAGTCTCATGTGTGGCAGCAAAATGCTTTTACCAGTGTGAGACATCTCCATATCTTTTCTTTTCTCCCTG
 45 AGGTGGGGGCTTGTTCATAGCCCAACTGGCTTTGCACTTGCAGTTCAAAAGTGAATCCCTGTCTCCACCTCTAGAGTA
 TTGGAATTACGATGTGTACTACCACCTGACTGGATCATTAACTCTTTGATGGGGCGGGGAAGCGACATGCTGCAGG
 TGAAGGGATGACTGGACTGGACATGAGCGTGAAGCCAGAGAACAGCTTCAGTCTAATGCTCTCCCACTGAGCTATTT
 GGTGTGCCAGAGAACAACTTACAGAAAGTCTCAGTGCCATGTGGATTGCGGGTGGAGTTCAACTCATCAGCTTGACAT
 50 TGGCTCCCTCTACCCGAGGCTCTCTACTCTCTACCTAGATCATTAACTCTTTTAAAGAGACTTATAGGGGCG
 TGGAGAGATGGCTCAGCCGTTAAGAGCACCGAATGCCCTTCCAGAGGTCTGAGTTCAATCCAGCATGCCATTGCTGG
 GCAGTAGGGGGCGCAGGTGTTCAACGTGAGTAGCTGTGCCAGTTTCCCGGTGGAGAACCTCTTGACACCTGCTGTG
 CCTGGTCATTCTGGGTGGGTGCATGGTGATATGCTTGTGTATGGAAGACTTTGACTGTTACAGTGAAGTTGGGCTTCCA
 CAGTTACCACGTCTCCCTGTTTCTTGACGGCCGGGTGCTTGTCCATTGCGCGAGGGCTACAGCCGCTCCCCAACGCTA
 55 GTTATCGCCTACCTCATGATGCGGCAGAGATGGAGCTCAAGTCTGCTCTGAGTACTGTGAGGCAGAAATCGTGAGATCGG
 CCCCAACGATGGCTTCTGGCCCAACTCTGCCAGCTCAATGACAGACTAGCCAAGGAGGGCAAGGTGAAACTCTAGGGTG
 CCCACAGCCTCTTTTGAGAGGTCTGACTGGGAGGGCCCTGGCAGCCTGTTTAGGAAACACAGTATACCCACTCCCTGC
 ACCACAGACAGTGCACATCTGTCCACTCTGTCTCTGGGGGCCACTCCACCTTAGGGAGCAGATGAAGAAGCTC
 CCTAAGAAGTTCTGCTCTTAGCCATCTTCTCTGTAATTTATGTCTCTCCCTGAGGTGAGGTTGAGGTTTATGTCCTG
 60 TCTGTGGCATAGATACATCTCAGTGACCCAGGGTGGGAGGGCTATCAGGTGATGGCCCGGACACGGGCCTCTTCAT
 GACCCCTCCCCACCTGGGTTCTTCTGTGTGGTCCAGAACACAGAGCTGGTAAAGGAACTATGCAAAACAGGGCCCTG
 ACCTCCCCATGTCTGTCTCTGCTCTCACAGCCGACAGCCCTGCTGAGGCAGACGAATGACATTAACTCTGAAGCAG
 AGTGGAGATAGATTAGTGATAGATTTCAAAAGAGAGGAAAGGCTGCATTTTAAATTTATTTCTTGAATTAAGTGT
 65 AGATACTACATAGGGGCCCTTGGGTAAGCAATCCATTTTTCCAGAGGCTATCTTGATTCTTTGGAATGTTTAAAGTGT
 GCCTTGGCAGAGAGCTTACGATCTATATCTGCTGCTTCCAGAGCCTTCCCTGAGGATGGCTCTGTTCTTTGCTTGTGTA
 AGAGCGATGCCCTGGGCAGGGTTTCCCCCTTTTCAAGAAATACAGGGTGTAAAGTCCAGCCTATTACAACAAACAAACAA
 CAAACAAACAAAGGACCTCCATTGTGGAATTCAGAGGATTTTATCTGAAATTATAGTGTGTTGAGTGTCAAGTCAATCAC
 GCCAAGTGTCTGCCATCTGCTTGTCTATTCTAAGAATAATTAGGAGGAGGAACCTAGCCAAATTCAGCTCATGTCGTGG
 GTGTGTGCACGGGTGCATATGTTGGAAGGGGTGCTGTCCCTTGGGGACAGAGGAAATGAAAGGGCCCTCTGCTCAC
 CTGGCCCTTACGGGAGGCTCTGCTGCTTCCACGGTGTCTGTGCAGGATCTGAAACTGACTCGCTGAGACAGAAAGGAG

ATGAGTTCGAATCCCCAGCAACCATGTGGAATAAACCTTCTAACCTCAGAGTTGAGGGGAAAGGCAGGTGGATTCTGG
 GGGCTTACTGGCCAGCTAGCCAGCCTAACCTAAATGTCTCAGTCAGAGATCCTGTCTCAGGGAAATACTGGGAGAATGA
 CTGAGAAAGACACCTCCTCAGGTCTCCCATGCACCACACAGACACAGGGGGGGGGTAATGTAATAAGCTAAGAAATA
 5 ATGAGGGAAATGATTTTTTGTCTAAGAAATGAAATCTGTGTTGGCCGCAAGAAGCCTGGCCAGGGAAGGAAGTGCCTTTG
 GCACACAGCCTATAAGTCACCATGAGTTCCTGGCTAAGAAATCAGATGTAATGGAGCCAGGTCCCTCTTGCTGGTGG
 TTGCCCTCTCCACTGGTTTGAAGAGAAATCAAGAGAGATCTCCTTGGTCAGAAATGTAGGTGCTGAGCAATGTGGAGC
 TGGGGTCAATGGGATTCTTTAAAGGCATCCTTCCCAGGGCTGGGTCTACTTCAATAGTAGGGTGTGTCACAGCAAGC
 GTGAGACCTAGGTTAGAGTCCCCAGAAATCTGCCCAACCCCCCAAAAGGCATCCTTCTGCTCTGGGTGGGTGGGGG
 10 GAGCAACACCTTTAACTAAGACCATTAGCTGGCAGGGGTAAACAAATGACCTTGGCTAGAGGAATTTGGTCAAGCTGGAT
 TCCGCTTCTGTAGAAGCCCCACTTGTTCCTTTGTTAAGCTGGCCACAGTTTGTTTTGAATGCTTGAAGGCCCCAG
 GGAGCCAGACAATTAAGCCAAAGCTCATTGATATCTGAAAACACAGCCTGACTGCCCTGCCCTGGGAGGTACTGG
 GAGAGCTGGCTGTGCTCCCTGCCTCACCACAGCCCCCCCCCAACACACACTCCTCGGGTCACTGGGAGGTGCCAGCAG
 CAATTTGGAAGTTTACTGAGCTTGAGAAGTCTTGGGAGGGCTGACGCTAAGCACACCCCTTCTCCACCCCCCCCCACCCC
 15 ACCCGCTGAGGAGGAGGTGAGGAAACATGGGACAGCCTGCTCCAGCCGCTCTTATTGGTATGCTGAGGAGGAGG
 GGGCTTTAAAGGCAACCGTATCTAGGCTGGACACTGGAGCCTGTGCTACCGAGTGCCTCCTCCACTGGCAGCATGC
 AGCCCTCACTAGCCCCGTGCCTCATCTGCCTACTTGTGCACGCTGCCTTCTGTGCTGTGAGGGGCCAGGGGTGGCAAGCC
 TTCAGGAATGATGCCACAGAGGTATCCCAGGGCTTGGAGAGTACCCGAGCCTCCTCTGAGAAACACAGACCATGAA
 CCGGGCGGGAATGGAGGCAGACCTCCCCACCATCCCTATGACGCCAAGGTACGGGATGAAGAAGCACATTATGGGGG
 GGGGGTCTGGGAGGTGACTGGGGTGGTTTAGCATCTTCTTTCAGAGGTTTGTGTGGGTGGCTAGCCTCTGCTACATCA
 20 GGGCAGGGACACATTGCTTGAAGAATACTAGCAGCATTAGAACCTGGAGGGCAGCATTGGGGGGCTGGTAGAGAGC
 ACCCAAGGCAGGGTGGAGGCTGAGGTGAGCGAAGCTGGCATTAAACAGGGCATGGGCTGTATGATGGTCCAGAGAATC
 TCCTCTAAGGATGAGGACACAGGTGAGTCTAGCTGTGACCACTGGGGAAGTATGTTGAGGCTGGATGCCAGATG
 CCATCCATGGCTGTACTATATCCCATGACCCACCATGAGGTAAAGAAGGCCAGCTTGAAGTGGAGAAACCCGAGA
 GGCTCTGAGATAAAGTACCTGGGAGTAAGAAGAGCTGAGACTGGAAGCTGGTTGATCCAGATGCAAGGCAACCCTAG
 25 ATTGGGTTTGGGTGGGAACCTGAAGCCAGGAGGAATCCCTTTAGTTCCCCCTTGCCAGGGTCTGCTCAATGAGCCAGA
 GGGTTAGCATTAAAGAACAGGGTTTGTAGGTGGCATGTGACATGAGGGGCAGCTGAGTGAATGTCCCCGTATGAGCA
 CAGGTGGCACCCTGCTGCTGAGCTTGACCTTGACCCAGCTTGGCTCATTCCTGAGGACAGCAGAACTGTGGAGGC
 AGAGCCAGCACAGAGAGATGCTGGGTGGGGTGGGGTATCAGCCAGGAAGTACAGCAATGAATGGGTGGGGTGG
 CAGCTGGAGGGACACTCCAGAGAAATGACCTGTGCTGCTCACCATTGTGTGGGAGGAGAGCTCATTTCAGCTTGCAC
 30 CACATGCTGTCTCTCTGCTCTAGCCAGTAAGGGATGTGGAGGAAGGGCCACCCCAAGGAGCATGCAATGCAGTCA
 CGTTTTTGCAGAGGAAGTCTTGAAGGCACTATTCTTGAAGGCCCAAACTAGTCTCTCCCTGGGCAACAGG
 CCTCCCCACATACCCTCTGAGGGGTGAGTAAATTAAGCCAGCCACAGAAGGGTGGCAAGGCCCTACACCTCCCCCT
 GTGTGCCCCCCCCCCCCCGTGAAGGTGCATCTGGCCCTCTGCCCTCTGGCTTGTGTACGGGATTTTTTTTTCTCT
 TTATGTCTATTTGATCTGACACCATGGAACCTTTTGGAGGTAGACAGGACCCACATGGAATTAGTTAAAGCCTCCCAT
 35 CCATCTAAGCTCATGCTGAGCTGAGCTTGACCTTGACCCAGCTTGGCTCATTCCTGAGGACAGCAGAACTGTGGCAT
 CCAACCCAATCTCCTTCCCGGAGAACAGACTCTAAGTCAGATCCAGCCACCTTGAAGTAAACAGCTCAAGGTACACAGA
 ACAAGAGAGTCTGTATACAGCAGGTGCTAAACAAATGCTTGTGTAGCAAAAGCTATAGGTTTGGGTGAGAACTCCGA
 CCAAGTTCGGAGTGAAGAGCGAAAGGCCCTCTACTCGCCACCGCCCCGCCCCACCTGGGGTCTTATAACAGATCACTT
 TCACCTTGGCGGAGCCAGAGAGCCCTGGCATCTAGGTAGCCCCCCCCCGCCCCCGCAAGCAGCCGACCTGGCC
 40 TTTGGGGCAAGTTCTTTCTCAGCTGGAACCTGTGATAATGAGGGGTGGAGCGCGCCGCTTGTGCTTTCAGTCT
 AATGAATCTTATCCCTACCACCTGCCCTTCTACCCGCTCCTCCACAGCAGCTGTCTGATTATTACCTCAATTAAC
 CTCACCTCTTTCTCCATCTCTGAGGATACCGCCCTGTGCCAGTGGCTGGTAAAGGAGCTTAGGAAGGACAGAGCCAG
 GTGTGGCTAGAGGCTACAGGCAGGGCTGGGGATGAGGAGCTAACTGGAAGAGTGTTTGGTTAGTAGGCACAAAGCCTT
 45 GGTGGGATCCCTAGTACCGGAGAGTGGAGATGGGCGCTGAGAAGTTCAAGACCATCCATCTAACTACAGCCAGT
 TTGAGGCCAGCCTGGGCTACATAAAAAACCAATCTCAAAAGCTGCCAATTCTGATTCTGTGCCACGTAGTGCCGATGTA
 ATAGTGGATGAAGTCGTTGAATCCTGGGGCAACCTATTTTACAGATGTGGGGAAAGCAACTTAAAGTACCTGCCACA
 GATCACAAGAAAGTAAGTGACAGAGCTCCAGTGTTCATCCTGGGTTCCAAGGACAGGGAGAGAGAAGCCAGGGTGGG
 50 ATCTCATTGCTCCCCCGGCTCTCTTCTATAATCCATACAGATTGAAAGCGCAGGGCAGGTTTGGAAAGAGAGAAAG
 GGTGGAAGGAGCAGACAGTCTGGCTAGGCTGCAGCCCTCACGCATCCCTCTCTCCGAGATGTGTCCGAGTACAGCT
 GCCCGAGCTGCATACACCCGCTTCTGACAGACGGCCCATGCCGAGCGCAAGCCGCTCACCAGATTGGTGTGCTCC
 GGCCAGTGGGCCCCCGCGGGCTGTGCTCCCAACGCCATCGGGCGCGTGAAGTGGTGGCGCCGAACGACCGGATTTCG
 55 GTCTGCTGCTGCTGCAAGTGAAGCGCCTCACCCGCTTCCACAACAGTCCGAGCTCAAGGACTTCGGGCCGGAGACC
 GCGCGGCCGAGAAGGGTGCAGCGCGCGGCCCGCGCGCGGGAGCCAAAGCCAAACAGGCGAGCTGGAGAAGCCCTA
 CTAGAGCGAGCCCGCGCTATGAGCCCCCGCGGATCCGATTCTGTTTCACTGTAAAGCCTGCAGCCCAAGGCCAGGGGT
 GCCAACTTTCCAGACCGTGTGGAGTTCCAGCCAGTAGAGACCGAGGTCCTTCTGCCGCTCGGGGGATGGGGAGG
 60 GGGTGGGGTTCCCGCGGGCCAGGAGAGGAAGCTTGAGCTCCAGACTCTGCTAGCCCCGGGTGGGATGGGGGTCTTTCTA
 CCTCGCCGACCTATACAGGACAAGGCAGTGTTCACCTTAAAGGGAAGGGAGTGTGAACGAAAGACCTGGGACTGG
 TTATGGACGTACAGTAAGATCTACTCTTCCACCAAAATGTAAGCCTGCGTGGGCTAGATAGGGTTTCTGACCTGACC
 TGGCCACTGAGTGTGATGTTGGGCTACGTGGTCTCTTTTGGTACGGTCTCTTTGTAATAAGGACCGGAACCTGCT
 65 GAGATTCCAAGGATTGGGGTACCCCGTGTAGACTGGTGAGAGAGAGAGAGAACAGGGGAGGGTTAGGGGAGAGATTGTGG
 TGGGCAACCGCTAGAAGAAGCTGTTTGTGGCTCCAGCCTCGCCGCTCAGAGGTTTGGCTTCCCCACTCCTTCTC
 TCAATCTGCTTCAATCCATATCTGGGATAGGGAAGGCCAGGGTCCGAGAGATGGTGAAGGGGCCAGAAATCACACTC
 CTGGCCCCCGAAGAGCAGTGTCCCGCCCCCACTGCCTTGTCTATTTGTAAGGGATTTTCTACACAACAGTTTAAGGT
 CGTTGGAGGAACTGGGCTTGCACCTCCATCTTGTCTTGTCCCTTGGCAGGACACCACTCTGCTGCCACCCACCG
 ACACATTTCTGTCTAGAAACAGAGCGTGTGCTGTCTCTGAGACAGCATATCTTACATTAAGAAATAATACGGG
 GGGGGGGGGGAGGGGCCAAGTGTATACATATGCTGAGAAGCTGTGAGGCGCACAGCACCCACAATCTTTTGT
 AAATCATTTCCAGACACCTCTTACTTCTGTGTAGATTTAATTGTTAAAGGGGAGGAGAGAGCGTTTGTAAACAGAA

[illegible]

5
10
15
20
25
30
35
40
45
50
55
60
65

Sequence ID No. 18: Human Beer Genomic Sequence (This gene has two exons, at positions 161-427 and 3186-5219).

35 tagaggagaa gtctttgggg agggtttgct ctgagcacac ccctttccct ccctccgggg 60
ctgagggaaa catgggacca gccctgcccc agcctgtcct cattggctgg catgaagcag 120
40 agaggggctt taaaaaggcg accgtgtctc ggctggagac cagagcctgt gctactggaa 180
ggtggcgtgc cctcctctgg ctggtaccat gcagctccca ctggccctgt gtctcgtctg 240
cctgctggta cacacagcct tccgtgtagt ggagggccag ggggtggcagg cgttcaagaa 300
45 tgatgccacg gaaatcatcc ccgagctcgg agagtacccc gagcctccac cggagctgga 360
gaacaacaag accatgaacc gggcgagaaa cggagggcgg cctccccacc acccctttga 420
50 gaccaaaggt atgggggtgga ggagagaatt cttagtaaaa gatcctgggg aggtttttaga 480
aacttctctt tgggaggctt ggaagactgg ggtagacca gtgaagattg ctggcctctg 540
ccagcactgg tcgaggaaca gtcttgccctg gaggtggggg aagaatggct cgctgggtgca 600
55 gccttcaaat tcaggtgcag aggcattgagg caacagacgc tggtagagagc ccagggcagg 660
gaggacgctg ggggtggtgag ggtatggcat cagggcatca gaacaggctc aggggctcag 720
60 aaaagaaaag gtttcaaaga atctcctcct gggaatatag gagccacgtc cagctgctgg 780

35 tagaggagaa gtctttgggg agggtttgct ctgagcacac ccctttccct ccctccgggg 60
ctgagggaaa catgggacca gccctgcccc agcctgtcct cattggctgg catgaagcag 120
40 agaggggctt taaaaaggcg accgtgtctc ggctggagac cagagcctgt gctactggaa 180
gggtggcgtgc cctcctctgg ctggtacat gcagctccca ctggccctgt gtctcgtctg 240
cctgctggta cacacagcct tccgtgtagt ggagggccag ggggtggcagg cgttcaagaa 300
45 tgatgccacg gaaatcatcc ccgagctcgg agagtacccc gagcctccac cggagctgga 360
gaacaacaag accatgaacc gggcggagaa cggagggcgg cctccccacc acccctttga 420
50 gaccaaaggt atggggtgga ggagagaatt cttagtaaaa gatcctgggg aggttttaga 480
aacttctctt tgggaggctt ggaagactgg ggtagacca gtgaagattg ctggcctctg 540
ccagcactgg tcgaggaaca gtcttgctg gaggtggggg aagaatggct cgctggtgca 600
55 gccttcaaat tcaggtgcag aggcattgagg caacagacgc tggtgagagc ccagggcagg 660
gaggacgctg ggggtggtgag ggtatggcat cagggcatca gaacaggctc aggggctcag 720
60 aaaagaaaag gtttcaaaga atctcctcct gggaatatag gagccacgtc cagctgctgg 780

taccactggg aagggaaaca ggtaaggag cctcccatcc acagaacagc acctgtgggg 840
 caccggacac tctatgctgg tgggtggctgt cccaccaca cagaccaca tcatggaatc 900
 5 cccaggaggt gaacccccag ctgaagggg aagaaacagg ttccaggcac tcagtaactt 960
 ggtagtgaga agagctgagg tgtgaacctg gtttgatcca actgcaagat agccctggtg 1020
 10 tgtggggggg tgtgggggac agatctccac aaagcagtgg ggaggaaggc cagagaggca 1080
 cccctgcagt gtgcattgcc catggcctgc ccaggagct ggcacttgaa ggaatgggag 1140
 ttttcggcac agttttagcc cctgacatgg gtgcagctga gtccaggccc tggaggggag 1200
 15 agcagcatcc tctgtgcagg agtagggaca tctgtcctca gcagccaccc cagtcccaac 1260
 cttgcctcat tccaggggag ggagaaggaa gaggaaccct gggttcctgg tcaggcctgc 1320
 20 acagagaagc ccaggtgaca gtgtgcatct ggctctataa ttggcaggaa tcctgaggcc 1380
 atgggggcgt ctgaaatgac acttcagact aagagcttcc ctgtcctctg gccattatcc 1440
 aggtggcaga gaagtccact gccaggctc ctggaccca gccctcccc cctcacaacc 1500
 25 tgttgggact atggggtgct aaaaaggga actgcatggg aggccagcca ggaccctccg 1560
 tcttcaaat ggaggacaag ggcgcctccc ccacagctc cccttctagg caaggtcagc 1620
 30 tgggctccag cgactgcctg aagggtgta aggaaccaa acacaaaatg tccaccttgc 1680
 tggactccca cgagaggcca cagccctga ggaagccaca tgctcaaac aaagtcatga 1740
 tctgcagagg aagtgcctgg cctaggggag ctattctcga aaagccgcaa aatgccccct 1800
 35 tccctgggca aatgcccccc tgaccacaca cacattccag ccctgcagag gtgaggatgc 1860
 aaaccagccc acagaccaga aagcagcccc agacgatggc agtggccaca tctcccctgc 1920
 40 tgtgcttget cttcagagtg ggggtggggg gtggccttct ctgtcccctc tctggtttgg 1980
 tcttaagact atttttcatt ctttcttgtc acattggaac tatccccatg aaacctttgg 2040
 ggggtggactg gtactcacac gacgaccagc tatttaaaaa gctcccacc atctaagtcc 2100
 45 accataggag acatggtcaa ggtgtgtgca ggggatcagg ccaggcctcg gagcccaatc 2160
 tctgcctgcc caggagatg caccatgagg cgccattca gataacacag aacaagaaat 2220
 50 gtgccagca gagagccagg tcaatgtttg tggcagctga acctgtaggt tttgggtcag 2280
 agctcagggc ccctatggtg ggaaagtaac gacagtaaaa agcagccctc agtccatcc 2340
 cccagcccag cctcccatgg atgctogaac gcagagcctc cactcttgcc ggagccaaaa 2400
 55

ggtgctggga cccagggaa gtggagtccg gagatgcagc ccagcctttt gggcaagttc 2460
 ttttctctgg ctgggcctca gtattctcat tgataatgag ggggttgagc acactgcctt 2520
 5 tgattccttt caagtctaata gaattcctgt cctgatcacc tccccttcag tccctgcctt 2580
 ccacagcagc tgccctgatt tattaccttc aattaacctc tactcctttc tccatccccct 2640
 10 gtccacccct cccaagtggc tggaaaagga atttgggaga agccagagcc aggcagaagg 2700
 tgtgctgagt acttaccctg cccaggccag ggaccctgag gcacaagtgt ggcttaaata 2760
 ataagaagac ccagaagag aaatgataat aataatacat aacagccgac gctttcagct 2820
 15 atatgtgcca aatggtatatt tctgcattgc gtgtgtaatg gattaactcg caatgcttgg 2880
 ggcgccccat tttgcagaca ggaagaagag agagggttaag gaacttgccc aagatgacac 2940
 ctgcagtgag cgatggagcc ctggtgtttg aacccagca gtcatttgcc tccgagggga 3000
 20 caggggtgcgc aggagagctt tccaccagct ctagagcatc tgggaccttc ctgcaataga 3060
 tgttcagggg caaaagcctc tggagacagg cttggcaaaa gcagggtggt ggtggagaga 3120
 25 gacgggcccgc tccagggcag ggggtggccag gcgggcccgc accctcacgc gcgcctctct 3180
 ccacagacgt gtccgagtac agctgccgag agctgcactt caccgctac gtgaccgatg 3240
 ggccgtgccc cagcgccaag ccggtcacgc agctggtgtg ctccggccag tgcggccccg 3300
 30 cgcgcctgct gcccaacgac atcgccgagc gcaagtgggt gcgacctagt gggccccgact 3360
 tccgctgcat ccccgaccgc taccgcgcgc agcgctgca gctgctgtgt cccggtggtg 3420
 35 aggcgcccgc cgcgcgcaag gtgcgcctgg tggcctcgtg caagtgcaag cgcctcacc 3480
 gcttcacaaa ccagtccgag ctcaaggact tgggaccga ggccgctcgg ccgcagaagg 3540
 gccggaagcc gcggccccgc gcccgagcgc ccaaagccaa ccaggccgag ctggagaacg 3600
 40 cctactagag cccgcccgcg cccctcccca ccggcggggc ccccgccct gaaccgcgc 3660
 cccacatttc tgcctctgc gcgtggtttg attgtttata tttcattgta aatgcctgca 3720
 45 acccaggga gggggtgag accttccagg ccctgaggaa tcccgggcgc cggcaaggcc 3780
 cccctcagcc cgccagctga ggggtccac ggggcagggg aggaattga ggtcacaga 3840
 cactgagcca cgagccccg cctctggggc cgctacctt tgcgtgctcc acttcagagg 3900
 50 aggcagaaat ggaagcattt tcaccgcctt ggggttttaa gggagcgggt tgggagtggg 3960
 aaagtccagg gactggttaa gaaagtggga taagattccc ccttgcaact cgctgccat 4020
 55 cagaaagcct gaggcgtgcc cagagcaca gactgggggc aactgtagat gtggtttcta 4080

gtectggctc tgccactaac ttgctgtgta accttgaact acacaattct ccttcgggac 4140
 ctcaatttcc actttgtaaa atgaggggtg aggtgggaat aggatctcga ggagactatt 4200
 5 ggcataatgat tccaaggact ccagtgcctt ttgaatgggc agaggtgaga gagagagaga 4260
 gaaagagaga gaatgaatgc agttgcattg attcagtgcc aaggtcactt ccagaattca 4320
 10 gagttgtgat gctctcttct gacagccaaa gatgaaaaac aaacagaaaa aaaaaagtaa 4380
 agagtctatt tatggctgac atatttacgg ctgacaaact cctggaagaa gctatgctgc 4440
 ttcccagcct ggcttccccg gatgtttggc tacctccacc cctccatctc aaagaaataa 4500
 15 catcatccat tggggtagaa aaggagaggg tccgaggggtg gtgggagggg tagaaatcac 4560
 atccgcccc aactcccaaa gagcagcatc cctccccga cccatagcca tgttttaaag 4620
 20 tcaccttccg aagagaagtg aaaggttcaa ggacactggc cttgcaggcc cgaggagca 4680
 gccatcacia actcacagac cagcacatcc cttttgagac accgccttct gccaccact 4740
 cacggacaca tttctgcta gaaaacagct tcttactgct cttacatgtg atggcatatc 4800
 25 ttacactaaa agaataattat tgggggaaaa actacaagtg ctgtacatat gctgagaaac 4860
 tgcagagcat aatagctgcc acccaaaaat ctttttgaaa atcatttcca gacaacctct 4920
 30 tactttctgt gtagttttta attgttaaaa aaaaaagtt ttaaacagaa gcacatgaca 4980
 tatgaaagcc tgcaggactg gtcgtttttt tggcaattct tccacgtggg acttgtccac 5040
 aagaatgaaa gtagtggttt ttaaagagtt aagttacata tttattttct cacttaagtt 5100
 35 atttatgcaa aagtttttct ttagagaaat gacaatgtta atattgcttt atgaattaac 5160
 agtctgttct tccagagtcc agagacattg ttaataaaga caatgaatca tgaccgaaag 5220
 40 gatgtggtct cattttgtca accacacatg acgtcatttc tgtcaaagtt gacacccttc 5280
 tcttggtcac tagagctcca accttgga cacccttgac tgctctctgg tggcccttgt 5340
 ggcaattatg tcttcctttg aaaagtcattg tttatccctt cctttccaaa cccagaccgc 5400
 45 atttcttcac ccagggcattg gtaataacct cagccttgta tccttttagc agcctccct 5460
 ccatgctggc ttccaaaatg ctgttctcat tgtatcactc cctgctcaa aagccttcca 5520
 50 tagctcccc ttgccagga tcaagtgcag ttccctatc tgacatggga ggccttctct 5580
 gcttgactcc cactccac tccaccaagc ttctactga ctccaaatgg tcatgcagat 5640
 ccctgcttcc ttagtttgcc atccacactt agcaccacca ataactaatc ctctttcttt 5700
 55

aggattcaca ttacttgtca tctcttcccc taacottcca gagatgttcc aatctcccat 5760
 gatccctctc tctcttgagg ttccagcccc ttttgtctac accactactt tggttcctaa 5820
 5 ttctgttttc catttgacag tcattcatgg aggaccagcc tggccaagtc ctgcttagta 5880
 ctggcataga caacacaaag ccaagtacaa ttcaggacca gctcacagga aacttcatct 5940
 tcttcgaagt gtggatttga tgctctctgg gtagaaatgt aggatcttca aaagtgggccc 6000
 10 agctctctgc acttctctca aagtctctgc tccccagggt gtcttaatag tgctggatgc 6060
 tagctgagtt agcatcttca gatgaagagt aacctaaag ttactcttca gttgccctaa 6120
 15 ggtgggatgg tcaactggaa agctttaaat taagtccagc ctaccttggg ggaaccacc 6180
 cccacaaaga aagctgaggt cctctctgat gacttgtcag ttaactacc aataaccac 6240
 ttgaattaat catcatcatc aagtcttga taggtgtgag tgggtatcag tggccggtcc 6300
 20 ctctctgggg ctccagcccc cgaggaggcc tcagttagcc cctgcagaaa atccatgcat 6360
 catgagtgtc tcagggccca gaatatgaga gcaggtagga aacagagaca tcttccatcc 6420
 25 ctgagaggca gtgcggtcca gtgggtgggg acacgggctc tgggtcaggt ttgtgtgtgt 6480
 tgtttgtttg ttttgagaca gagtctcgt ctattgccca ggctggagtg cagtgtcaca 6540
 atctcggett actgcaactt ctgccttccc ggattcaagt gattctcctg cctcagcctc 6600
 30 cagagtagct gggattacag gtgcgtgccca ccacgcctgg ctaatttttg tatttttgat 6660
 agagacgggg ttccaccatg ttggccaggc tagtctcgaa ctcttgacct caagtgatct 6720
 35 gcctgcctcg gcctcccaa gtgctgggat tacaggcgtg agccaccaca cccagcccca 6780
 gggttggtgtt tgaatctgag gagactgaag caccaagggg ttaaattgtt tgcccacagc 6840
 catacttggg ctcagttcct tgccctaccc ctacttgag ctgcttagaa cctggtgggc 6900
 40 acatgggcaa taaccaggtc aactgtttt gtaccaagt ttatgggaat ccaagatagg 6960
 agtaatttgc tctgtggagg ggatgaggga tagtggttag ggaaagcttc acaaagtggg 7020
 45 tgttgcttag agattttcca ggtggagaag ggggcttcta ggcagaaggc atagcccaag 7080
 caaagactgc aagtgcattg ctgctcatgg gtagaagaga atccaccatt cctcaacatg 7140
 taccgagtcc ttgccatgtg caaggcaaca tgggggtacc aggaattcca agcaatgtcc 7200
 50 aaacctaggg tctgctttct gggacctgaa gatacaggat ggatcagccc aggctgcaat 7260
 cccattacca cgagggggaa aaaaacctga aggctaaatt gtaggtcggg ttagaggtta 7320
 55 tttatggaaa gttatattct acctacatgg ggtctataag cctggcgcca atcagaaaag 7380

gaacaaacaa cagacctagc tgggaggggc agcattttgt tgtagggggc ggggcacatg 7440
 ttctgggggt acagccagac tcagggcttg tattaatagt ctgagagtaa gacagacaga 7500
 5 gggatagaag gaaataggtc cctttctctc tctctctctc tctctctctc actctctctc 7560
 tctctcacac acacacacag acacacacac acgctctgta ggggtctact tatgctccaa 7620
 10 gtacaaatca ggccacattt acacaaggag gtaaaggaaa agaacgttgg aggagccaca 7680
 ggaccccaaa attccctgtt ttccctgaat caggcaggac ttacgcagct gggaggggtg 7740
 agagcctgca gaagccacct gcgagtaagc caagttcaga gtcacagaca ccaaagctg 7800
 15 gtgccatgtc ccacaccgc ccacctcca cctgctcctt gacacagccc tgtgctccac 7860
 aaccggctc ccagatcatt gattatagct ctggggcctg caccgtcctt cctgccacat 7920
 20 cccacccca ttcttgaac ctgccctctg tcttctccct tgtccaaggg caggcaaggg 7980
 ctgagctatt gggcagctt gaccaacagc tgaggctcct tttgtggctg gagatgcagg 8040
 aggcagggga atattcctct tagtcaatgc gaccatgtgc ctggtttgcc cagggtggtc 8100
 25 tcgtttacac ctgtaggcca agcgttaatta ttaacagctc ccacttctac tctaaaaaat 8160
 gacccaatct gggcagtaaa ttatatggtg cccatgctat taagagctgc aacttgctgg 8220
 30 gcgtggtggc tcacacctgt aatcccagta ctttgggacg tcaaggcggg tggatcacct 8280
 gaggtcacga gtagagact ggctggcca gcatggcaaa acccatctt tactaaaaat 8340
 aaaaaatta gcaaggcatg gtggcatgca cctgtaatcc cagggtactcg ggaggctgag 8400
 35 acaggagaat ggctgaacc caggaggcag aggttgagc gagccaagat tgtgccactg 8460
 ccctccagcc ctggcaacag agcaagactt catctcaaaa gaaaaggat actgtcaatc 8520
 40 actgcaggaa gaaccaggt aatgaatgag gagaagagag gggctgagtc accatagtgg 8580
 cagcaccgac tcctgcagga aaggcgagac actgggtcat ggggtactgaa ggggtgccctg 8640
 aatgacgttc tgctttagag accgaacctg agccctgaaa gtgcatgcct gttcatgggt 8700
 45 gagagactaa attcatcatt ccttggcagg tactgaatcc tttcttacgg ctgccctcca 8760
 atgccaatt tcctacaat tgtctggggt gcctaagctt ctgccacca agagggccag 8820
 50 agctggcagc gagcagctgc aggtaggaga gataggatcc cataaggag gtgggaaaga 8880
 gagatggaag gagaggggtg cagagcacac acctccctg cctgacaact tcctgagggc 8940
 tggatcatgcc agcagattta aggcggaggc aggggagatg gggcgggaga ggaagtgaaa 9000
 55

aaggagaggg tggggatgga gaggaagaga gggatgatcat tcattcattc cattgctact 9060
 gactggatgc cagctgtgag ccaggcacca ccctagctct gggcatgtgg ttgtaatctt 9120
 5 ggagcctcat ggagctcaca gggagtgtg gcaaggagat ggataatgga cggataacaa 9180
 ataaacattt agtacaatgt ccgggaatgg aaagttctcg aaagaaaaat aaagctgggtg 9240
 agcatataga cagccctgaa ggcggccagg ccaggcattt ctgaggaggt ggcatttgag 9300
 10 c 9301

From the foregoing, it will be appreciated that, although specific
 15 embodiments of the invention have been described herein for purposes of illustration,
 various modifications may be made without deviating from the spirit and scope of the
 invention. Accordingly, the invention is not limited except as by the appended claims.